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DETAILED PROTOCOL – DATA COORDINATING CENTER 
“Randomized Trial of  Maternal Vitamin D Supplementation to Prevent Childhood Asthma 
(VDAART: Vitamin D Antenatal Asthma Reduction Trial)” 
 
I. Background and Significance  
 Asthma is one of the leading causes of morbidity in children with 90% of all cases 
diagnosed by age 61, 2. It remains the most common chronic disease of childhood in the world3, 
4, and incurs significant healthcare costs5, 6. The burden of the disease in both the developed 
and the developing world is significant and increasing rapidly with over 300 million people 
affected worldwide. Thus, preventing the development of this disorder would be of great public 
health importance. 
Vitamin D deficiency has been documented in many populations worldwide7, 8, and has 
been reported in healthy children, young adults (especially African Americans), and middle-aged 
and elderly adults7, 8. Vitamin D deficiency has occurred despite fortification of foods in some 
countries and despite intake of multivitamins containing vitamin D. This suggests that as 
countries adopt a western lifestyle, there is shift from outdoor activities to more time spent 
indoors. For example, it is estimated that in the US alone, Americans spend an average of 93% 
of their time indoors9. Relevant to this proposal, pregnant and lactating mothers and their 
neonates are at especially high risk for vitamin D deficiency10-13. Preliminary data from 
ongoing clinical trials show that many infants whose mothers are not being supplemented with 
sufficient doses of vitamin D have circulating 25(OH)D levels in the “insufficient” range (defined 
as levels between 10 - 25 ng/ml)14. Furthermore, it has recently been documented that 50% of 
mothers and 65% of their newborn infants from an inner city hospital were vitamin D deficient, 
with levels <12 ng/ml (or <30 nmol/L)15, despite the fact that most mothers were taking their 
prenatal vitamins. This analysis also showed a strong positive correlation between maternal and 
newborn plasma levels, providing further evidence that infant vitamin D status is dependent on 
maternal vitamin D status. These results are similar to other recent reports that show a high 
prevalence of vitamin D deficiency in pregnant women and their newborns, even in some sun 
replete areas of the world. The prevalence of deficiency (25(OH)D levels < 10ng/ml among 
pregnant women in these studies were: 80% in Iran16, 42% in Northern India17, 61% in New 
Zealand18, and 60-84% among non-Western women in the Netherlands19. 
The importance of vitamin D deficiency in pregnancy in relation to asthma development 
is that it has many recognized effects in on the developing lung and immune system. Nguyen 
and coworkers, through a series of studies in fetal rat lung, have identified the type II alveolar 
cells as a target for 1,25(OH)2D3 action. Firstly, they identified specific binding sites (vitamin D 
receptors) for 1,25(OH)2D3 that are distinguishable at a time corresponding to the start of type II 
pneumocyte differentiation and onset of surfactant secretion20. Next, with the use of monoclonal 
antibodies, they localized these vitamin D receptors to type II pneumocytes21.Thirdly, in 
explanted fetal rat lung tissue, they showed that 1,25(OH)2D3 accelerated the decrease in type II 
cells glycogen content and increased surfactant synthesis and surfactant secretion22, 23. Vitamin 
D was about half as potent as an equivalent dose of dexamethasone in stimulating surfactant 
synthesis and secretion. They also showed that a paracrine system for vitamin D is present in 
rat fetal lung and function during the last 3 days of pregnancy21, and that some of the effects of 
vitamin D may be mediated by fructose 1,6 biphosphatase, whose gene contains a vitamin D 
response element in the promoter region24. These recent observations strongly suggest that 
vitamin D plays a role in lung maturation late in pregnancy, and support earlier 
observations such as the association of respiratory distress in vitamin D deficient 
preterm infants (“rachitic respiratory distress”)25. In humans, the effect of vitamin D on 
surfactant production has been confirmed26, although the mechanisms appear to be 
more complex than in the rat27. 
  
Aside from effects on type II pneumocytes and surfactant production, vitamin D also 
appears to have effects on lung growth and development. Gaultier et al28 studied lung 
mechanics in 50-day old rats born to mothers deprived of dietary vitamin D and reported 
significantly decreased lung compliance compared with rats born to mothers whose diet was 
supplemented with vitamin D, suggesting that disturbances in lung growth occurred in the 
vitamin D deficient rats. In humans, vitamin D also has been shown to play a role in the 
developing lung. Early studies used the presence of calbindin, a vitamin D dependent calcium 
binding protein, as a molecular marker of 1,25(OH)2D3 action in tissues. Among many other 
tissues, Brun et al29 reported high levels of calbindin in human fetal lung tissue at 14-32 weeks 
of gestation, suggesting that vitamin D plays a role in fetal lung development, as early as 14 
weeks. Lunghi and colleagues30 obtained normal human fetal (16 weeks gestation) lung 
fibroblasts and reported that in the presence of vitamin D, pyruvate kinase activity and lactate 
production of the cells increased. Other findings included a decrease in cell number and DNA 
synthesis in the vitamin D exposed cells compared with control cells. Subsequently, they 
showed that the vitamin D receptor was present in these human fetal fibroblasts31 and 
confirmed their original findings in fetal lung fibroblasts in a subsequent study on senescent 
human lung fibroblasts32. Thus, these animal and human tissue studies show that later in 
pregnancy, vitamin D stimulates lung maturation and surfactant production and 
secretion. Additionally, the data shows that at various points in fetal development, as 
early as 14 weeks of gestation, vitamin D has a regulatory role in fetal lung growth and 
development. 
We have recently shown in two independent birth cohorts that higher maternal intakes 
during pregnancy of vitamin D from both foods and supplements were associated with an 
almost 60% reduction of asthma and recurrent wheezing in 3-5 yr old children33, 34.  
We propose to conduct a double-blind, multicenter, placebo-controlled clinical trial of 
vitamin D supplementation in pregnant mothers to prevent the development of asthma and 
allergies in their children. The trial will be composed of a Data Coordinating Center and three 
Clinical Centers. The DCC will be composed of Brigham and Women’s Hospital investigators 
led by Drs. Scott T. Weiss and Augusto A. Litonjua, and Dr. Bruce Hollis from the Medical 
University of South Carolina. Members of the DCC will only see de-identified data and 
samples, and will not have any direct contact with recruited subjects. Members of the 
DCC will not participate in recruitment of subjects. 
 
II. Hypothesis and Specific Aims 
 Our hypothesis is that supplementing pregnant women with sufficient vitamin D will 
decrease the incidence of allergies, asthma and wheezing illnesses in children. The initial basis 
for this hypothesis is our finding in two separate birth cohorts of the protective effect of vitamin D 
intake on wheezing illnesses in 3-5 yr old children. Our birth cohort studies are consistent with 
data from studies that have investigated animal fetal models and human fetal lung tissue that 
show that (1) vitamin D receptors are present in the fetal lung, (2) vitamin D enhances lung 
maturation in the last stages of pregnancy, (3) vitamin D controls growth and development of 
the fetal lung, and (4) profile of human cord blood cell response to antigens is affected by 
vitamin D. Finally, there is a large amount of literature that shows that there is a high prevalence 
of vitamin D deficiency among women of child-bearing age and in pregnant women, such that 
infants are being born deficient in vitamin D. Furthermore, in both our birth cohorts, vitamin D 
intake in the first year of life and in childhood did not modify the association of maternal vitamin 
D intakes with any of the wheeze outcomes. Taken together, these data strongly suggest that 
the right time to intervene is during pregnancy. Therefore, we propose a two-arm, randomized, 
double-blind, placebo-controlled, multi-center clinical trial to determine whether vitamin D 
supplementation in the pregnant mother will prevent asthma and allergy at age 3. We will utilize 
asthma/recurrent wheezing as our primary end point and allergy and lower respiratory infection 
  
as secondary end points. We will recruit 870 pregnant women during the first trimester of 
pregnancy and randomize them to one of two treatment arms of a 5-year clinical trial: the 
addition of 4000 IU daily of vitamin D to usual pregnancy vitamin D supplementation (daily 
prenatal vitamins with 400 IU vitamin D) in the treatment group compared with placebo plus 
usual vitamin D supplementation (daily prenatal vitamins with 400 IU vitamin D) in the control 
group. Because we expect an 8% rate of miscarriages and stillbirths, and about 18% 
withdrawals or loss to follow-up, we expect that we will have 660 children (330 in each arm) for 
analysis of the primary outcome at 3 years of age.  
 
Our primary aims are: 
1. To determine whether a vitamin D dose of 4,000 IU per day vs the standard 400 IU/day in 
pregnancy is sufficient to maintain mothers’ vitamin D levels in the immune-sufficient range 
of ≥ 30 ng/ml 25(OH)D. 
 
2. To determine whether sufficient vitamin D supplementation in the pregnant mother is 
associated with reduced incidence of asthma in the child during the first 3 years of life. Our 
primary outcomes will be doctor’s diagnosis of asthma and/or recurrent wheeze in the child 
at age 3 years. 
 
In addition to our primary aims, we have the following secondary aims of the trial: 
3. To determine whether sufficient vitamin D supplementation in the pregnant mother is 
associated with reduced secondary outcomes in the child of (a) allergic sensitization (total 
and specific IgE), (b) doctor’s diagnosis of eczema and (c) lower respiratory tract infections 
during the first 3 years of life.  
  
4. To determine whether sufficient vitamin D supplementation in the pregnant mother is 
associated with improved vitamin D status in their offspring through measurement of 
25(OH)D levels in cord blood (at delivery), and children’s blood (at 1 and 3 yrs of age). 
 
III. Vitamin D supplementation: safety considerations.  
The current adequate intake (AI) for pregnant and lactating women is 200 IU/day 
(although most prenatal vitamins contain 400 IU vitamin D). However, multiple studies have 
shown that these current recommendations result in a high degree of vitamin D deficiency in 
different adult populations35-37. One recent study supplemented 160 minority women in the UK 
with 800-1600 IU/day vitamin D throughout their pregnancies37. The investigators found a mean 
increase in circulating 25(OH)D concentrations from 5.8 ±0.9 ng/ml at the beginning of 
pregnancy to 11.2 ± 6.4 ng/ml at term after vitamin D supplementation. Therefore, mothers who 
were deficient at the beginning of their pregnancy were still deficient at the end of their 
pregnancy after supplementation, despite supplementation with a higher that recommended 
dose of vitamin D. A more recent study has supported these findings. Talwar et al 38 studied 208 
postmenopausal African American women over 3 years. Their results showed that a dose of 
2,000 IU/day raised 25(OH)D levels to 30 ng/ml in only 60% of the participants. This finding is 
relevant because pregnant women have greater vitamin D requirements (due to the growing 
fetus) than postmenopausal women. The results of these studies point out that the AI for vitamin 
D during pregnancy is grossly inadequate.  Given that a single minimal erythemic dose 
(MED) exposure (for a Caucasian individual, this is approximated by ~10-12 minutes of 
peak summer sun exposure) will release ~10,000 – 20,000 IU vitamin D into the circulation 
within 24 hours39, the dose of vitamin D supplementation required to maintain adequate 
vitamin D status in adults is likely to be orders of magnitude greater than the current AI. 
 
  
TABLE 1. Summary of high-dose vitamin D supplementation studies in healthy adults and pregnant and 
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* 25(OH)D, 25-hydroxyvitamin D. 
† Sunlight exposure was not discussed in the studies by Brooke et al, Cockburn et al, Delvin et al, Mallet et al, and Datta et al. 
Minimal sunlight exposure was controlled for in the studies by Ala-Houhala, Vieth et al, Heaney et al, and Hollis and Wagner. 
‡ It is likely that the wrong dose was reported. The response observed is one that would be expected after supplementation with 
10,000 IU/d for 3 mos. 
 
The safety of giving “large” (relative to current AI, but not to normal responses to sun exposure) 
doses of vitamin D and the potential risk of vitamin D toxicity are valid concerns. The exact 
amount of vitamin D required to induce toxicity in humans is unknown. The safe Tolerable 
Upper Intake Level (UL) for vitamin D was set at 2,000 IU/day by the Food and Nutrition Board 
(FNB)49 in 1997. However, this recommendation was not based on current evidence, and is 
viewed by many as being too restrictive. Vieth47 estimates that the physiologic limit for daily 
vitamin D intake is 10,000 – 20,000 IU/day, and toxicity has never occurred when physiologic 
amounts are ingested. The data on safety of vitamin D supplementation in physiologic doses 
and animal models of toxicity have been extensively reviewed by Dr. Hollis, who is a co-
investigator on this proposal10. In this review, several studies of high-dose vitamin D 
  
supplementation (ranging from 400 IU/day to 10,000 IU/day) conducted in healthy adults and 
pregnant and lactating women were noted, and these studies are summarized in Table 1. It is 
noteworthy that none of these studies have reported adverse outcomes due to supplementation. 
Supporting the notion that high-dose supplementation is safe, Hathcock and co-workers50 
reviewed new evidence in addition to the evidence reviewed by Dr. Hollis in 2004, and applying 
the risk assessment methodology used by the FNB, concluded that the absence of toxicity in 
trials conducted on healthy adults supported the selection of 10,000 IU/day as the new daily UL 
for vitamin D. We should note here that we are proposing a dose that is less than half of this. 
Furthermore, as noted above, Dr. Hollis’ group is conducting a Phase 3 trial of vitamin D 
supplementation of up to 4,000 IU/day during pregnancy (http://clinicaltrials.gov; RO1 HD 
043921). Dr Wagner (Dr. Hollis’ co-investigator) has generously supplied us the October, 2008 
Data Safety Monitoring Committee (DSMC) report for their trial. To date 347 women have 
completed the study and have delivered their babies and no episodes of vitamin D 
toxicity have occurred in the women, nor have adverse reactions been found in the 
fetuses or infants. The rate of spontaneous abortions, or other pregnancy related 
complications such as prematurity, have not increased in the vitamin D supplemented 
arms. Indeed in these subjects followed for 3123 person months of follow up, a total of 92 
“adverse events” have been reported to the trial’s DSMC. These events included diabetes 
(n=18), preeclampsia (n=5), gestational diabetes (n=17), hypertension (n=14), preterm 
labor (n=29), premature rupture of membranes (n=1), deep vein thrombosis (n=2), 
maternal infection (n=6), and placental abnormality (n=1). In detailed reviews, none of 
these pregnancy complications were attributed to vitamin D supplementation. 
Additionally, no neonatal physical abnormalities were detected on examination (C. 
Wagner, personal communication). Therefore, the administration of 4,000 IU/day of vitamin D 
to pregnant women is safe. Dr. Hollis holds an IND with the FDA for safety of vitamin D 
supplementation in pregnancy (IND 66,346). He has shown that this dose is appropriate to bring 
levels in all of the women, regardless of race/ethnicity, to sufficient levels. Furthermore, the 
4,000 IU/day dose eliminated all seasonal variation in 25(OH)D levels, which lower doses did 
not. His trials and data from others show that this dose is safe and not associated with any 
adverse effects in the mother or in the fetus/infant. This protocol will be covered under Dr. Hollis’ 
IND.  
  
Figure 1. Mean 25(OH)D levels in African American, Caucasian, and Hispanic pregnant women in the three 
supplementation groups. 
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Dr. Hollis’ trial has also generated more preliminary data regarding the response to the various 
doses of vitamin D. Figure 1 shows the response to varying doses of vitamin D in pregnant 
  
women from 3 ethnic groups: Caucasian (n=38 in Control group; n=37 in 2,000 IU, and n=39 in 
4,000 IU), African American (n=24 in Control; n=35 in 2,000 IU; and n=26 in 4,000 IU), and 
Hispanic (n=45 in Control; n=48 in 2,000 IU; and n=44 in 4,000 IU). Baseline 25(OH)D levels 
varied by ethnic group, with African Americans having the lowest levels and Caucasians having 
the highest baseline levels. The 2000 IU/day dose raised the circulating 25(OH)D levels to a 
mean of about 38 ng/ml, and only approximately 60% achieved levels of >30 ng/ml. The 4000 
IU/day dose most rapidly and consistently increased 25(OH)D levels in the participants from all 
ethnic groups, with a mean of about 45 ng/ml, and practically all participants achieved levels of 
at least 30 ng/ml. Additionally, the 4000 IU/day dose eliminated all seasonal variation in 
circulating 25(OH)D levels. There were no instances of adverse events from the 4000 IU/day 
dose, either in the mother or the infant, even in those mothers whose beginning 25(OH)D levels 
were > 30 ng/ml. Thus, 4000 IU/day of vitamin D was the dose that achieved sufficient 
supplementation in the pregnant women. The preliminary results and experience from Dr. 
Hollis’ clinical trials have provided valuable information for our current proposal, 
regarding the dosing and safety of vitamin D supplementation in pregnancy.   
 
 
IV. Study Overview and Subject Selection 
This is a multicenter, randomized, double-blind, controlled clinical trial that compares 
high-dose vitamin D3 supplementation (4,400 IU/day) vs. usual dose vitamin D3 supplementation 
(400 IU/day) in pregnancy to prevent asthma in the women’s children. The study base will be all 
pregnant women from each Clinical Center who have a personal history of asthma and/or 
allergies or a history of asthma and/or allergies in the biologic father of the child (i.e. a “high risk” 
cohort for asthma and allergies in the child). Seven hundred twenty (360 in each arm) will be 
followed through their pregnancy and delivery, and their infants will be followed up to the age of 
3 yrs. All infants who are consuming < 1000 ml of formula per day will be offered vitamin D 
supplementation (400 IU/day) in accordance with the most recent recommendations from the 
American Academy of Pediatrics51. This includes all infants who are breastfed, either partially or 
exclusively, and all formula-fed infants until they consume at least 1000 ml of formula. The 
primary outcomes are doctor-diagnosis of asthma and recurrent wheezing at age 3 yrs. Due to 
dropouts from miscarriages, stillbirths, other pregnancy complications, and loss-to-follow-up, so 
we expect that we will be left with 660 3-yr old children (300 in each arm) for the analyses.  
Women who come into their Obstetrician’s clinics for their first pre-natal visit will be 
screened on a daily basis by Research Coordinator and a physician co-investigator will verify 
eligibility criteria. 
 
Inclusion Criteria (applied to the pregnant women) 
• Personal history of asthma, eczema, allergic rhinitis or a history of asthma, eczema, 
allergic rhinitis in the biological father of the child 
• Gestational age between 10 and 18  weeks at the time of randomization 
• Maternal age between 18 and 35 years 
• Not a current smoker 
• English- or Spanish-speaking 
• Intent to participate for the full 4 years (through pregnancy and then until the 3rd birthday 
of the child) 
Exclusion Criteria 
• Not meeting Inclusion Criteria 
• Gestational age >18 weeks  
• Presence of chronic medical conditions: (i) Hypertension, (ii) Type 1 or type 2 diabetes 
mellitus, (iii) Parathyroid disease, and (iv) Uncontrolled thyroid disease. 
• Taking vitamin D supplements containing > 2,000 IU/day of vitamin D3 
  
  
• Multiple gestation pregnancy (i.e. twins, triplets, etc.) 
• Pregnancy achieved by assisted reproduction techniques (e.g. IUI, IVF) 
Both arms of the study will get prenatal multivitamins which contain 400 IU vitamin D. Additional 
supplementation will occur in a double blind placebo controlled fashion with one arm receiving 
an additional 4000 IU of vitamin D (total Vitamin D 4400 IU daily), and the other arm receiving a 
matching placebo. We will not exclude subjects who have “normal” levels at the beginning of the 
trial, since many studies have now documented that a large proportion of pregnant women have 
insufficient levels. Even women who may have normal levels may have insufficient levels at 
other times during their pregnancy (i.e. during winter). The 4400 IU dose has been shown to 
remove seasonal variation in vitamin D levels. 
 
V. Recruitment. The recruitment goal for each site will be 290 subjects. As we anticipate 
miscarriages and stillbirths (about 8%52), and a 17-18% dropout by the end of the 3-year follow-
up of the children, this number should give us the target of 220 3-yr old children per Clinical 
Center or a total of 660 3-yr old children at the end of the trial. The 3 clinical centers have 
considerable experience and a proven track record in recruiting participants for longitudinal 
studies of asthma. We expect that each center will be able to fulfill the recruitment goals in 9-12 
months.  
The study coordinator at each Clinical Center will obtain the schedules for all prenatal visits for 
the week, and scheduled visits will be reviewed for potential subjects. At their first prenatal visit, 
participants will be contacted by the Study Coordinator and interest in participating in the study 
will be assessed; if the participant is interested, then a screening questionnaire inquiring about a 
history of asthma or allergies in the patient or the biologic father of the child, a copy of the 
description of the study, and a consent form will be given to her. An enrollment/randomization 
visit will be scheduled within 1 week of the prenatal visit, where a review of the study 
procedures and consent form will be performed, and consent will be obtained. At that visit, a 
detailed symptom questionnaire, short food frequency questionnaire, and habitual sun exposure 
questionnaire will be administered, and determination of skin pigmentation will be performed. 
After randomization, the Study Coordinator will note the subject’s scheduled visits with her 
obstetrician and will make sure that urine samples are collected at each of these scheduled 
clinical prenatal visits. At each of these clinical prenatal visits, a short maternal health 
questionnaire will be administered, MEMS cap information will be downloaded, and refill of the 
Study medication and prenatal vitamins will be perfomed. The Study Coordinator and RAs will 
also conduct a monthly review of electronic medical records to review any complications of 
pregnancy. A follow-up telephone call at 6 weeks post randomization will occur to promote 
adherence and to administer a maternal questionnaire that asks about over-the-counter 
medications, smoking, alcohol consumption, and symptoms. An in-person research prenatal 
visit will be scheduled at 6-8 weeks post-randomization for a blood draw, questionnaire 
administration, and refill of Study Medication and prenatal vitamins. Another follow-up telephone 
call will occur at 26 weeks to promote adherence. At delivery, an aliquot of blood drawn from the 
mother for clinical purposes will be retrieved, and cord blood will also be collected. After 
delivery, monthly calls to inquire about the health and symptoms of the infant will be done for 
the first 6 months. After the first 6 months, calls will become quarterly. Yearly visits for the child 
will also be scheduled. The questionnaires and measurements to be performed are summarized 
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Screening visit: This screening visit will occur at the subjects’ first pre-natal visit. Each day, the 
study nurse/RA will review scheduled prenatal visits in the participating Clinical Center obstetric 
practices for the following day (Monday schedules will be reviewed the previous Friday), and will 
identify potential subjects who are presenting for their first prenatal visit. During the visit, the 
study nurse/RA will describe the study and will present the potential subject with a written 
description of the study and will review the eligibility criteria via a screening questionnaire. If the 
subject is eligible, does not meet any exclusion criteria, and expresses interest in the study, a 
   
follow-up visit will be scheduled within a week. At this point, the subject will be issued a unique 
screening ID, which will be attached to her pertinent screening information. 
Enrollment visit: Within 1 week of the screening visit, but not later than the 22nd week of 
gestation, the study nurse/RA will meet with the subject, and the study description will be 
reviewed. The rest of the visit will entail completion of informed consent forms, completion of the 
health questionnaire, completion of the food frequency questionnaire, sun exposure 
questionnaire, and a blood draw for 25(OH)D measurement. 
Randomization and Treatment Assignment:  Participants who are deemed eligible to participate 
will be randomized by the Data Coordinating Center (DCC) to either of the 2 arms of the trial. 
Only those who firmly agree to follow-up until the child is 3 years old will be randomized.  
Randomization will be performed prior to enrollment of any study participants by the 
DCC using a system that automates the random assignment of treatment groups to Study ID 
numbers. The randomization scheme will employ permuted blocks, and one blocked allocation 
list per stratum (study site and ethnic group) will be generated. That is, separate permuted block 
randomization lists will be maintained for each ethnic group (e.g., Caucasian/Non-Hispanics, 
Caucasian/Hispanic, African-American, and Other) within each study site. This will assure that 
within each site, there is approximate balance across arms over the course of enrollment, and 
that within ethnic groups within site, there is also approximately equal representation on both 
arms. A woman who is deemed eligible will receive the next available Study ID number for her 
given study center site and ethnic group.  The Study ID will be linked to the women’s Screening 
ID.  It should be noted that women who are deemed ineligible will not receive Study IDs (i.e. 
randomization to a treatment), thus, this will help insure balance in treatment and control groups 
by not ‘wasting’ randomization assignments on ineligible subjects.  
When a potential participant reports for the Enrollment Visit, informed consent will be 
obtained and a formal eligibility determination will be made. Women that consent and meet all 
eligibility criteria will be sequentially assigned a five-digit Study Identification Number (Study ID). 
The first digit of the Study ID will identify the site (St. Louis, San Diego, or Boston) and the next 
three digits will identify the participant; and the last digit will be a check digit that is calculated 
from a formula to insure the accuracy of data entry. Each Study ID number is pre-assigned a 
randomization assignment during the randomization process performed by the DCC before the 
study starts. The Study ID number assigned to a participant will determine treatment arm, and 
the study medication provided for a specific Study ID number will be dispensed to that 
participant. The schedule of visits, calls, and data collection points are summarized in Table 2. 
 
VI. Data Collection 
A. Screening Questionnaire. This short questionnaire will be administered at the screening 
visit at the time of the first pre-natal visit. This questionnaire will be used to obtain information on 
each participating woman and her husband/partner regarding demographics; physician-diagnosed 
illnesses; respiratory symptoms; smoking by members of the household; history of asthma, hay 
fever, eczema, or allergies; indicators of asthma severity; use of medications; and cigarette 
smoking. This questionnaire will also inquire about the diagnosis of asthma and allergies in the 
mother and the biologic father of the child, and whether the mother is willing to participate in the 
trial. 
 
B. Maternal Behavior, Symptoms, and Medication Inventory 
 This questionnaire will be administered to the mother by the Study Coordinator at the 
scheduled telephone calls. The mother will be asked to complete this health assessment 
questionnaire to ascertain her: 
a. Use of prescription medications 
b. Use of over-the-counter preparations that may influence vitamin D and calcium homeostasis. 
c. Use of cigarettes and alcohol 
  
d. Report of headaches—frequency and severity 
e. Report of swelling of feet and hands 
f. Employment during pregnancy: hours and type of work 
 
C. Monthly Review of Medical Records (paper-based) and Electronic Medical Records 
(EMR) 
 EMR systems are in place at each of the clinical centers. Each month, the Study 
Coordinator or the RA will review the Obstetric EMR of each of the participants for any potential 
complication of pregnancy. Examples include but are not limited to the following: (a) 
Preeclampsia, (b) HELLP (Hemolytic anemia, Elevated Liver enzymes, Low Platelet count) 
syndrome, (c) Gestational diabetes, (d) Hypertension, (e) Preterm labor, (f) Premature rupture 
of membranes (PROM), (g) Deep venous thrombosis or a coagulopathy, (h) Maternal infection 
such as varicella or herpes (1o or 2o), (i) Placental abnormalities such as previa or marginal 
abruption. For centers where EMRs are not complete, paper medical records will be reviewed 
and the relevant information extracted. 
 
D. Measurement of 25(OH)D 
 Blood will be drawn from the mothers at randomization, the in-person research prenatal 
visit, and at delivery. Cord blood will also be collected at delivery. Blood from the child will be 
collected at 1 yr and at 3 yrs. All specimens will be shipped to the DCC, where they will be 
logged in and processed. Aliquots will be sent to Heartland Assays, Inc from the DCC for 
measurement of 25(OH)D. Measurement of 25(OH)D will be performed as previously 
described53. Twenty five (25) microliters of serum or plasma (EDTA or Heparin) is required for 
the 25-OH-D extraction, however, 100 microliter samples will be sent to allow for duplicate 
measurements on each sample. The 25-OH-D assay consists of a two-step procedure. The first 
procedure involves a rapid extraction of 25-OH-D and other hydroxylated metabolites from 
serum or plasma with acetonitrile. Following extraction, the treated sample is then assayed 
using an equilibrium RIA procedure. The RIA method is based on an antibody that is co-specific 
for 25-OH-D2 and 25-OH-D3. The sample, antibody and tracer are incubated for 120 minutes at 
20-25°C. Phase separation is accomplished after a 20-minute incubation at 20-25°C  with a 
second antibody-precipitating complex. An NSB/Addition buffer is added after this incubation 
prior to centrifugation to aid in reducing non-specific binding. 25-(OH)D-equivalent values will be 
calculated directly by the γ-radiation counting system with use of a smooth-spline method. The 
results will be expressed in terms of 25-(OH)D equivalents.  
 In order to monitor assay performance each assay will include one in-house control 
sample.  The control will be treated as unknown specimen and multiple (5) determinations will 
be made. Assay variation will be determined and acceptable performance limits will be defined 
as ≤15 C.V.  In addition 20% of the samples will also be measured in Dr. Hollis’ laboratory in the 
Medical University of South Carolina. 
Heartland Assays, Inc, is located at the Iowa State University Research Park, Ames, IA, 
and is a joint venture between Dr. Bruce Hollis, Medical University of South Carolina and Dr. 
Ronald Horst, Adjunct Professor and Collaborator, Iowa State University, Ames IA54.  Dr. Hollis 
and Dr. Horst have over 60 years of combined experience in the development and application of 
vitamin D assays in both human and veterinary medicine54-58.  Each has made significant 
contributions to the assessment of vitamin D status as affected by a number of physiological 
states in humans and animals.  Most notably and more recently has been Dr Hollis’ 
determination that measurement of 25(OH)D is the best circulating biomarker to reflect vitamin 
D status39, 59, 60. Similar findings where reported by the Horst Lab regarding vitamin D status in 
poultry61. Dr. Hollis’ laboratory has measured 25(OH)D for large epidemiologic studies dealing 
with pregnant women10, 45.   
 
  
E. Urinary Ca++/Cr ratios 
 At each monthly prenatal visit, mothers will provide a urine sample (“clean catch”). 
Because dairy products and higher calcium foods can affect urine calcium levels, mothers will 
be instructed to avoid dairy products in the hour prior to their scheduled visit. Urine samples will 
be sent to each Clinical Center’s Clinical Chemistry Laboratory for urinary calcium and 
creatinine measurement, and the urinary calcium to creatinine ratio will be derived. Dr. Hollis 
has used this measure to monitor women on vitamin D supplements in his other trials and has 
shown that this is the earliest sign of impending toxicity. 
 
F. Food Frequency Questionnaire. Maternal dietary intake of vitamin D will be assessed using 
a standardized, validated food frequency questionnaire62. This questionnaire has been slightly 
modified to apply to pregnant women and has been validated in pregnancy63. Mothers will be 
asked to complete the FFQ on enrollment in the 1st trimester. A second questionnaire will be 
completed at the 28-32-week visit. Assessment of the responses to these questionnaires will 
help account for dietary sources of vitamin D in addition to the study intervention. In addition, 
the FFQ will measure other nutrients that may have confounding effects, and which we will be 
able to adjust in the analyses. Filled out questionnaires will be sent to the Harvard Nutrition 
Questionnaire Services Center at the Harvard School of Public Health for scanning and 
processing. Individual nutrients will be calculated using the Harvard nutrient composition 
database, which contains food composition values from the US Department of Agriculture, 
supplemented by other sources64.  
 
G. Sun Exposure Questionnaire. We will collect UV exposure history using a modification of 
the UV exposure questionnaire that is used in the Nurses’ Health Study65. Briefly, this 
questionnaire will inquire about UV exposure information such as average hours per week spent 
outdoors in summer and winter, sunscreen habits, and average times for sunlamp use or 
tanning salon attendance. 
 
H. Measurement of Skin Pigmentation. Pregnant mothers will have the degree of 
pigmentation/melanin measured at study entry, at 28-32 weeks using the Smart Probe 400 
(IMS, Inc., Milford, CT) and a skin tone chart (IMS, Inc.). This is a spectrophotometer device that 
measures degrees of pigmentation on a continuous scale from 0 to 100, 0 being absolute black 
and 100 being absolute white. Each mother will have pigmentation measurements recorded 
from her exposed forearm, underarm, and stomach, with two readings averaged and recorded. 
 
I. Labor and Delivery Information and Questionnaires: At delivery, the research assistant will 
collect information on type of delivery (caesarian vs vaginal), birthweight and other anthropometric 
measurers, need of oxygen, etc. (see Appendix for Labor and Delivery questionnaire).  
 
J. Infant Follow-up Questionnaires. Every month for the first 6 months after delivery, we will 
administer a questionnaire to the child’s caretaker (in most instances, this will be the mother) to 
obtain information on the neonate general and respiratory health, with particular attention given to 
symptoms suggestive of asthma, wheeze, allergies, and atopic eczema. This questionnaire will 
also inquire about respiratory infections (upper, including ear infections, and lower tract infections, 
including bronchiolitis), medication use, particularly antibiotics, and smoking by adults in the home. 
Questions inquiring about breastfeeding, formula feeding, and introduction of solid foods will also 
be included. At the third month after delivery and every third month (quarterly) thereafter, the longer 
version of the questionnaire will be administered. In addition to the questions in the monthly 
questionnaire, this questionnaire will inquire about home characteristics, caregiver stress, pets in 
the home, and day care. At the first year questionnaire and each year thereafter, we will also 
inquire about the child’s diet, using a short food-frequency questionnaire. 
  
 
K. Total and specific IgE: Total serum IgE levels will be determined in samples from the child (at 
age 3 year) by the UniCAP 250 system (Pharmacia & Upjohn, Kalamazoo, MI), with samples 
measured in duplicate. Serum from each subject will also be assayed for IgE to 11 allergens (dust 
mite [D. farinae and D. pteronyssinus], cockroach [Bla g], cat dander, dog dander, mixed grass 
pollen, mixed tree pollen, Alternaria tenuis, egg, milk, and peanut) using the UniCAP 250 system 
(Pharmacia & Upjohn, Kalamazoo, MI). For specific IgE, the enzyme-immunoassay is based on the 
sandwich technique, utilizing a solid phase (allergen-impregnated discs) for separation.66, 67 
 
L. DNA Extraction and Samples for Gene Expression Studies: We will extract high molecular 
weight genomic DNA from the white blood cells from maternal peripheral blood and cord blood 
with commercially available PureGene Kits (Gentra Systems, Minneapolis, MN). Optical density 
(OD) will be measured to confirm DNA quality and quantity for each sample. This amount is 
sufficient to perform approximately 16,000 genotype assays using PCR technology (assuming a 
conservative use of 25 ng/reaction, although we routinely amplify single copy gene sequences 
from 10 ng of genomic DNA). Every sample undergoes additional quality control before 
use/release by subjecting it to PCR amplification. After DNA quantification, samples will be 
adjusted to TE buffer and partitioned into aliquots stored at -80°C. Information about quantity 
and storage of extracted DNA will be added as variables to each patient’s database. DNA 
samples will then be stored at the Channing Laboratory for future genetic studies. 
 From the scheduled blood draws from the mothers and cord blood, we will include 
samples for gene expression studies. For mothers, two 2.5 PAXgene tubes and one 8.5 cc CPT 
tube will be drawn on entry into the study, 2 months post-enrollment, at the 30 week visit, at 
delivery, and at the child 1-yr visit. Two 2.5 cc PAXgene tubes and one 8.5 cc CPT tube will also 
be saved from the cord blood draw. These samples will be used to understand the genetics and 
gene expression of fetal development and asthma in future studies with a special focus on the 
relationship to vitamin D. While genetics and gene expression are not currently part of the 
specific aims of this protocol, it is imperative that samples be collected because the time window 
for appropriate collection is short (i.e. during pregnancy and delivery of the baby). 
 
M. Manufacture and Distribution of Study Medications; The MEMS System 
 The study medications, including all prenatal vitamins, the vitamin D tablets, and the 
placebo tablets will be manufactured by Tishcon Corp. Founded in 1976, Tishcon Corp. 
(www.tishcon.com) is a leading manufacturer and marketer of vitamins, related dietary and 
herbal supplements, and private label non-prescription (OTC) pharmaceuticals in tablet, hard 
gelatin capsule, soft gelatin capsule and powder dosage forms. Tishcon is one of 12 soft gelatin 
capsule manufacturers in the United States. The pills and capsules will be sent in bulk from 
Tishcon to the DCC. The DCC will contract with the Brigham and Women’s Hospital Pharmacy 
to package and label the pills in bottles with the MEMS caps. Once packaged and labeled with 
Study ID numbers, the pill bottles will be shipped to the respective Clinical Centers. Random 
pills from each lot will be sent to Dr. Hollis’ lab where the vitamin D amount will be quantified for 
quality purposes. Each participant will receive 2 bottles – one bottle will contain the standard 
prenatal vitamins with 400 IU vitamin D, and will be labeled accordingly, and the other bottle will 
contain the intervention pill containing 4,000 IU vitamin D or a placebo. 
The MEMS System. The MEMS® - Medication Events Monitoring Systems is a pill bottle 
equipped with special cap that includes an electronic microchip that stores the date and time of 
each opening of bottle. The MEMS monitors are drug packages with integral electronic micro 
circuitry designed to compile the dosing histories of ambulatory patients’ prescribed 
medications. Each monitor consists of a conventional medicine bottle fitted with a special 
closure that records the time and date of each opening and closing of the container through 
integrated microcircuitry.  The MEMS® stores up to 3800 medication events in non-volatile 
  
EEPROM memory, allows wireless data transfer, fits standard pharmacy bottles 38mm-400, 
42mm-400, and 45mm-400 thread closure, provides 36 months battery life, and is water-
resistant and CE marked. Monitors are designed to be used by one patient with one drug. A 
Reader allows transferring the dose timing data from the MEMS to a MS-Windows based 
computer. The MEMS monitors have demonstrated reliability and validity and have been widely 
used with great success in clinical trial research68, including NHLBI sponsored studies in the 
Childhood Asthma Research and Education Network69, 70 and asthma clinical research 
sponsored by industry71. The MEMS® - Medication Events Monitoring Systems is manufactured 
by Aardex LTD (http://www.aardexgroup.com) with a subsidiary in California for ease of 
ordering.  
Data from the MEMS system will be downloaded monthly. The data from the pre-natal 
follow-up visits will be used to provide feedback to the participant, reinforcing those subjects 
with good adherence and providing extra teaching and encouragement for those with 
suboptimal adherence. These data can be used to derive a summary adherence measure that 
can be used as a covariate in our analyses and also for secondary analyses that exclude any 
women who have taken less than 50% of the prescribed study medication. 
 
N. Statistical considerations 
N.1. Overview 
 This is a randomized, double blinded, multi-center, placebo controlled, clinical trial of 
prenatal vitamin exposure as a preventive measure to reduce the risk of asthma and recurrent 
wheeze in childhood.  There will be approximately 870 pregnant women enrolled, targeting an 
evaluable study population of 660 women randomized to Vitamin D supplementation of 4400 IU 
or 400 IU (standard prenatal supplementation).  The treatment arms will be balanced 
(approximately n=300 in each arm, with some fluctuation possible owing to differential 
miscarriage or loss to follow-up, both expected to be completely at random). The primary 
outcome is doctor-diagnosed asthma and recurrent wheeze at 3 years of age.  Secondary 
outcomes include allergy, doctor’s diagnosis of eczema, and lower respiratory infection (LRI), at 
three years of age. The primary interpretive paradigm for analysis of this study is intent to treat. 
N.2 Analytic plan 
All analyses to be described will occur in a framework of continuous quality assurance and 
verification.  Preliminary statistical analysis will be used to describe the univariate distributions 
of key measures of interest to detect outliers or data anomalies that need to be addressed by 
data editing or sequestration of doubtful entries.  Additionally, these analyses will examine 
whether any important risk factors for childhood asthma are imbalanced across treatment arm, 
as well as assess whether differential loss to follow-up is present across treatment groups.  
Detailed blinded codebooks will be provided to investigators as data accumulate to facilitate 
efficient substantive verification of basic distributional summaries and joint distributions of 
measured factors. 
N.2.a. Plan for Specific Aim 1 
For this analysis, our N will be 800, since most of the dropouts will be expected to occur after 
delivery. Thus, the expected drop in N due to the 8% miscarriage rate was applied. We will test 
the hypothesis that the dose of 4,000 IU per day is sufficient to get 90% of the women to a 
sufficient level of 25(OH)D of at least 30 ng/ml, primarily using a logistic regression model, with 
randomization group (i.e. intervention group vs. usual care) as the independent variable. The 
dependent variable will be 25(OH)D level at delivery. We will adjust our analyses for other 
covariates that may affect 25(OH)D level, such as sun exposure (from the SmartProbe and the 
sun exposure questionnaire), age, and diet (calculated vitamin D intakes from dietary sources).  
N.2.b. Plan for Specific Aim 2 
The hypothesis that the incidence of asthma and recurrent wheeze at age three years is 
reduced in the high-dose Vitamin D supplementation group will be tested using logistic 
  
regression, allowing for fixed effects of center.  Additional analyses will consider the modification 
of vitamin D exposure effects by maternal and child demographic/behavioral factors such as 
maternal age, BMI and weight gain during pregnancy, maternal history of asthma/allergy, and 
other factors potentially associated with asthma and/or Vitamin D exposure.   The variables to 
be considered are summarized in Table 3. For variables that are measured post-natally, recall 
bias is a potential confounder among parents of infants diagnosed with asthma. However, the 
prospective nature of the data collection should limit the extent of this and other potential 
sources of bias. Due to the design of this clinical trial, we expect that the randomization process 
will distribute these variables equally between the intervention and control groups. However, we 
will check the distribution of these variables prior to conducting the analyses, and will adjust for 
variables that may be unevenly distributed across treatment and control groups. 
  
Table 3. Information on selected potential confounders of the relationship between 25(OH)D levels and 
asthma/recurrent wheeze in 3-yr old children 
Prenatal variables Socioeconomic status 
 Maternal diet 
 Maternal sun exposure behavior 
 Maternal age and parity 
 Maternal history of asthma and allergies 
 Maternal pre-pregnancy BMI and weight gain in 
pregnancy 
 Maternal medication use in pregnancy (antibiotics, 
acetaminophen, NSAIDs, etc.) 
 Pregnancy complications (e.g. gestational diabetes, 
pre-eclampsia) 
Delivery variables Gestational age 
 Mode of delivery (caesarian section, normal vaginal 
delivery) 
 Birthweight, length, head circumference 
 Oxygen use 
 Need for NICU stay 
Postpartum and 
infancy variables 
Breastfeeding or bottlefeeding 
 Type of formula 
 Timing and type of solid food introduction 
 Daycare, including timing of and type of daycare 
(home vs institution) 
 Pets in the home 
 Other siblings in the home (gender and number) 
 Smoking in the home 
 Childhood diet  
 Sun exposure behaviors in the child 
 
Letting Mi be an indicator function for the primary endpoint, asthma, for the ith subject, 
the model is:   
iiiiii aaxaxM ,2211 , ),|1Pr(logit γγβα +++==  
where xi denotes an indicator function for level of vitamin D supplementation (0=400 IU, 1=4400 
IU) in the ith subject, while a1,i and a2,i are indicator functions for study center.  The specific aim 
for this outcome tests the hypothesis that β=0, asthma and recurrent wheeze incidence do not 
significantly differ across treatment groups, after adjusting for the potential effects of study 
center heterogeneity. 
To assess modification of vitamin D exposure levels by other demographic and/or 
behavioral variables, the model is: 
∑∑+++== ++ k kk iikkikiiiiii zxzaaxaxM ηδγγβα ,2211 , ),|1Pr(logit  
  
where zki represents the k measured covariates for each subject, and the other variables are as 
described above.  This model addresses two hypotheses.  First, main effects testing for 
behavioral/demographic covariates (Table 9), or the hypothesis that δk=0, will be used to 
examine whether maternal age, BMI, or other factors predict asthma and recurrent wheeze risk 
at age 3.  More importantly, inclusion of any significant main effects will adjust for any 
distributional imbalances of these factors across the Vitamin D supplemented and placebo 
groups.   Second, this model tests the hypothesis that ηk=0, or whether any maternal, child, or 
demographic/behavioral covariates modify the relationship between vitamin D intake and our 
primary outcome.  To obtain a parsimonious model and limit multiple testing, only covariates 
with significant main effects and strong biologic plausibility for an exposure-dependent impact 
on asthma/recurrent wheeze risk will be considered for interaction testing with Vitamin D 
supplementation status. For example, only the prenatal and some delivery variables (e.g., 
gestational age, birthweight, length) listed in Table 9 will be considered, as the factors  
modifying the impact of Vitamin D supplementation on asthma and/or recurrent wheeze should 
occur temporally (i.e. in utero). 
N.2.b.1. Interim Analyses for Specific Aim 2 
 For the primary aim of asthma and recurrent wheeze, we have developed an interim 
analysis plan to monitor this composite endpoint over the three years of subject follow-up.  This 
sequential monitoring plan consists of two interim analyses (conducted at year 3 month 12 or 
when all first year study visit data are available and year 4 month 12/when all first and second 
year visit data are available), and a final analysis at the end of year 5, when the three-year 
follow-up has been completed on all subjects.  For maximum flexibility in the analysis, we will 
use a Lan-Demets alpha spending function72 with O’Brien-Fleming bounds.  While the power 
simulations described in section O.2 use stopping boundaries that are designed for 3 ‘looks’ 
over the study period, the Lan-DeMets procedure provides a spending function approach which 
does not require pre-specification of the frequency or timing of interim looks.  This can be 
advantageous if the timing of data collection varies of if the need for more frequent monitoring 
arises.  Conservative O’Brien-Fleming bounds are used to preserve most of the type-I error for 
the final analysis.  The specific boundaries for the interim analyses are provided in section O.2.  
Only the primary endpoint of asthma and/or recurrent wheeze will be monitored sequentially.  If 
the boundaries are crossed at either the first or second year analyses, results will be 
immediately reported and the study will be stopped.   
 
N.2.c Plan for Specific Aim 3 
Incidence of allergy, doctor’s diagnosis of eczema, and lower respiratory tract infection 
(LRI) at age 3 will be individually assessed.  Like asthma and recurrent wheeze, two of the three 
secondary outcomes are dichotomous endpoints, and will be analyzed using logistic regression.  
For allergy, logistic regression will be used for specific IgE and linear regression will be used for 
log transformed total serum IgE level.  Both a primary analysis of the relationship between 
Vitamin D and the secondary outcome of interest will be conducted, as well as additional 
analyses including demographic and environmental risk factors for allergy, eczema, and LRI.  
The primary analysis, as well as additional analyses testing main demographic/behavioral 
effects and effect modification, will be conducted along the lines of analyses described for 
Specific Aim 2. The covariates to be considered for main effects and interaction analyses will be 
identical to those outlined for Specific Aim 2. 
 
N.2.d. Plan for Specific Aim 4 
 This specific aim investigates the immediate and long-term impact of vitamin D 
supplementation on circulating 25(OH)D blood levels.  The immediate impact of Vitamin D on 
25(OH)D will be assessed through maternal plasma and cord blood measurements taken at 
  
delivery.  The long-term influence will be examined via longitudinal analyses using children’s 
blood measurements obtained at ages 1 and 3.  
The hypotheses that 25(OH)D levels in maternal plasma and cord blood will be higher in 
the 4400 IU group will be tested using standard linear regression. If necessary, 25(OH)D levels 
will be transformed to meet the distributional requirements for the analysis. The 25(OH)D levels 
in maternal plasma and cord blood will be treated as separate outcomes, although both testing 
procedures for each analysis will be similar and are described jointly below.  As with specific 
aims 1 and 2, the primary analysis will examine the relationship between 25(OH)D and Vitamin 
D levels, while the secondary analysis will include other important demographic and 
environmental factors related to 25(OH)D levels, such as climate and dietary vitamin D intake, 
testing for main effects and effect modification for these factors. 
Letting yi denote the 25(OH)D levels for each subject (as measured in mother’s plasma 
for the first hypothesis, and cord blood for the second hypothesis), the model for the primary 
analysis is: 
iiiii aaxy εγγβα ++++= ,22,11  
where the covariates and parameters are as defined in Specific Aim 1.  However, Specific Aim 3 
tests the hypothesis that β=0, 25(OH)D levels do not significantly differ across the Vitamin D 
supplemented and control groups. All relevant covariates listed in Table 3 will be considered for 
the final model.  For example, covariates measured post-natally would not be considered for 
inclusion in the analysis of maternal plasma or cord blood at delivery.  Additionally, factors 
known to be directly associated with OH(25)D levels (i.e. sun exposure behavior, diet, ethnicity), 
will be included in the final model even if they are not statistically significant predictors of 
circulating vitamin D levels.  
To assess modification of 25(OH)D levels by other demographic and behavioral 
variables, the model is: 
ikiikkikiiii kk zxzaaxy εηδγγβα +++ ∑∑+++= ,22,11  
where the parameters are as defined in Specific Aim 1. The k measured covariates for these 
analyses will be environmental, maternal, and child factors specific to 25(OH)D levels, such as 
sun exposure behavior, dietary intake of Vitamin D, and ethnicity.  Additionally, any relevant 
covariates from Table 9 demonstrating main effects that have biologically plausible interactions 
with Vitamin D supplementation will be tested for effect modification. For both models, it is 
assumed that εi ~ N(0,σ2).  The hypothesis that δk=0 will be used to examine whether any of 
these factors predict 25(OH)D levels, and the results will be used to adjust for any distributional 
imbalances of these factors across Vitamin D supplementation groups.   As with the previous 
specific aims, we will also tests for effect modification via the hypothesis that ηk=0, or whether 
any maternal, child, or demographic/environmental covariates modify the relationship between 
vitamin D intake and circulating 25(OH)D levels in mother’s plasma or cord blood.  Additionally, 
we will follow the guidelines outlined in Specific Aim 2 to obtain the most parsimonious model. 
The hypothesis that 25(OH)D levels in the child’s blood will be higher in the 4400 IU 
group at birth, age 1 and age 3 will be tested using a repeated measures analysis framework 
such as generalized estimating equations. 
N.3 Multiple comparisons. 
All pre-specified hypotheses will be tested individually at the 0.05 level of significance, 
using a conservative two-sided alternative hypothesis (even when the stated hypothesis is one-
sided). More specifically, the primary and secondary hypotheses of Vitamin D supplementation 
and Asthma/Recurrent Wheeze, Allergy/Exczema/LRI, will not be adjusted for multiple 
comparisons, since they have been defined a priori and are limited in scope.  Additionally, an 
interim analysis plan has been developed for the primary outcome to adjust for the number of 
times (3) asthma and/or recurrent wheeze will be analyzed over the study period.  Since 
  
25(OH)D status is being examined in 5 separate analyses (maternal plasma at 26-28 weeks, 
maternal plasma at delivery, cord blood at delivery, infant plasma at years 1 and 3), this 
analysis will be adjusted for 5 multiple comparisons (i.e., using Bonferroni correction). Finally, 
any findings with respect to interaction terms (i.e., exploring whether environmental and 
demographic covariates affect the relationship between Vitamin D supplementation and the 
outcome of interest) for any of the hypotheses will be adjusted (i.e., using FDR methodology) for 
the number of models tested, and interaction testing will be limited to those defined in sections 
D.14.2a-c, in order to limit the potential for spurious findings. Any serendipitous findings coming 
from exploratory analyses will be clearly reported as such, and test statistic p-values will be 
adjusted by the number of exploratory hypotheses considered (using FDR or another 
appropriate procedure for multiple comparisons adjustment).   
 
O. Power and sample size 
O.1. Power for Specific Aim 1. We will have excellent power to detect an increase of 20-60% 
in the proportion of mothers with 25(OH)D levels > 30 ng/ml between the intervention and the 
control group, as shown in Table  . We expect that there will be 400 women in each arm for this 
analysis due to the 8% miscarriage rate. We do not expect there to be significant LTF by 
delivery. 
  
Table 4. Power to detect a 20-60% absolute increase in the proportion of mother’s with 25(OH)D > 
30 ng/ml for 800  patients in a multi-site study* 
 
Proportion of mothers with 25(OH)D 
> 30 ng/ml in 4400 IU group 
Proportion of mothers with 
25(OH)D > 30 ng/ml in 400  IU 
group 90% 80% 70% 
 0.50 >0.999 >0.999 >0.999 
 0.40 >0.999 >0.999 >0.999 
 0.30 >0.999 >0.999 >0.999 
* 8% miscarriage rate 
 
 
O.2. Power for Specific Aim 2.  The trial is designed to detect a 25% reduction in asthma and 
recurrent wheeze incidence at 3 years in the vitamin D supplemented (4400 IU) group.  Based 
on the observational results in the Viva Study, we estimate that the incidence of asthma and/or 
recurrent wheeze in the standard dosing group (400 IU) will be 40-50%.  This incidence 
estimate is based on observations from Project Viva and the URECA Project. In project Viva, 
the prevalence of persistent wheeze is 44% and of asthma is 56.2% in children born to 
families with parental history of asthma (about twice the prevalence in children without 
family history). These estimates are similar to those observed in the URECA Project in 
children who have turned 2 yrs old. The children in that cohort had a family history (mom or dad) 
of asthma or allergies. In the URECA cohort, 99 of 194 (51.0%) children who have reached their 
2nd birthday, have experienced "wheezing or asthma by age 2." These observed rates in 2 
cohorts give us confidence that we will see similar rates when we recruit the high-risk (for 
asthma and allergies in the child) pregnancies for this clinical trial. We anticipate an 8% 
miscarriage rate52 and 17-18% LTF among remaining subjects over the study period, resulting 
in an estimated sample size of 660 subjects (330 per arm) at the end of the study period.  Each 
power estimate is based on 10,000 simulations.  The simulations incorporate the interim 
analysis plan described in N.2.b.1.  For our group sequential design, we plan to use a Lan-
Demets spending function with three equally spaced looks (with respect to the amount of 
  
  
information collected) and O’Brien-Fleming type bounds. The software program LANDEM 
(http://www.biostat.wisc.edu/landemets/)73 was used to calculate the stopping boundar, which 
were |z|=3.7103, 2.5114, and 1.993 at the first, second, and third looks, respectively. The 
hypothesis tests are conducted with two-sided alternatives (i.e. a two-sided p-value), The power 
reflects the proportion of replicates where the Wald test statistic from the hypothesis test of β1=0 
is less than the stopping boundary specified for the first, second, or third looks, where β1 is the 
coefficient for Vitamin D supplementation status from the logistic regression model outlined in 
section,D.14.2.a.i.  The replication is considered a ‘success’ if the stopping boundary is 
exceeded at any of the analysis times. In the simulations, the incidence of asthma and/or 
recurrent wheeze at the first and second interim looks is proportionate to the overall incidence 
expected at the end of the study period (i.e. at the first look, the incidence is one-third of the 
specified rate; at the second look, it is two-thirds).  We do not expect incidence rates of 40-50% 
to be achieved until the third year of follow-up; therefore, the simulations reflect the approximate 
amount of information anticipated at each interim analysis.  
        Finally, in the simulation studies, we also incorporate study heterogeneity into the 
model by varying the incidence of asthma and/or recurrent wheeze in the control group (400 IU 
Vitamin D) across study sites. The incidence varies by an absolute difference of 10% (i.e., for a 
mean incidence of 50%, incidence rates varied from 45-55% across study sites).  Thus, the 
absolute reduction in incidence observed in the treated group (4400 IU Vitamin D) will also vary 
according to baseline incidence in the control group [i.e., assuming a 30% reduction in 
incidence, a site with a 50% incidence rate in the control group will have a 35% incidence rate 
(a 15% decrease) in the treated group, while a site with a 45% incidence in controls will have a 
31.5% incidence rate (a 13.5% decrease) among supplemented subjects].    
 
Table 5.  Power to detect a 20-30% reduction in asthma and recurrent wheeze for 660 patients in a 
multi-site study* 
Percent reduction in Asthma and/or 
 Recurrent Wheeze in 4400 IU group 
Mean Incidence of Asthma 
and/or Recurrent Wheeze in 
400  IU group 30% 25% 20% 
 0.50 0.974 0.906 0.726 
 0.45 0.950 0.837 0.653 
 0.40 0.901 0.773 0.574 
*18% LTF and 8% miscarriage rate 
  We anticipate that there will be excellent power (91%) to detect a 25% reduction in 
asthma, assuming a 50% incidence of asthma/recurrent wheeze in the 400 IU dosing group.  
Even if the children in this study have a lower incidence of asthma and recurrent wheeze than 
previous cohorts (i.e., 40-45%), we will still have good power (77-84%) to detect a 25% 
reduction in asthma and/or recurrent wheeze. To assess the potential impact of study center  
heterogeneity and interim analyses on power, powercalculations were conducted without 
adjustment for study-center and with a single analysis time point at the end of the study period 
(with a two-sided alpha=0.05).  The calculations were performed in STPLAN 
(http://biostatistics.mdanderson.org), using an arcsine approximation for the binomially 
distributed outcome.  Overall, the power estimates were consistently similar to the empirical 
estimates (shown in Table 5), with at most a 2% difference in absolute power.  Therefore, we do 
not anticipate that multiple study sites or incorporating interim analyses will considerably reduce 
study power. 
O.3. Power for Specific Aim 3. The estimated incidence of doctor’s diagnosis of allergy (IgE), 
eczema, and and lower respiratory infection (LRI)  at year 3 in the Viva cohort are 30%, 36%, 
and 45%, respectively, among the children with a parental history of asthma or allergies. 
Estimates of eczema and LRI differ from those submitted in the previous grant application, 
which were based on incidence of these secondary outcomes among all children (including 
those without a parental history of asthma and allergies). Additionally, information on allergy 
incidence in Project Viva is now available.  We anticipate a 30%-45% reduction in each of these 
outcomes in the high-dose Vitamin D supplementation (4400 IU) group, though a larger range is 
provided in table 6 below.  Each power calculation is based on 10,000 simulations, and are 
identical to the simulations described above, except that interim analyses are not planned for 
the secondary outcomes, and the studies are powered to detect an effect at the end of the three 
year follow-up period, with  a two-sided alpha level of 0.05. As with the methods described 
above, these simulations  incorporate an effect for study center heterogeneity in baseline 
incidence of secondary outcomes (i.e., incidence across sites varies by 10%)  and 8/18% losses 
to miscarriage and follow-up/miscarriage, respectively.  
With a 30% reduction in incidence, we anticipate that there will be good power (83.4%) 
to detect a clinically important difference in risk of    eczema.  Due to the lower incidence of 
allergy,a 35% reduction is required to have very good (89.0%) power.  Additionally, since LRI is 
more prevalent at age 3, only a 25% reduction is required to have 85.8% power.  Even if the 
incidence of these outcomes is 5% lower than the estimated rates in Viva, there will still be 
sufficient power to detect an effect of treatment. Overall, there is strong evidence that we will be 
adequately powered to detect a risk difference intreatment group (4400 IU Vitamin D) for the 
secondary outcomes, in addition to our primary outcome of interest, asthma and recurrent 
wheeze. 
O.4. Power for Specific Aim 4. The 
research to date on the impact on 
Vitamin D supplementation of 25(OH)D 
is presented in Table 1.  As noted in the 
table, only 4 studies have been 
conducted on pregnant women, all had 
fewer than 100 subjects, and the 
maximum daily dose for these studies 
was 1,600 IU. The only data available 
on 25(OH)D status in the 
supplementation ranges we are 
proposing has been provided by Dr. 
Bruce Hollis (unpublished data, see 
section III).  In a study of 400 pregnant 
women (African Americans. Hispanic, 
and Caucasians) on either 4000 IU (supplemented) or 400 IU (control) of Vitamin D daily, the 
maternal plasma 25(OH) D levels were 46 ng/mL in supplemented subjects, and 32 ng/mL in 
controls after 8 months of supplementation, an overall difference of 14 ng/mL.  The estimated 
standard deviation for 25(OH)D levels in these ranges is 16.   
Table 6. Power to detect a 25-35% reduction in secondary 
outcomes for 870 subjects  in a multi-site study, (effectively 
660 patients, assuming an 8% miscarriage rate and  18% 
loss to follow-up) 
Percent reduction in secondary 
  outcome in 4400 IU group 
Mean Incidence of 
secondary outcome 
in 400  IU group 35% 30% 25% 
 0.50 0.998 0.982 0.913 
 0.45 0.992 0.958 0.858 
 0.40 0.973 0.906 0.779 
 0.35 0.936 0.845 0.691 
 0.30 0.890 0.736 0.608 
 0.25 0.795 0.654 0.531 
Based on the observed differences/variation in 25(OH)D levels, we used simulation 
studies to estimate the power to detect a mean difference of 3-15 ng/mL across the 
supplemented and control groups in maternal plasma at 26-28 weeks, as well as maternal 
plasma and cord blood at delivery, using an estimated standard deviation of 16.  We anticipate 
that the difference in 25(OH)D levels in maternal plasma across treatment groups will less 
pronounced at the 26-28 week measurement period (e.g., 5-10 ng/ML), and we do not expect to 
observe a significant difference by supplementation status in circulating vitamin D in infants at 1 
and 3 years of age, since no post-natal treatment intervention is planned.  The simulations were 
generated in a similar manner to method described for Specific Aim 2, except that linear 
regression (rather than logistic) was used to model the relationship between circulating Vitamin 
  
D and Vitamin D supplementation status. Study heterogeneity was incorporated into the model 
by allowing OH(25)D levels to vary by 10 ng/mL across study sites.  Since this phenotype will be 
measured five times throughout the studyperiod, the power was defined as the proportion of 
replicates with a Wald test statistic (i.e., testing the null hypothesis that the coefficient for 
Vitamin D supplementation status is 0) 2-sided p-value was less than 0.01 (0.05/5).  The results 






Table 7. Power to detect a 3-15 ng/mL difference in 25(OH)D for 870 subjects  in a multi-site study, (effectively 
660 patients, assuming an 8% miscarriage rate and  18% loss to follow-up). 
Mean change in 25(OH)D levels in 
4400 IU group (ng/mL) Power 
 3 0.444 
 5 0.925 
 10 0.999 
 15 0.999 
For a mean difference greater than 3 ng/mL, we anticipate having excellent power to detect a 
difference in 25(OH)D status across treatment groups.  This difference of at least this magnitude 
should be observed in both maternal plasma measurements and cord blood, given the 
preliminary data (a difference of 14 ng/mL in maternal plasma) provided by Dr. Hollis.  To 
ensure that the results were not affected by incorporating an effect for study center, the 
simulations were conducted assuming homogenous effects across study sites.   The power 
estimates were within 1.5% of those provided above, and are likely due to variation in estimates 
via simulation. Therefore, we are confident that we have excellent power to achieve this specific 
aim. 
O.5 Missing data considerations 
It is expected that missing data will be infrequent, that the treatment is sufficiently benign 
that any missingness would be unrelated to treatment group, and that the outcome 
ascertainment process is compatible with standard medical care for children.  Thus it is 
reasonable to predict that missing data would be missing “completely at random” (MCAR) and 
that inference based on the complete cases would be valid, though only slightly inefficient, if 
missingness is rare (less than 5%) .  Methods are available to assess the compatibility of 
response patterns with the MCAR condition (Chen and Little, 1999), and these will be used to 
diagnose the missing data situation.  If there missingness is not rare, and it is desired to 
improve the efficiency of the analysis, two possible approaches to handling the imputation are 
described below. 
Approach A: Impute the overall (ignoring treatment assignment) incidence of asthma and 
recurrent wheeze (or the incidence of the secondary outcome of interest) for children that are 
lost to follow-up, and analyze the resulting imputed dataset as if complete. This is a crude but 
very simple approach that is often proposed.  Approach B: Use subject-specific modeling to 
determine an imputation distribution for those who drop out.  Specifically, model the risk of 
asthma and recurrent wheeze (or secondary outcome) among completers as a function of 
baseline covariates, ignoring treatment assignment. Use the covariates zi observed on dropouts 
to predict logit[Pr(Mi|zi,)].  The predicted estimate is then perturbed by repeatedly drawing 
randomly from a distribution whose variance is the sample variance in the group of completers.  
Both analyses will be conducted to examine the similarity of results to the complete case 
analysis.  If the results are consonant, for simplicity, the complete case analysis will be reported 
along with any variations in findings from the described imputation strategies.  
 
  
VII. Study Implementation and logistics 
A. Clinical Center Organizational Structure and Infrastructure  
Each Clinical Center has a set organization structure with clearly defined personnel 
roles, a well-maintained computer infrastructure, and plans to establish numerous mechanisms 
to promote the flow of information between study center sites and the DCC. 
B.  CCC Organizational Structure  
 Dr. Strunk and colleagues at the Washington University in St. Louis, MO has been 
designated as the lead Clinical Center for this grant. Dr. O’Connor at Boston University Medical 
Center and Dr. Zeiger at Kaiser Permanente and University of California at San Diego are the 
PIs of their respective Clinical Centers. Dr. Strunk will schedule and lead regular conference 
calls to discuss the processes of recruiting, adherence, and retention throughout the trial, and 
will report directly to Dr. Weiss at the the DCC.  
Because recruitment of participants will take place in Obstetrics Clinics, it will be crucial 
for each Clinical Center to establish ties and obtain cooperation from their respective Obstetric 
practices. All three centers have working relationships with the Obstetric practices from prior 
recruitment efforts. In the St. Louis Center, Dr. George Macones will support the trial by setting 
into place the system to recruit the pregnant women and obtain the necessary samples of 
peripheral blood during the prenatal visits and peripheral and cord blood at the time of delivery 
as well as obtaining urine to be measured for creatinine and calcium as safety for vitamin 
administration during pregnancy. Dr. Macones will assure that the OB practitioners are engaged 
in the trial and will support enrollment of their patients into the trial. Dr. Linda Heffner, MD, PhD 
(Chair, Dept. of OB and Gyn) and Ms. Margaret Shepherd, CNM (OB Department Manager), will 
fulfill the same roles for the BUMC and Kaiser Permanente San Diego Clinical Centers, 
respectively. 
In each Center, a Research Patient Coordinator will be responsible for recruiting 
pregnant women into the trial at the time of their first visit to the OB offices and retaining them 
during the 4 years of their involvement in the trial.  Specific activities of this Patient Coordinator 
will include but not be limited to: 
• Working with the clerical staff of the OB department to assure that a brochure describing 
the vitamin D trial is included in the materials sent to the pregnant women giving 
information about the first OB visit. 
• Working with the staff at the OB offices to determine when eligible women will have their 
first OB visit and being in the clinic to meet the women to give them information about 
the study, determine their level of interest, perform appropriate screening, give the 
informed consent and arrange a time for discussion of the trial and the consent and 
answer any questions.   
• Make an appointment in the GCRC or the Allergy Research Department for enrollment 
and initiation of the study medication.  The trial will also provide standardized prenatal 
vitamins, which will be initiated at this visit. 
• Remain in contact with the scheduled phone calls and as needed for problem solving 
about taking study medication and the prenatal vitamin. 
• Work with the staff in labor and delivery to establish as system for collection of 
peripheral blood from the mother to be used for assay of vitamin D and the cord blood 
for assay of vitamin D and for use in extraction of DNA to be used in the genetic studies.   
• Visit the now new mother and her baby after delivery to deliver a small gift and further 
develop the relationship that will assure long-term follow-up of the child with the quarterly 
phone calls and annual visits. 
Each Center will also have a second Research Patient Coordinator or Study Nurse who will be a 
partner of the other research patient coordinator in performing all the duties listed to assure 
recruitment and retention of the women and their offspring. 
  
 
C. DCC Organizational Structure and Infrastructure  
The DCC has a set organization structure with clearly defined personnel roles, a well-
maintained computer infrastructure, and plans to establish numerous mechanisms to promote 
the flow of information between study center sites and the DCC. 
 
D. DCC Organizational Structure  
The DCC will be chaired by Dr. Scott Weiss and Dr. Augusto Litonjua, and the statistical 
and informatics component will be managed by Dr. Vincent Carey. The DCC informatics 
operations will be executed by Dr. Carey’s staff, who have an outstanding track record running 
multicenter trials funded by AHRQ and NHLBI since the mid 1990s. Nancy Laranjo will be the 
Senior Data Manager for the trial, and she will be supported by Melissa McEnery, Deputy Data 
Manager, John Ziniti, Senior Programmer, and Shelly Magno, Administrator.  In consultation 
with Dr. Carey, Ms. Laranjo will specify the general communications and data archive workflows 
for the support and programming staff members.  As the design of forms and general data flow 
processes evolves, prototypes and “dry run” exercises will be carried out with the clinical sites to 
verify the soundness and feasibility of the operations plan.  The detailed task sets will be noted 
in the DCC Manual of Operations, which will be available through the internal study web site.  
The DCC will have full staff meetings attended by one of the PIs every month, and basic staff 
meetings every week. In addition, the chairs of the DCC will have a conference call with the PIs 
of the Clinical Centers once a month to obtain updates on recruitment and progress of the trial, 
and discuss any issues that pertain to the conduct of the trial.  
 
 
E. Computing facility and software description 
The clinical centers will be informatically supported by the DCC at the Channing 
Laboratory.  
 
F. Trial Website 
 Each Center’s participants will have access to the trial website. The DCC will establish a 
website with both public and private (SSL regulated, LDAP database of all study investigators or 
support staff needing website access will be established with private passwords) web portals at 
the beginning of the recruitment period. The public pages will provide information on the scope 
and background of study to assist in recruitment. Additionally, centers will be given links to be 
able independently generate and update region-specific (i.e., center directions and contact 
information) pages.  The private pages will allow for general posting of any protocols changes or 
announcements, current versions of forms, minutes of phone calls, manuscripts in development, 
allow investigators to monitor recruitment process, and provide other general information.  
Patient-level treatment information, medical history, or endpoint information will not be linked to 
the website.  The website will be maintained throughout the trial and closeout period, and 
aggregate study findings will be posted at the end of the trial. 
 
G. Data management and tracking 
 Clinical data from screening (first-prenatal visit), each subsequent pre-natal visit, delivery 
day, quarterly follow-up questionnaires, and clinic assessment visits at 1, 2, and 3 years are 
entered on forms at each study center at the time of the patient visit/contact.  The forms will be 
reviewed by the center coordinator, and copies sent weekly to the data monitor at the DCC.  We 
have chosen this method for data entry, as this is easily auditable and cheap. We have the 
capability to set up a web-based data-entry for each Clinical Center, as investigators at the DCC 
have done in their previous projects and we will consider the feasibility and cost of this alternate 
approach.  
  
 Calcium/creatinine ratios will be conducted by the study center laboratory on the day of 
the patient visit. The calcium/creatinine ratios will be reviewed by the laboratory head at each 
center.  Alert values will be established and if reached will lead to immediate contact to the 
Study Coordinator and contact with the participant will be attempted within 24 hours of 
identification.  Blood draws for 25(OH)D levels will be sent from the study center laboratory to 
the DCC on a weekly basis, where they will be logged in and aliquots sent to Heartland Assays, 
Inc for 25(OH)D assays.   
Upon receipt on collected forms, all data forms (lab work and patient questionnaires, 
clinical assessments, etc.) will be double entered at the DCC with range, logic, and missing data 
checks built into the data entry software application.  The data entry software will be configured 
to be schema-driven, so that an abstract schematic design is at the base, and the concrete 
(XML) schema that specifies form content and logic is automatically transformed to a functional 
data entry application.  We currently use Altova XMLSpy and Microsoft InfoPath technologies to 
implement the schema-driven design. Forms with missing (illegible entries will be considered 
missing for the purposes of data entry) and/or inaccurate (i.e. out-of-range) entries will not be 
accepted into the system database, but will be cycled back to the site for correction.  
For clinical data, the data monitor will send weekly reports of missing or inappropriate 
entries to the study project coordinators for clarification and resolution. Additionally, cross-form 
edit checks will be performed on a monthly basis, to detect unresolved problems.  Data 
inconsistencies occurring across forms will be resolved with the assistance of study center staff.  
Standardized edit reports that summarize problems in the database provide an additional 
method of assuring data quality.  To ensure accuracy of patient identification numbers (in 
particular, minimizing transposition error), digit checks will be utilized.  Digit checks will identify 
whether there are inconsistencies in patient identification numbers across collection time points.  
Once data have been verified, data will be archived on a monthly basis as a SAS dataset.  Data 
will be stored in coded form (i.e. numeric coding for ethnicity or gender) using standard 
codebooks currently implemented  
 For each patient, a data collection tracking query will be developed, which will contain 
expected time points for each data form/lab work, based upon patient’s initial enrollment date.  
Forms more than one week late (from enrollment to delivery) or one month late (after delivery to 
year 3) will be flagged as missing, and a query will be generated for each site that contains a list 
of patient IDs and their outstanding forms/lab data.  The data manager at the DCC will follow-up 
with site coordinators to track down any missing forms.  For patients at-risk of dropping out (i.e. 
missed appointment or non-response to questionnaire request), the study coordinator or 
research assistant will make repeated attempts to contact the patient. A subject will be dropped 
only with explicit withdrawal request by the pregnant woman (initially) and later, the parent of the 
infant/child. Even with missed appointments or calls, every effort will be made to complete the 
final in-person visit when the child is 3 yrs old. 
 
H. Data Security and Confidentiality 
All computer files are stored in password-controlled accounts on DCC computers.  There 
will be an SSL regulated private web portal established for the study at the DCC, LDAP 
database of all study investigators or support staff will be established with private passwords 
allocated to all who have a need to examine the study web site 
Each participant will be assigned a unique study identification number.  Once these data 
are linked (after a subject successfully enters randomization phase from screening), the study 
identification number will be the primary identification number. The data coordinating center and 
trial statisticians will not have access to only the unique identification number and therefore 
cannot link names to data. Files of study data will include the screening and study identification 
number but not participant names.  Any hardcopy of data forms obtained by the coordinating 
  
unit (for example, as part of spot-checking for quality control) are will be maintained in locked 
file cabinets.  
At the clinical centers, data are collected on forms with fields for study identification 
number but without a field for the participant’s name. Still, separate lists of participant names, 
identification numbers, and contact information are used during the study to maintain contact 
with participants and eventually to provide feedback on study and personal results.   These lists 
will only be available to Center Co-PIs and staff with direct patient contact.  All hardcopies of 
forms are stored in locked file cabinets. All computer files are password protected.  Participant 
results will only be released to the participant unless he/she provides written approval to release 
data (e.g. laboratory results to personal provider).   Data will be only be presented and 
published in aggregate, i.e. no identifying characteristics of participants will be published or 
presented.   
 
I.  QC protocol 
 To ensure uniform data collection and reporting procedures, training and certification of 
study center research assistants (RAs) will occur at the DCC.  Additionally, there will be a 
weekly conference call between the DCC deputy data manager and the site coordinators at 
each center to globally address any screening or data collection issues and maintain study-wide 
consistency in procedures.  Monthly conference calls will be conducted between the DCC PI 
and all site investigators to check progress and data integrity.    Patient recruitment and follow-
up, as well as data collection and archiving procedures, will be monitored by the DCC with bi-
annual site visits. 20% of the patient questionnaires and lab forms will be randomly sampled and 
queried against stored values in the DCC database and archives. 
 To verify the accuracy of 25(OH)D measurements  obtained by Heartland Assay, Inc., 
20% of the maternal blood samples (obtained at baseline and week 30), as well as maternal 
and cord blood samples at delivery, will also be sent to Dr. Hollis’ lab.  Any discrepant lab 
values will be checked to determine the source of the variation.  If appropriate, a replicate assay 
will be conducted.  Samples will also be obtained from each lot of the Vitamin D supplement 
(4000 IU Vitamin D) and prenatal vitamins (400 IU Vitamin D) and sent to the lab of Dr. Hollis for 
analysis to ensure the level of Vitamin D compound in each is with the range specified in trial 
protocol. 
 The DCC will provide monthly reports on the timeliness, quality and completeness of the 
data to the Steering Committee, organized by type of visit, e.g. screening visit 1, randomization 
day, 6-month visit, etc, and by specific data form.  The Steering Committee will remain informed 
of any potential screening or data collection issues (with patient forms or lab work) and be able 




Until the end of the trial, all investigators, clinical staff and participants are masked to 
trial outcome data, with the exception of the trial statisticians, the data manager, and the Data, 
Safety and Monitoring Committee.  Due to the nature of the intervention, laboratory technicians 
and staff obtaining calcium/creatinine ratios and 25(OH)D levels may be able to infer treatment 
group assignment.   However, 25(OH)D levels will be measured by Heartland Assays, Inc. in 
Ames, IA, and results of these assays will be sent only to the DCC.    Therefore, we do not 
anticipate any issues with unintentional unblinding of study investigators or clinical staff through 
routine contact between Heartland Assays and study sites.  For quality control purposes, 20% of 
the blood samples will also be sent to Dr. Hollis’ lab for 25(OH)D measurement.  However, we 
will adhere to established procedures to maintain separation between laboratory staff and 
clinical staff that have patient contact.  For quality assurance, Dr. Hollis will receive a report of 
  
measured 25(OH)D levels that are stripped of all identifying patient information (identifier and 
clinical information).   
  To ensure rapid intervention in the unexpected event of out-of-range (≥1.0 mmol/mmol) 
calcium/creatinine ratios, urinary calcium and creatinine measurement will be conducted at each 
Clinical Center’s Clinical Chemistry Laboratory.  Again, we will adhere to established 
procedures to maintain separation between laboratory staff and clinical staff that have patient 
contact or are responsible for measuring primary or secondary endpoint outcomes.  In the event 
of an out-of-range calcium/creatinine ratio, the Center Primary Investigator will be unblinded, the 
patient will be contacted for follow-up, and the DCC and NIH project officer will be notified. 
Given the benign treatment intervention, the manufacturing of prenatal vitamins, placebo 
and Vitamin D supplement by the same drug company (Tishcon Corp), the distribution of study 
vitamins by the DCC, off-site assays of 25(OH)D levels, protocols to maintain separation 
between information available to laboratory staff, trial statisticians, the DCC, and site clinical 
staff and investigators, we anticipate that we will successfully maintain blinding of all 
investigators, clinical staff and participants to both treatment intervention and trial outcome until 
the end of the trial.   
 
K. Data Safety and Monitoring of Each Subject 
An external Data Safety and Monitoring Committee (DSMC), composed of a vitamin D 
metabolism expert, an early life asthma epidemiologist, and a statistician will be appointed.  The 
committee will be convened prior to study initiation to review the protocol and to examine and 
comment upon “shell” reports that will be used to illustrate data accumulation as the study 
proceeds.  The DSMC will determine the frequency and venue of study review meetings; we 
propose that reviews will occur as the enrollment process hits 50% and 100% of goal, and when 
the median follow-up times for enrolled patients hit 24, and 36 months.  It may be possible to 
consolidate meetings if these events are close to coincident.  Because the treatment is known to 
be benign, we propose that conference calls will be an adequate approach to DSMC meetings. 
All study subjects will be monitored for hypervitaminosis D. Operationally, we will define 
caution by urinary calcium/creatinine ratio ≥ 1.0 mmol/mmol from the samples that are obtained 
monthly starting 1 month after randomization. Whenever any patient exceeds the caution limit, 
the study medication will be temporally discontinued and a specific case study will be initiated to 
examine the contribution of confounding factors (e.g. possibility of volume restriction, diet with 
excessive vitamin D intake, sunlight exposure, other over the counter pills, etc.). A serum 
vitamin D level will also be obtained.  If a basis for an elevated urinary calcium/creatinine cannot 
be determined and/or if the serum vitamin D level is >120 ng/ml, the study medicine will be 
stopped and the woman will be followed in the intention-to-treat paradigm.. The appropriate IRB 
will be notified, and the NIH and FDA will be notified per their protocols. The DSMB will be 
convened via fax and teleconference to review any subject who exceeds these predefined 
hypervitaminosis D limits. After the detailed case review has been performed by the clinical 
center to ascertain the cause of the hypervitaminosis D in the subject and reviewed by the 
DSMB to make an informed decision about the study’s continuation. If the elevated levels in the 
subject are attributed to the vitamin D supplement, the subject will be withdrawn from 
supplementation but will continue to be monitored.  
 
L. Interim Analyses 
For the primary aim of asthma and recurrent wheeze, we have developed an interim 
analysis plan to monitor this composite endpoint over the three years of subject follow-up.  This 
sequential monitoring plan consists of two interim analyses (conducted at year 3 month 12 or 
when all first year study visit data are available and year 4 month 12/when all first and second 
year visit data are available), and a final analysis at the end of year 5, when the three-year 
follow-up has been completed on all subjects.  For maximum flexibility in the analysis, we will 
  
use a Lan-Demets alpha spending function72 with O’Brien-Fleming bounds.  For our group 
sequential design, we plan to use a Lan-Demets spending function with three equally spaced 
looks (with respect to the amount of information collected) and O’Brien-Fleming type bounds. 
The software program LANDEM (http://www.biostat.wisc.edu/landemets/)73 was used to 
calculate the stopping boundar, which were |z|=3.7103, 2.5114, and 1.993 at the first, second, 
and third looks, respectively. The hypothesis tests are conducted with two-sided alternatives 
(i.e. a two-sided p-value), The power reflects the proportion of replicates where the Wald test 
statistic from the hypothesis test of β1=0 is less than the stopping boundary specified for the 
first, second, or third looks, where β1 is the coefficient for Vitamin D supplementation status.  
The replication is considered a ‘success’ if the stopping boundary is exceeded at any of the 
analysis times. In the simulations, the incidence of asthma and/or recurrent wheeze at the first 
and second interim looks is proportionate to the overall incidence expected at the end of the 
study period (i.e. at the first look, the incidence is one-third of the specified rate; at the second 
look, it is two-thirds).  We do not expect incidence rates of 40-50% to be achieved until the third 
year of follow-up; therefore, the simulations reflect the approximate amount of information 
anticipated at each interim analysis. Only the primary endpoint of asthma and/or recurrent 
wheeze will be monitored sequentially.  If the boundaries are crossed at either the first or 
second year analyses, results will be immediately reported and the study will be stopped.   
 
M. Adverse Events. There are expected Adverse Events that occur with pregnancy, and they 
include pre-eclampsia, perinatal infections, anemia, prolonged rupture of the membranes and 
preterm labor, abnormal labor, and meconium staining. For the fetus/infant, Adverse Events 
include preterm delivery with birthweight <1500g, NICU admissions, hypoglycemia, and fetal 
abnormalities. If a serious Adverse Event occurs, the IRB and NIH will be notified in a timely 
manner. The mother’s blood work will be reviewed and if there are abnormal levels of vitamin D 
or of urinary Ca/Cr, the DSMC will be notified. The DSMC will have access to the vitamin D 
dose to which each subject has been randomized. In the event of intrauterine/fetal death or 
perinatal death, information regarding the complications of the pregnancy, the events that led up 
to the fetal or perinatal death, and whether fetal anomalies were present will be recorded. 
Maternal vitamin D/calcium parameters will be measured within 24 hours after delivery, and the 
DSMC, IRBs, NIH, and FDA will be notified. It should be reiterated that vitamin D 4,000 IU/day 
has not been linked with any of these adverse events. 
 
VIII. HUMAN SUBJECTS RESEARCH 
Protection of Human Subjects 
Risks to the Subjects 
Human Subjects Involvement and Characteristics: For this project, we will be conducting a 
clinical trial of “high dose” vitamin D supplementation vs. “usual dose” prenatal vitamins in 
pregnant women for the prevention of asthma and allergies in the women’s offspring at 3 years 
of age. We propose to randomize 720 pregnant women during their 1st trimester with 360 
women to the “high dose” arm and 360 women to the usual care arm, follow them through their 
pregnancy and delivery, and follow the women and their offspring until the 3rd birthday of the 
children in the expectation to evaluate at least 600 three year olds. A brief study description and 
a copy of the consent form will be given to pregnant women receiving their care at 3 Clinical 
Centers (Boston, St. Louis, and San Diego) at their first prenatal visit (between 8 and 16 weeks 
gestation). Women interested in the study will be invited to a separate visit for more detailed 
explanation and providing informed consent. There are several reasons for this separate visit: 1) 
allow the pregnant women to review the informed consent, and 2) to assure as much as 
possible the dedication of the women to participation in the study until the 3rd birthday of their 
child. Pregnant women will be selected on the basis of an age >18 years but <35 years, ability 
to speak English or Spanish, intention to participate in the trial for the full 4 years, no pre-
  
existing type 1 or type 2 diabetes mellitus, hypertension, and parathyroid or uncontrolled thyroid 
disease. Written informed consent (in English or Spanish, according to individual preferences) 
will be obtained from each subject by study coordinators at each Clinical Center prior to 
voluntary participation. Participating women will be followed during the remainder of their 
pregnancy, and their newborns will be followed after delivery. 
Sources of Research Material: Data from questionnaires, maternal (labor and delivery) and 
neonatal medical records will be used for research purposes only. Peripheral blood will be 
obtained from the mothers at a prenatal visit, 14 weeks after enrollment, and at delivery for 
measurement of vitamin D levels. Cord blood will be obtained from the research subjects to be 
used by the investigators for measurement of vitamin D levels and storage of white cell pellets 
for future genetic studies. Peripheral blood will be obtained from the children to be used by the 
investigators for measurement of vitamin D levels at 1 yr and 3yrs and total and allergen-
specific IgE in the child at 3 yrs. These blood samples will be used by the investigators for 
research purposes only; the results will be kept strictly confidential. With parental permission, 
results of measurements of serum total and allergen-specific IgE at age 3 years will be sent to 
the child’s primary care physician.  
The major risk involved with vitamin D toxicity is hypercalcemia, which can be detected 
by measurement in serum or by calcium excretion in urine. Based on Dr. Hollis’ extensive 
review of the literature and his experience with his current vitamin D supplementation in 
pregnancy trial, vitamin D supplementation of 4,400 IU/day throughout pregnancy is safe. 
Nevertheless, we will be monitoring urine calcium-to-creatinine ratios as a measure to calcium 
excretion in the urine each time the mothers come for their prenatal visits. This method of 
monitoring was chosen because it is reliable and does not require phlebotomy.  
Another risk of participation in this study is the social-psychological risk resulting from 
inadvertent disclosure of medical history information. This potential risk is guarded against by 
storage of completed questionnaires in a locked filing system and by labeling other 
phenotypic/genotypic data using ID numbers only. In certain instances, the funding agency for 
this grant may require posting of data for sharing with outside researchers. In these instances, 
these researchers will be asked to sign a statement of confidentiality before being allowed 
access to the data. In addition, no personal identifiers will be included in datasets that will be 
shared with outside researchers. 
The only potential risks of blood drawing are hematoma and infection at the skin site, 
minimal pain of venous puncture, uncommonly fainting reactions, and additionally discomfort 
and crying from the child. 
Adequacy of Protection against Risks 
Recruitment of Subjects and Informed Consent: Subjects will be recruited voluntarily from 
those meeting entry criteria. Written consent will be obtained from participating women before 
randomization, collection of questionnaire data, extraction of information from maternal (labor 
and delivery) and neonatal records, and samples of cord blood and peripheral blood. Subjects 
are under no obligation to participate. All signed consent forms are copied times three, one 
placed in the patient’s research file and a second in a common consent form folder for the 
study and a copy given to the patient. The consenting process is an ongoing process and 
participants will be informed of important new developments that relate importantly to the safety 
of the study. In addition at each follow-up visit study procedures and requirements are reviewed. 
Protection against Risks: To monitor for the rare potential for Vitamin D toxicity urine samples 
will be evaluated for Calcium/Creatinine at each clinical prenatal visit and for Vitamin D levels at 
the prenatal research visit 14 weeks post-randomization. Should levels of Calcium/Creatinine 
exceed 1.0 mmol/mmol or Vitamin D levels exceed 200 nmol, a specific case study will be 
initiated to examine the contribution of confounding factors (e.g. diet, sunlight exposure, other 
over the counter pills, etc.). The appropriate IRB will be notified, and the NIH and FDA will be 
notified per their protocols. The DSMC will be convened via fax and teleconference to review 
  
any subject who exceeds these predefined hypervitaminosis D limits. A detailed case review will 
be performed by the DSMC to ascertain the cause of the hypervitaminosis D in the subject and 
to make an informed decision about the study’s continuation. If the elevated levels in the subject 
are attributed to the vitamin D supplement, the subject will be withdrawn from supplementation 
but will continue to be monitored. As noted above, steps will be taken to ensure that study 
information remains confidential. As we have mentioned in the background section, there have 
been no reported adverse effects on the fetus due to vitamin D supplementation. By monitoring 
the urinary calcium/creatinine ratio in the pregnant mothers and ensuring that the vitamin D 
levels do not exceed 200 nmol, the risks to the fetus will be minimized. The discomforts 
associated with blood drawing are minimal. Phlebotomy will be performed by licensed 
phlebotomists or research assistants that are adequately trained for blood drawing in infants. 
For maternal samples, we will minimize blood draws by piggybacking the collection at delivery 
with the blood draw for clinical purposes. 
Potential Benefit to Individual Subjects and Society: For the participating mothers, a direct 
benefit will be close monitoring, and thus better adherence, of prenatal vitamin intake, which has 
already established benefits for fetal wellbeing. Additionally, even for those women in the 
placebo group, they will be receiving 400 IU of vitamin D per day in the prenatal vitamin that the 
study will be supplying for free. This 400 IU dose is twice that of the current AI 
recommendations of the IOM. The prenatal vitamins will be provided free of charge to all 
participants in the trial. The benefits of vitamin D on several outcomes related to bone health are 
well-documented74. In addition, there is emerging evidence that vitamin D may aid in combating 
infections, through its effects on innate immunity75, 76. This mechanism may also apply with 
infections during pregnancy77. Thus, mothers in the intervention arm will get the potential 
benefits of improved bone health and of a decrease in clinically significant infections.  
For infants in the trial, a potential benefit is the close monitoring for the development of 
asthma and allergies. Additionally, we will offer 400 IU/day of vitamin D to all the infants who 
consume less than 1000 ml of formula per day, according to the recommendations of the 
American Academy of Pediatrics. This include all children who are breastfed, either partially or 
exclusively and all formula-fed infants until they consume at least 1000 ml of formula per day. 
These vitamin D supplements will be provided free of charge to the infants in the trial.  
The potential benefit to society is significant if the trial shows a decrease in the 
prevalence of asthma, wheezing illnesses, and allergies at 3 years of age. Allergic diseases 
such as asthma are a major public health problem in the U.S. Since the risks involved in the 
protocol are small and the societal benefits are potentially large, the risk-benefit ratio is strongly 
on the side of benefit. 
Importance of the Knowledge to Be Gained: 
As previously stated, the main potential benefit of this research proposal is that it may lead to 
public health interventions that could lead to a decrease of up to 50% of the asthma prevalence 
worldwide, and may contribute to our understanding of the pathogenesis of allergic diseases 
such as asthma. While there are individual risks involved in this project, we will institute 
mechanisms to minimize these risks. Thus, because of the potentially great societal benefit, the 
individual risks are reasonable 
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DETAILED PROTOCOL  
“Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma” 
Acronym: VDAART (Vitamin D Antenatal Asthma Reduction Trial 
 
I. Background and Significance  
 Asthma is one of the leading causes of morbidity in children with 90% of all cases 
diagnosed by age 61, 2. It remains the most common chronic disease of childhood in the world3, 
4, and incurs significant healthcare costs5, 6. The burden of the disease in both the developed 
and the developing world is significant and increasing rapidly with over 300 million people 
affected worldwide. Thus, preventing the development of this disorder would be of great public 
health importance. 
Vitamin D deficiency has been documented in many populations worldwide7, 8, and has 
been reported in healthy children, young adults (especially African Americans), and middle-aged 
and elderly adults7, 8. Vitamin D deficiency has occurred despite fortification of foods in some 
countries and despite intake of multivitamins containing vitamin D. This suggests that as 
countries adopt a western lifestyle, there is shift from outdoor activities to more time spent 
indoors. For example, it is estimated that in the US alone, Americans spend an average of 93% 
of their time indoors9. Relevant to this study, pregnant and lactating mothers and their 
neonates are at especially high risk for vitamin D deficiency10-13. Preliminary data from 
ongoing clinical trials show that many infants whose mothers are not being supplemented with 
sufficient doses of vitamin D have circulating 25(OH)D levels in the “insufficient” range (defined 
as levels between 25 - 62.5 nmol/L)14. Furthermore, it has recently been documented that 50% 
of mothers and 65% of their newborn infants from an inner city hospital were vitamin D deficient, 
with levels <30 nmol/L15, despite the fact that most mothers were taking their prenatal vitamins. 
This analysis also showed a strong positive correlation between maternal and newborn plasma 
levels, providing further evidence that infant vitamin D status is dependent on maternal vitamin 
D status. These results are similar to other recent reports that show a high prevalence of vitamin 
D deficiency in pregnant women and their newborns, even in some sun replete areas of the 
world. The prevalence of deficiency (defined as 25(OH)D levels < 25 nmol/L among pregnant 
women in these studies were: 80% in Iran16, 42% in Northern India17, 61% in New Zealand18, 
and 60-84% among non-Western women in the Netherlands19. 
The importance of vitamin D deficiency in pregnancy in relation to asthma development 
is that it has many recognized effects in on the developing lung and immune system. Nguyen 
and coworkers, through a series of studies in fetal rat lung, have identified the type II alveolar 
cells as a target for 1,25(OH)2D3 action. Firstly, they identified specific binding sites (vitamin D 
receptors) for 1,25(OH)2D3 that are distinguishable at a time corresponding to the start of type II 
pneumocyte differentiation and onset of surfactant secretion20. Next, with the use of monoclonal 
antibodies, they localized these vitamin D receptors to type II pneumocytes21.Thirdly, in 
explanted fetal rat lung tissue, they showed that 1,25(OH)2D3 accelerated the decrease in type II 
cells glycogen content and increased surfactant synthesis and surfactant secretion22, 23. Vitamin 
D was about half as potent as an equivalent dose of dexamethasone in stimulating surfactant 
synthesis and secretion. They also showed that a paracrine system for vitamin D is present in 
rat fetal lung and function during the last 3 days of pregnancy21, and that some of the effects of 
vitamin D may be mediated by fructose 1,6 biphosphatase, whose gene contains a vitamin D 
response element in the promoter region24. These recent observations strongly suggest that 
vitamin D plays a role in lung maturation late in pregnancy, and support earlier 
observations such as the association of respiratory distress in vitamin D deficient 
preterm infants (“rachitic respiratory distress”)25. In humans, the effect of vitamin D on 
surfactant production has been confirmed26, although the mechanisms appear to be 
more complex than in the rat27. 
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Aside from effects on type II pneumocytes and surfactant production, vitamin D also 
appears to have effects on lung growth and development. Gaultier et al28 studied lung 
mechanics in 50-day old rats born to mothers deprived of dietary vitamin D and reported 
significantly decreased lung compliance compared with rats born to mothers whose diet was 
supplemented with vitamin D, suggesting that disturbances in lung growth occurred in the 
vitamin D deficient rats. In humans, vitamin D also has been shown to play a role in the 
developing lung. Early studies used the presence of calbindin, a vitamin D dependent calcium 
binding protein, as a molecular marker of 1,25(OH)2D3 action in tissues. Among many other 
tissues, Brun et al29 reported high levels of calbindin in human fetal lung tissue at 14-32 weeks 
of gestation, suggesting that vitamin D plays a role in fetal lung development, as early as 14 
weeks. Lunghi and colleagues30 obtained normal human fetal (16 weeks gestation) lung 
fibroblasts and reported that in the presence of vitamin D, pyruvate kinase activity and lactate 
production of the cells increased. Other findings included a decrease in cell number and DNA 
synthesis in the vitamin D exposed cells compared with control cells. Subsequently, they 
showed that the vitamin D receptor was present in these human fetal fibroblasts31 and 
confirmed their original findings in fetal lung fibroblasts in a subsequent study on senescent 
human lung fibroblasts32. Thus, these animal and human tissue studies show that later in 
pregnancy, vitamin D stimulates lung maturation and surfactant production and 
secretion. Additionally, the data shows that at various points in fetal development, as 
early as 14 weeks of gestation, vitamin D has a regulatory role in fetal lung growth and 
development. 
We have recently shown in two independent birth cohorts that higher maternal intakes 
during pregnancy of vitamin D from both foods and supplements were associated with an 
almost 60% reduction of asthma and recurrent wheezing in 3-5 yr old children33, 34.  
There is also evidence that vitamin D affects immune system development and function. 
The fetal immune system begins to develop early in gestation35. In humans, pre-B and pre-T 
cells arise by 8 weeks gestation, predominantly in the fetal liver. The thymus begins to develop 
at 6 weeks gestation, the spleen and lymph nodes later, and the gut-associated lymphoid tissue 
later still. These organs, however, continue to grow and develop for many years after birth. 
Vitamin D receptors (VDR)36, 37 and vitamin D metabolic enzymes7, 38 have been identified in 
many other tissues aside from bone and the intestine, suggesting involvement in the 
metabolism and function of many cell types. Specifically, VDR is expressed in cells of the 
immune system, such as T39, activated B cells40, and dendritic cells41. Evidence exists that 
vitamin D may induce a shift in the balance between Th1 and Th2-type cytokines toward Th2 
dominance42, 43. Reduced secretion of Th1 cytokines IL-2 and IFN-γ43-45 and an increase in the 
Th2 cytokine IL446, 47 have been observed in several experiments after treatment with 
1,24(OH)2D. These studies, however, did not investigate the developing fetal immune 
system. Evans, et al48 showed that human decidual cells are able to synthesize active 
1,25(OH)(2)D(3), particularly in early gestation (first trimester), and this may act in an 
autocrine/paracrine fashion to regulate both acquired and innate immune responses at the fetal-
maternal interface. More directly, Pichler et al.49, 50 showed that in CD4+ as well as CD8+ 
human cord blood cells, vitamin D inhibits not only IL-12-generated IFN-γ production, but also 
suppresses IL-4, and IL-4-induced expression of IL-13, thus, confirming that in the neonate, 
vitamin D regulates immune responses and contributes to the development of the 
immune system. The differences between the studies on the Th1-Th2 dominance lie in part, in 
the timing of vitamin D exposure of the cells to vitamin D (i.e. prenatal vs. postnatal). Thus, the 
response of “naïve” T-cells to vitamin D exposure may differ from that of mature cells when 
exposed to vitamin D50. In children with established asthma, we have recently shown that 
vitamin D levels were inversely associated with total IgE levels and with eosinophil count51. 
Others have also shown a relationship between vitamin D levels and total serum IgE in adults52. 
In addition, small trials have shown an effect of vitamin D on eczema. In one trial exposure to 
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tropical sunlight (presumably increasing vitamin D levels)53 and in another vitamin D 
supplementation have been shown to lead  to improvement in atopic eczema54. 
Aside from the effects of vitamin D on Th1 and Th2 responses, there is a growing 
recognition that it promotes the induction of T-reg cells55-57 . The characteristic features of Treg 
cells include the expression of potentially inhibitory cytokines (IL10 and TGFβ), and the ability to 
potently inhibit antigen-specific T cell activation58, 59. These effects of vitamin D on the immune 
system underlie the regulator role of vitamin D and are thought to be orchestrated by an array of 
intracellular signaling pathways in lymphocytes and antigen-presenting cells of which Il10 and 
TGFβ are the most important (reviewed in Griffin et al.60). These pathways lead to either over- 
or under-expression of genes. For example, vitamin D has been shown to modify levels or 
function of NF-κB proteins such as Rel-B and c-Rel.61-63 Additionally, there is recent evidence 
that vitamin D regulates many genes that have been associated with asthma64. Finally, vitamin 
D-dependent binding of vitamin D receptor (VDR) complexes directly to promoter regions of 
activation-induced genes in T lymphocytes has been shown65.  
 
 
II. Hypothesis and Specific Aims 
 Our hypothesis is that supplementing pregnant women with sufficient vitamin D will 
decrease the incidence of allergies, asthma and wheezing illnesses in children. The initial basis 
for this hypothesis is our finding in two separate birth cohorts of the protective effect of vitamin D 
intake on wheezing illnesses in 3-5 yr old children. Our birth cohort studies are consistent with 
data from studies that have investigated animal fetal models and human fetal lung tissue that 
show that (1) vitamin D receptors are present in the fetal lung, (2) vitamin D enhances lung 
maturation in the last stages of pregnancy, (3) vitamin D controls growth and development of 
the fetal lung, and (4) profile of human cord blood cell response to antigens is affected by 
vitamin D. Finally, there is a large amount of literature that shows that there is a high prevalence 
of vitamin D deficiency among women of child-bearing age and in pregnant women, such that 
infants are being born deficient in vitamin D. Furthermore, in both our birth cohorts, vitamin D 
intake in the first year of life and in childhood did not modify the association of maternal vitamin 
D intakes with any of the wheeze outcomes. Additionally, there is experimental data that vitamin 
D affects the development of the neonatal immune system. Taken together, these data strongly 
suggest that the right time to intervene is during pregnancy. Therefore, we propose a two-arm, 
randomized, double-blind, placebo-controlled, multi-center clinical trial to determine whether 
vitamin D supplementation in the pregnant mother will prevent asthma and allergy at age 3. We 
will utilize asthma/recurrent wheezing as our primary end point and allergy and lower respiratory 
infection as secondary end points. We will recruit 870 pregnant women during the first trimester 
of pregnancy and randomize them to one of two treatment arms of a 5-year clinical trial: the 
addition of 4000 IU daily of vitamin D to usual pregnancy vitamin D supplementation (daily 
prenatal vitamins with 400 IU vitamin D; total dose in the intervention arm of 4,400 IU/day) in the 
treatment group compared with placebo plus usual vitamin D supplementation (daily prenatal 
vitamins with 400 IU vitamin D) in the control group. Because we expect an 8% rate of 
miscarriages and stillbirths, and about 18% withdrawals or loss to follow-up, we expect that we 
will have 660 children (330 in each arm) for analysis of the primary outcome at 3 years of age.  
 
Our primary aims are: 
 
1. To determine whether vitamin D supplementation in the pregnant mother is associated with 
reduced incidence of asthma in the child during the first 3 years of life. Our primary 
outcomes will be doctor’s diagnosis of asthma and/or recurrent wheeze in the child  
at age 3 years. 
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2. To determine whether a vitamin D dose of 4,400 IU per day vs. the standard 400 IU/day in 
pregnancy is sufficient to maintain mothers’ vitamin D levels in the range of ≥ 75 nmol/L 
25(OH)D. 
 
In addition to our primary aims, we have the following secondary aims of the trial: 
3. To determine whether vitamin D supplementation in the pregnant mother is associated with 
reduced secondary outcomes in the neonate of cord blood total IgE, and reduced secondary 
outcomes in the 3-yr old child of (a) allergic sensitization (total and specific IgE), (b) 
eosinophil count, (c) doctor’s diagnosis of eczema and (d) lower respiratory tract infections.  
  
4. To determine whether vitamin D supplementation in the pregnant mother is associated with 
improved vitamin D status in their offspring through measurement of 25(OH)D levels in cord 
blood (at delivery), and children’s blood (at 1 and 3 yrs of age). 
 
5. To determine whether sufficient vitamin D supplementation in the pregnant mother is 
associated with reduced incidence of preterm birth (birth <37 weeks gestation), 
preeclampsia, gestational hypertension, and/or Hemolytic anemia, Elevated Liver enzymes, 




III. Vitamin D supplementation: safety considerations.  
The current adequate intake (AI) for pregnant and lactating women is 200 IU/day 
(although most prenatal vitamins contain 400 IU vitamin D). However, multiple studies have 
shown that these current recommendations result in a high degree of vitamin D deficiency in 
different adult populations66-68. One recent study supplemented 160 minority women in the UK 
with 800-1600 IU/day vitamin D throughout their pregnancies68. The investigators found a mean 
increase in circulating 25(OH)D concentrations from 14.5 ± 2.2 nmol/L at the beginning of 
pregnancy to 28 ± 16 nmol/L at term after vitamin D supplementation. Therefore, mothers who 
were deficient at the beginning of their pregnancy were still deficient at the end of their 
pregnancy after supplementation, despite supplementation with a higher than recommended 
dose of vitamin D. A more recent study has supported these findings. Talwar et al 69 studied 208 
postmenopausal African American women over 3 years. Their results showed that a dose of 
2,000 IU/day raised 25(OH)D levels to 75 nmol/L in only 60% of the participants. This finding is 
relevant because pregnant women have greater vitamin D requirements (due to the growing 
fetus) than postmenopausal women. The results of these studies point out that the AI for vitamin 
D during pregnancy is grossly inadequate.  Given that a single minimal erythemic dose 
(MED) exposure (for a Caucasian individual, this is approximated by ~10-12 minutes of 
peak summer sun exposure) will release ~10,000 – 20,000 IU vitamin D into the circulation 
within 24 hours70, the dose of vitamin D supplementation required to maintain adequate 
vitamin D status in adults is likely to be orders of magnitude greater than the current AI. 
The safety of giving “large” (relative to current AI, but not to normal responses to sun 
exposure) doses of vitamin D and the potential risk of vitamin D toxicity are valid concerns. The 
exact amount of vitamin D required to induce toxicity in humans is unknown. The safe Tolerable 
Upper Intake Level (UL) for vitamin D was set at 2,000 IU/day by the Food and Nutrition Board 
(FNB)71 in 1997. However, this recommendation was not based on current evidence, and is 
viewed by many as being too restrictive. Vieth72 estimates that the physiologic limit for daily 
vitamin D intake is 10,000 – 20,000 IU/day, and toxicity has never occurred when physiologic 
amounts are ingested. The data on safety of vitamin D supplementation in physiologic doses 
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and animal models of toxicity have been extensively reviewed by Dr. Hollis, who is a co-
investigator on this proposal10. In this review, several studies of high-dose vitamin D 
supplementation (ranging from 400 IU/day to 10,000 IU/day) conducted in healthy adults and 
pregnant and lactating women were noted, and these studies are summarized in Table 1. It is 
noteworthy that none of these studies have reported adverse outcomes due to supplementation. 
Supporting the notion that high-dose supplementation is safe, Hathcock and co-workers73 
reviewed new evidence in addition to the evidence reviewed by Dr. Hollis in 2004, and applying 
the risk assessment methodology used by the FNB, concluded that the absence of toxicity in 
trials conducted on healthy adults supported the selection of 10,000 IU/day as the new daily UL 
for vitamin D. We should note here that we are proposing a dose that is less than half of this. 
Furthermore, as noted above, Dr. Hollis’ group is conducting a Phase 3 trial of vitamin D 
supplementation of up to 4,400 IU/day during pregnancy (4,000 IU/day + prenatal vitamins)  
(http://clinicaltrials.gov; RO1 HD 043921). Dr Wagner (Dr. Hollis’ co-investigator) has 
generously supplied us the October, 2008 Data Safety Monitoring Committee (DSMC) report for 
their trial. To date 347 women have completed the study and have delivered their babies 
and no episodes of vitamin D toxicity have occurred in the women, nor have adverse 
reactions been found in the fetuses or infants. The rates of spontaneous abortions, or 
other pregnancy related complications such as prematurity, have not increased in the 
vitamin D supplemented arms. Indeed in these subjects followed for 3123 person months 
of follow up, a total of 92 “adverse events” have been reported to the trial’s DSMC. These 
events included diabetes (n=18), preeclampsia (n=5), gestational diabetes (n=17), 
hypertension (n=14), preterm labor (n=29), premature rupture of membranes (n=1), deep 
vein thrombosis (n=2), maternal infection (n=6), and placental abnormality (n=1). In 
detailed reviews, none of these pregnancy complications were attributed to vitamin D 
supplementation. Additionally, no neonatal physical abnormalities were detected on 
examination (C. Wagner, personal communication). Therefore, the administration of 4,400 
IU/day of vitamin D to pregnant women is safe. Dr. Hollis holds an IND with the FDA for safety 
of vitamin D supplementation in pregnancy (IND 66,346). He has shown that this dose is 
appropriate to bring levels in all of the women, regardless of race/ethnicity, to sufficient levels. 
Furthermore, the 4,400 IU/day dose eliminated all seasonal variation in 25(OH)D levels, which 
lower doses did not. His trials and data from others show that this dose is safe and not 
associated with any adverse effects in the mother or in the fetus/infant. This protocol will be 
covered under Dr. Hollis’ IND.  
Dr. Hollis’ trial has also generated more preliminary data regarding the response to the 
various doses of vitamin D. Figure 1 shows the response to varying doses of vitamin D in 
pregnant women from 3 ethnic groups: Caucasian (n=38 in Control group; n=37 in 2,400 IU, and 
n=39 in 4,400 IU), African American (n=24 in Control; n=35 in 2,400 IU; and n=26 in 4,400 IU), 
and Hispanic (n=45 in Control; n=48 in 2,000 IU; and n=44 in 4,000 IU). Baseline 25(OH)D 
levels varied by ethnic group, with African Americans having the lowest levels and Caucasians 
having the highest baseline levels. The 2400 IU/day dose raised the circulating 25(OH)D levels 
to a mean of about 95 nmol/L, and only approximately 60% achieved levels of >75 nmol/L. The 
4400 IU/day dose most rapidly and consistently increased 25(OH)D levels in the participants 
from all ethnic groups, with a mean of about 112 nmol/L, and practically all participants achieved 
levels of at least 75 nmol/L. Additionally, the 4400 IU/day dose eliminated all seasonal variation 
in circulating 25(OH)D levels. There were no instances of adverse events from the 4000 IU/day 
dose, either in the mother or the infant, even in those mothers whose beginning 25(OH)D levels 
were > 75 nmol/L. Thus, 4400 IU/day of vitamin D was the dose that achieved sufficient 
supplementation in the pregnant women. The preliminary results and experience from Dr. 
Hollis’ clinical trials have provided valuable information for our current proposal, 
regarding the dosing and safety of vitamin D supplementation in pregnancy.   
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TABLE 1. Summary of published high-dose vitamin D supplementation studies in healthy adults and 
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1,000 3 32±105 65±17.5 +32 
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* 25(OH)D, 25-hydroxyvitamin D. 
† Sunlight exposure was not discussed in the studies by Brooke et al, Cockburn et al, Delvin et al, Mallet et al, and Datta et al. 
Minimal sunlight exposure was controlled for in the studies by Ala-Houhala, Vieth et al, Heaney et al, and Hollis and Wagner. 
‡ It is likely that the wrong dose was reported. The response observed is one that would be expected after supplementation with 
10,000 IU/d for 3 mos. 
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IV. Study Overview and Subject Selection 
This is a multicenter, randomized, double-blind, controlled clinical trial that compares 
high-dose vitamin D3 supplementation (4,400 IU/day) vs. usual dose vitamin D3 supplementation 
(400 IU/day) in pregnancy to prevent asthma in the women’s children. The study base will be all 
pregnant women from each Clinical Center who have a personal history of asthma and/or 
allergies or a history of asthma and/or allergies in the biologic father of the child (i.e. a “high risk” 
cohort for asthma and allergies in the child). Eight hundred seventy women (435 in each arm) 
will be followed through their pregnancy and delivery, and their infants will be followed up to the 
age of 3 yrs. All infants who are consuming < 1000 ml of formula per day will be offered vitamin 
D supplementation (400 IU/day) in accordance with the most recent recommendations from the 
American Academy of Pediatrics82. This includes all infants who are breastfed, either partially or 
exclusively, and all formula-fed infants until they consume at least 1000 ml of formula. The 
primary outcomes are doctor-diagnosis of asthma and recurrent wheezing at age 3 yrs. Due to 
dropouts from miscarriages, stillbirths, other pregnancy complications, and loss-to-follow-up, we 
expect that we will be left with 660 3-yr old children (330 in each arm) for the analyses of the 
primary outcome (see Specific Aims in Section II above).  
Women who come into their Obstetrician’s clinics for their first pre-natal visit will be 
screened on a daily basis by a Study Coordinator and a physician co-investigator will verify 
eligibility criteria. 
 
Inclusion Criteria (applied to the pregnant women) 
• Personal history of asthma, eczema, allergic rhinitis or a history of asthma, eczema, 
allergic rhinitis in the biological father of the child 
• Gestational age between 10 and 18  weeks at the time of randomization 
• Maternal age between 18 and 39 years 
• Not a current smoker (defined as not having smoked for at least 1 month prior to 
enrollment) and not a user of other nicotine products (e.g. nicotine patch) for at least 1 
month prior to enrollment 
• English- or Spanish-speaking 
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• Intent to participate for the full 4 years (through pregnancy and then until the 3rd birthday 
of the child) 
 
Exclusion Criteria 
• Not meeting Inclusion Criteria 
• Gestational age >18 weeks  
• Presence of chronic medical conditions: (i) Hypertension on medications, (ii) Type 1 or 
type 2 diabetes mellitus, (iii) Parathyroid disease, (iv) Uncontrolled thyroid disease, v) 
kidney stones, and (vi) Sarcoidosis 
• Taking vitamin D supplements containing > 2,000 IU/day of vitamin D3 
• Multiple gestation pregnancy (i.e. twins, triplets, etc.)  
• Pregnancy achieved by assisted reproduction techniques (e.g. IUI, IVF) 
• Current use of illicit drugs (defined as any use in the past 6 months prior to enrollment) 
• previously enrolled in this study for a prior pregnancy 
• Any major fetal anomalies detected prior to delivery 
• Any condition, in the opinion of the Principal Investigator, that would inhibit compliance 
with the study medications or inhibit long-term participation in the trial 
• Patient health questionnaire depression scale >/=15 
 
Both arms of the study will get prenatal multivitamins which contain 400 IU vitamin D. Additional 
supplementation will occur in a double blind placebo controlled fashion with one arm receiving 
an additional 4000 IU of vitamin D (total vitamin D 4400 IU daily), and the other arm receiving a 
matching placebo. We will not exclude subjects who have “normal” levels at the beginning of the 
trial, since many studies have now documented that a large proportion of pregnant women have 
insufficient levels. Even women who may have normal levels may have insufficient levels at 
other times during their pregnancy (i.e. during winter). The 4400 IU dose has been shown to 
remove seasonal variation in vitamin D levels. 
 
V. Recruitment. The recruitment goal for each site will be 290 subjects. As we anticipate 
miscarriages and stillbirths (about 8%83), and a 17-18% dropout by the end of the 3-year follow-
up of the children, this number should give us the target of 220 3-yr old children per Clinical 
Center or a total of 660 3-yr old children at the end of the trial. The 3 clinical centers have 
considerable experience and a proven track record in recruiting participants for longitudinal 
studies of asthma. We expect that each center will be able to fulfill the recruitment goals in 18-
24 months.  
Screening visit: This screening visit will occur at the subjects’ pre-natal visit before or around 18 
weeks gestation.  The study coordinator at each Clinical Center will obtain the schedules for all 
prenatal visits for the week, and scheduled visits will be reviewed for potential subjects. During 
the visit, the Study Coordinator/RA will describe the study, present the potential subject with a 
written description of the study, and review the eligibility criteria via a screening questionnaire 
and a study admissions criteria questionnaire. If the subject is eligible, does not meet any 
exclusion criteria, and expresses interest in the study, the subject will either be enrolled at this 
visit or an enrollment visit will be scheduled within one month.  
Enrollment visit: A separate enrollment/randomization visit will be scheduled within one month of 
the prenatal visit, but not later than the 18th week of gestation.  In some instances, enrollment 
will occur at the time the subject is screened. At this visit, the Study Coordinator/RA will review 
the study procedures and consent form.  Once subject consent is obtained, the subject will be 
assigned a Study ID and several questionnaires will be administered, a skin pigmentation test 
will be performed, and blood will be drawn and stored for 25 (OH) D measurements. After 
questionnaires have been answered and the subject does not meet any further exclusion 
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criteria, the subject will be randomized to one of the treatment arms (see Section VII.C. for 
details of randomization). 
Follow-up: After enrollment, the Study Coordinator will note the subject’s scheduled visits with 
her obstetrician and will make sure that urine samples are collected at each of these scheduled 
monthly clinical prenatal visits. Also at these monthly visits, a short maternal health 
questionnaire will be administered, MEMS cap information will be downloaded, and study 
medication and prenatal vitamins will be refilled. Additionally, the Study Coordinator and RAs 
will conduct a monthly review of electronic medical records to check for pregnancy 
complications. At 32-38 weeks gestation, in addition to the monthly routine, a blood draw, skin 
pigmentation determination, and a number of the questionnaires that were administered at the 
enrollment visit will be repeated.  At delivery, cord blood will be collected and the Study 
Coordinator and RAs will collect information regarding the type of delivery, birthweight, and 
other anthropometric measures.  After delivery, the research staff will make quarterly calls in the 
first year to inquire about the health and symptoms of the infant in addition to the type and 
frequency of feeding of the child and supplement use.  A number of the questionnaires 
administered during pregnancy will also be re-administered to the mother. The mother and child 
will come in for 3 yearly follow-up visits, during which blood will be drawn, skin pigmentation 
tests will be performed, and additional questionnaires will be administered, as well as 
anthropometric measurements of the child.  The flow chart for the trial is diagrammed in Figure 
2. All questionnaires and measurements to be performed are summarized in Table 2. 
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Figure 2. Flow Chart of VDAART Study 
 
 
 Screening Visit 
Enrollment Visit & 
Randomization 
(Gestational Week 10-18). 
Target N = 870 
• Questionnaires 
• Blood draw 
 
Study Medication, Vitamin D, and 
Prenatal Vitamins 
Target N = 435 
Placebo (Prenatal Vitamins only) 
Target N = 435 
Monthly Prenatal Visits through 
delivery.  
• Questionnaires 
• Urine Ca/Cr ratio 
• Blood draw at 32 weeks 
gestation.  
• Cord blood draw at delivery. 
 
 
Monthly Prenatal Visits through 
delivery. 
• Questionnaires 
• Urine Ca/Cr ratio 
• Blood draw at 32 weeks 
gestation. 
• Cord blood draw at delivery. 
 
 
One follow-up visit during year 1, 
2, and 3 and 
quarterly phone calls. 
 
• Questionnaires 
• Blood draw at year 1 (mother 
and child) 
• Blood draw at year 3 (child 
only) 
 
One follow-up visit during year 1, 
2, and 3 and 
quarterly phone calls. 
 
• Questionnaires 
• Blood draw at year 1 (mother 
and child) 
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delivery Year 1 Year 2 Year 3 
Study Admission Criteria 
Questionnaire x     
    
Maternal Questionnaire  x         
Food Questionnaire (Maternal) x  x   x x   
Food Questionnaire (Child)       x x x 
Baseline Sun Exposure 
Questionnaire x     
    
Follow-Up Sun Exposure 










Monthly Maternal Questionnaire  x x       
Medical Record Review 
(electronic and/or paper) x x x   
    
Determination of skin 




 x (child) 













 x4 (child) 
Urine for Ca/Cr ratio5  x x       
Patient Health Questionnaire x  x    x x x 
Hardships Questionnaire x      x x x 
Labor and Delivery Form    x      
Quarterly Infant Follow-up 
Questionnaire     x 
 x x x 
In-person visit x  x    x x x 











   
 
 1 Mother: 25(OH)D, blood for DNA extraction and gene expression studies.  
  
 2 Child: 25(OH)D, total IgE, and blood for DNA extraction and gene expression studies. 
 
 3 Child: total IgE and 25(OH)D 
 
 4 Child: total IgE, eosinophil, and 25(OH)D  
 
 5  Urinary calcium, creatinine. 
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VI. Data Collection 
A. Definition of Outcome Variables 
A.1. Asthma and recurrent wheeze. Asthma will be defined as a parent’s report of physician’s 
diagnosis at any time during the first three years of life, based on questionnaire responses. A 
diagnosis of asthma in early childhood is difficult, as only a third of children who wheeze before 
the age of 3 years will develop asthma. However, children who experience more frequent 
(recurrent) wheeze in early life are more likely to develop asthma84, 85. We will define recurrent 
wheezing as at least one report of wheezing in the third year of life plus any report of wheezing 
in any of the first two years of life. The primary outcome of the trial will be development of a 
doctor’s diagnosis of asthma and/or recurrent wheeze. We will also consider other wheezing 
phenotypes. Persistent wheezing will be defined as ≥ 2 reports of wheezing in each of the three 
years of the child’s life. Any wheeze will be defined as any report of wheezing in any of the three 
years of the child’s life. 
 
A.2. Eczema. Similarly to the case for asthma and wheeze, eczema will be defined based on 
responses to questionnaires. We will use the standardized questions from the International 
Study for Asthma and Allergy in Children which asks about an itchy rash with a specific 
distribution. We will also enquire about a physician’s diagnosis of eczema. 
 
A.3. Serum Total and Allergen-Specific IgE; Eosinophil count. Total serum IgE will be 
measured from cord blood samples, and from year 1 and year 3 samples from the children. In 
addition, allergen-specific IgE and eosinophil counts will be measured from the year 3 samples 
from the children. Total IgE will be measured in the Channing Laboratory by the UniCAP 250 
system (Phadia AB in Portage, MI ), with samples measured in duplicate. Serum from each child 
will also be assayed for IgE to 13 allergens (dust mite [D. farinae], cockroach [Bla g], cat dander, 
dog dander, rye grass pollen, ragweed pollen, Alternaria tenuis, Aspergillus, wheat, soybean, egg 
white, milk, and peanut) using the UniCAP system (Phadia AB in Portage, MI ). For specific IgE, 
the enzyme-immunoassay is based on the sandwich technique, utilizing a solid phase (allergen-
impregnated discs) for separation. Sensitization to common allergens can be detected by 
measuring serum IgE specific to those allergens. We will define sensitization to each allergen as 
a specific IgE level ≥ 0.35 IU/ml. Atopy will then be defined as sensitization to at least one of the 
13 allergens included in the study. Total serum IgE is increased in atopic individuals. For the 
statistical analysis, total serum IgE will be transformed to a log natural scale, in recognition of the 
distribution of total serum IgE in human populations86. Total eosinophil counts will be determined at 
each clinical center’s laboratory. 
 
A.4. Respiratory tract infections. Lower respiratory tract infections (LRIs) will be defined based 
on parental responses to questionnaires. LRIs will be defined as a parental report of a physician’s 
diagnosis of pneumonia, bronchiolitis, bronchitis, or croup (laryngotracheobronchitis).  
 
B. Screening Questionnaire. This short questionnaire will be administered/obtained at the 
screening visit at the time of the first pre-natal visit to determine eligibility based on the presence 
or absence of asthma or allergies in the mother or in the biologic father of the child. If the 
subject or the biologic father has either asthma or allergies, then the Study Admissions Criteria 
Form that inquires about the other inclusion and exclusion criteria will be filled out.  
 
C. Baseline Maternal Questionnaire. This questionnaire will inquire about details regarding 
her asthma and allergy symptoms, demographic information on herself and the biologic father of 
the child, and smoking in the home. For mothers with asthma, this questionnaire also includes 
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questions from the Asthma Control Test (ACT)87, a validated questionnaire inquiring about 
control of asthma in the past 4 weeks. 
 
D. Monthly Maternal Questionnaire. This questionnaire will be administered to the mother by 
the Study Coordinator at the monthly scheduled prenatal visits. The mother will be asked to 
complete this health assessment questionnaire to ascertain: 
a. Any change in her health status 
b. Use of prescription medications 
c. Use of over-the-counter preparations that may influence vitamin D and calcium homeostasis. 
d. Use of cigarettes, alcoholic beverages and nutritional supplements 
e. Level of asthma control, for those with asthma, using the ACT  
 
E. Monthly Review of Medical Records (paper-based) and Electronic Medical Records 
(EMR) 
 Each month, the Study Coordinator or the RA will review the Obstetric medical record of 
each of the participants for any potential complication of pregnancy. Examples include but are 
not limited to the following: (a) Preeclampsia, (b) HELLP (Hemolytic anemia, Elevated Liver 
enzymes, Low Platelet count) syndrome, (c) Gestational diabetes, (d) Hypertension, (e) Preterm 
delivery, (f) Premature rupture of membranes (PROM), (g) Deep venous thrombosis or a 
coagulopathy, (h) Maternal infection such as varicella or herpes (1o or 2o), (i) Placental 
abnormalities such as previa or marginal abruption. For centers where EMRs are not complete, 
paper medical records will be reviewed and the relevant information extracted. 
 
F. Measurement of 25(OH)D 
 Blood will be drawn from the mothers at randomization, at the in-person research 
prenatal visit at 32-38 weeks gestation, and at 1 yr after delivery. Cord blood will also be 
collected at delivery. Blood from the child will be collected at 1 yr and at 3 yrs. All specimens will 
be shipped to the DCC, where they will be logged in and processed. Measurement of 25(OH)D 
will be performed at the Channing Laboratory DCC as previously described88. Twenty five (25) 
microliters of serum or plasma (EDTA or Heparin) is required for the 25-OH-D extraction, 
however, 100 microliter samples will be aliquoted to allow for duplicate measurements on each 
sample. A chemiluminescence assay will be employed. The LIAISON
® 
25 OH Vitamin D assay 
(DiaSorin, Inc., Stillwater, MN) is a direct competitive chemiluminescence immunoassay (CLIA) 
for quantitative determination of total 25 OH vitamin D in serum or plasma. During the first 
incubation, 25 OH Vitamin D is dissociated from its binding protein and binds to the specific 
antibody on the solid phase. After 10 minutes the tracer, (vitamin D linked to an isoluminol 
derivative) is added. After a second 10 minute incubation, the unbound material is removed with 
a wash cycle. Subsequently, the starter reagents are added to initiate a flash chemiluminescent 
reaction. The light signal is measured by a photomultiplier as relative light units (RLU) and is 
inversely proportional to the concentration of 25 OH vitamin D present in calibrators, controls, or 
samples. In order to monitor assay performance each assay will include one quality control 
sample.  The control will be treated as unknown specimen and multiple (5) determinations will 
be made. Assay variation will be determined and acceptable performance limits will be defined 
as ≤15 C.V.  In addition 20% of the samples will also be re-measured in Dr. Hollis’ laboratory in 





.   
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G. Urinary Ca++/Cr ratios 
 At each monthly prenatal visit, mothers will provide a urine sample (“clean catch”). 
Because dehydration can affect urine calcium levels, mothers will be instructed to maintain good 
hydration throughout their pregnancy. Urine samples will be sent to each Clinical Center’s 
Clinical Chemistry Laboratory for urinary calcium and creatinine measurement, and the urinary 
calcium to creatinine ratio will be derived. Dr. Hollis has used this measure to monitor women on 
vitamin D supplements in his other trials and has shown that this is the earliest sign of 
impending toxicity. 
If an elevated Ca/Cr ratio is found, the woman will be asked to stop the study pills. An 
elevated Ca/Cr ratio will be defined as ≥ 1.55, when measured on the mmol scale, or ≥0.55, 
when measured on the mg/mg scale. She will be asked to stop the study medication and to 
return for a repeat evaluation after being instructed to increase her fluid intake, to ascertain 
whether this was due to dehydration or true hypercalciuria. If the repeat test is normal she will 
resume the study medication and continue in the study. If the repeat test remains elevated, she 
will have further blood tests including serum 25(OH)D levels and calcium level, if these are 
within normal limits, she will restart her study medication and continue on the study. If her serum 
25(OH)D and calcium levels are elevated, she will be withdrawn from study treatment and be 
further evaluated by her doctor as appropriate. This will be recorded as aserious adverse event. 
(Please see Section VII. J. for further details). 
If there is a subsequent elevated urine Ca:Cr ratio, but it is a lower than the initial 
elevated urine Ca:Cr ratio, she will be reminded to maintain hydration by drinking water daily, 
and will continue on her study medication. If the subsequent elevated urine Ca:Cr ratio is 
greater than the initial elevated ratio, she will be asked to stop her study medication, and 
reminded to drink non-caffeinated fluid. The woman will return to the clinic center and have a 
blood draw for serum Ca and 25(OH)D measurement. If these are within normal limits, study 
medication will resume. If the values of either are out of normal limits, the subject will be 
withdrawn from study treatment, but continued to be followed under the intention-to-treat 
paradigm. A serious adverse event will be submitted to the DCC and she will be referred to her 
physician for follow up treatment. 
 
H. Food Frequency Questionnaire. Maternal dietary intake of vitamin D will be assessed using 
a standardized, validated brief food frequency questionnaire89, 90. This questionnaire has been 
modified to apply to pregnant women and has been validated against the longer semi-
quantitative food frequency questionnaire89, 90. Mothers will be asked to complete the FFQ on 
enrollment. A second questionnaire will be completed at the 32-38-week visit. Additional 
questionnaires will be completed at 6 months and at 1 year post-partum. Assessment of the 
responses to these questionnaires will help account for dietary sources of vitamin D in addition 
to the study intervention. In addition, the FFQ will measure other nutrients and supplements that 
may have confounding effects, and which we will be able to adjust in the analyses. Filled out 
questionnaires will be sent to the Harvard Nutrition Questionnaire Services Center at the 
Harvard School of Public Health for scanning and processing. Individual nutrients will be 
calculated using the Harvard nutrient composition database, which contains food composition 
values from the US Department of Agriculture, supplemented by other sources91.  
 
I. Sun Exposure Questionnaire. We will collect UV exposure history using a modification of 
the UV exposure questionnaire that is used in the Nurses’ Health Study92. Briefly, this 
questionnaire will inquire about UV exposure information such as average hours per week spent 
outdoors in summer and winter, sunscreen habits, and average times for sunlamp use or 
tanning salon attendance. 
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J. Measurement of Skin Pigmentation. Mothers will have the degree of pigmentation/melanin 
measured at study entry, at 32-38 weeks, and at the 1 year visit using the Smart Probe 400 
(IMS, Inc., Milford, CT) and a skin tone chart (IMS, Inc.). This is a spectrophotometer device that 
measures degrees of pigmentation on a continuous scale from 0 to 100, 0 being absolute black 
and 100 being absolute white. Each mother will have pigmentation measurements recorded 
from her forehead, exposed forearm, underarm, and abdomen, with two readings from each site 
averaged and recorded.  
 
K. Stress and Depression Questionnaires.  
Patient Health Questionnaire: The Patient Health Questionnaire (PHQ-9) Depression scale is 
being used in VDAART to assess depressive symptomatology in women. This is a 9-item scale 
with scores ranging from 0 to 27 with a general question about if these problems have interfered 
with their lives. A commonly used cut-off score of 15 or higher along with rating that it is 
“somewhat difficult” or greater in interfering with your life is considered clinically significant. The 
PHQ-9 has been shown to have reasonable sensitivity, specificity and positive predictive value 
for clinical depression in community samples. This severity score is the sum of the columns for 
questions 0-9. Question 9 is important since it asks about thoughts of self harm and any 
response of 1-3 would be considered clinically significant. If a subject’s score is =/>15: 1) Prior 
to randomization: suicidal ideation or a score of 15 or higher on the depression scale 
questionnaire has been added as exclusion criteria to the study. The participant will be 
counseled by the Study Coordinator and the PI will be notified. The participant will then be 
referred back to her obstetrician for further psychiatric evaluation.  2) Post randomization: 
suicidal ideation or a score of 15 or more on the depression scale will be recorded in a specific 
study form and trigger 1) notification to PI and obstetrician and 2) a referral to a psychiatrist  or 
psychosocial specialist. The findings of this report will determine whether the patient can 
continue in the study. 
Hardships Questionnaire: These questionnaires are designed to see whether depression, 
financial strain, and perceived stress are effect modifiers of the immune system changes from 
vitamin D supplementation. These would be collected at the enrollment visit, and annually at the 
year 1, 2, and 3 visits since chronic stresses have been shown in other cohort studies to affect 
immune system function. Depression may also be effected by Vitamin D supplementation and 
sunlight, which would be a question that could be asked in this study. 
 
L. Labor and Delivery Information and Questionnaires: At delivery, the research assistant will 
collect information on type of delivery (caesarian vs. vaginal), birthweight and other anthropometric 
measurers, need of oxygen, etc. Data from routine hospital newborn screen will be obtained for all 
infants. 
 
M. Infant Follow-up Questionnaires. Every 3 months, we will administer a questionnaire to the 
child’s caretaker (in most instances, this will be the mother) to obtain information on the neonate’s 
general and respiratory health, with particular attention given to symptoms suggestive of asthma, 
wheeze, allergies, and atopic eczema. This questionnaire will also inquire about respiratory 
infections (upper, including ear infections, and lower tract infections, including bronchiolitis), 
medication use, particularly antibiotics, and smoking by adults in the home. Questions inquiring 
about breastfeeding, formula feeding, and introduction of solid foods will also be included. At the 
first year visit and each year thereafter, we will also inquire about the child’s diet, using a short 
food-frequency questionnaire. We will also obtain several anthropometric measurements.  
 
N. DNA Extraction and Samples for Gene Expression Studies: We will extract high molecular 
weight genomic DNA from the white blood cells from maternal peripheral blood and cord blood 
with commercially available PureGene Kits (Gentra Systems, Minneapolis, MN). Optical density 
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(OD) will be measured to confirm DNA quality and quantity for each sample. This amount is 
sufficient to perform approximately 16,000 genotype assays using PCR technology (assuming a 
conservative use of 25 ng/reaction, although we routinely amplify single copy gene sequences 
from 10 ng of genomic DNA). Every sample undergoes additional quality control before 
use/release by subjecting it to PCR amplification. After DNA quantification, samples will be 
adjusted to TE buffer and partitioned into aliquots stored at -80°C. Information about quantity 
and storage of extracted DNA will be added as variables to each patient’s database. DNA 
samples will then be stored at the Channing Laboratory for future genetic studies. 
 From the scheduled blood draws from the mothers and cord blood, we will include 
samples for gene expression studies. For mothers, two 2.5 PAXgene tubes at enrollment, the 
32-38 week gestation visit, and at the child 1-yr visit. Two 2.5 cc PAXgene tubes will also be 
saved from the cord blood draw. These samples will be used to understand the genetics and 
gene expression of fetal development and asthma in future studies with a special focus on the 
relationship to vitamin D. While genetics and gene expression are not currently part of the 
specific aims of this protocol, it is imperative that samples be collected because the time window 
for appropriate collection is short (i.e. during pregnancy and delivery of the baby). 
 
O. Manufacture and Distribution of Study Medications; the MEMS System 
 The study medications, including all prenatal vitamins, the vitamin D tablets, and the 
placebo tablets will be manufactured by Tishcon Corp. Founded in 1976, Tishcon Corp. 
(www.tishcon.com) is a leading manufacturer and marketer of vitamins, related dietary and 
herbal supplements, and private label non-prescription (OTC) pharmaceuticals in tablet, hard 
gelatin capsule, soft gelatin capsule and powder dosage forms. Tishcon is one of 12 soft gelatin 
capsule manufacturers in the United States. The pills and capsules will be sent in bulk from 
Tishcon to the DCC. The DCC will contract with the Brigham and Women’s Hospital Pharmacy 
to package and label the pills in bottles. Once packaged and labeled with Study ID numbers, the 
pill bottles will be shipped to the respective Clinical Centers where a MEMS cap will be utilized 
on each assigned bottle. Random pills from each lot will be sent to Dr. Hollis’ lab where the 
vitamin D amount will be quantified for quality purposes. Each participant will receive 2 bottles – 
one bottle will contain the standard prenatal vitamins with 400 IU vitamin D, and will be labeled 
accordingly, and the other bottle will contain the intervention pill containing 4,000 IU vitamin D or 
a placebo. 
The MEMS System. The MEMS® - Medication Events Monitoring Systems is a pill bottle 
equipped with special cap that includes an electronic microchip that stores the date and time of 
each opening of bottle. The MEMS monitors are drug packages with integral electronic micro 
circuitry designed to compile the dosing histories of ambulatory patients’ prescribed 
medications. Each monitor consists of a conventional medicine bottle fitted with a special 
closure that records the time and date of each opening and closing of the container through 
integrated microcircuitry.  The MEMS® stores up to 3800 medication events in non-volatile 
EEPROM memory, allows wireless data transfer, fits standard pharmacy bottles 38mm-400, 
42mm-400, and 45mm-400 thread closure, provides 36 months battery life, and is water-
resistant and CE marked. Monitors are designed to be used by one patient with one drug. A 
Reader allows transferring the dose timing data from the MEMS to a MS-Windows based 
computer. The MEMS monitors have demonstrated reliability and validity and have been widely 
used with great success in clinical trial research93, including NHLBI sponsored studies in the 
Childhood Asthma Research and Education Network94, 95 and asthma clinical research 
sponsored by industry96. The MEMS® - Medication Events Monitoring Systems is manufactured 
by Aardex LTD (http://www.aardexgroup.com) with a subsidiary in California for ease of 
ordering.  
Data from the MEMS system will be downloaded at the monthly prenatal visits and after 
delivery. The data from the pre-natal follow-up visit will be used to provide feedback to the 
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participant, reinforcing those subjects with good adherence and providing extra teaching and 
encouragement for those with suboptimal adherence. The data from both pre-natal follow-up 
and post-natal downloads can be used to derive a summary adherence measure that can be 
used as a covariate in our analyses and also for secondary analyses that exclude any women 
who have taken less than 50% of the prescribed study medication. 
 
P. Statistical considerations 
P.1. Overview 
 This is a randomized, double blinded, multi-center, placebo controlled, clinical trial of 
prenatal vitamin exposure as a preventive measure to reduce the risk of asthma and recurrent 
wheeze in childhood.  There will be approximately 870 pregnant women enrolled, targeting an 
evaluable study population of 660 women randomized to Vitamin D supplementation of 4400 IU 
or 400 IU (standard prenatal supplementation).  The treatment arms will be balanced 
(approximately n=330 in each arm, with some fluctuation possible owing to differential 
miscarriage or loss to follow-up, both expected to be completely at random). The primary 
outcome is doctor-diagnosed asthma and recurrent wheeze at 3 years of age.  Secondary 
outcomes include maternal 25(OH)D levels and children’s allergy, doctor’s diagnosis of eczema, 
and lower respiratory infection (LRI), at three years of age. The primary interpretive paradigm 
for analysis of this study is intent to treat. 
P.2 Analytic plan 
All analyses to be described will occur in a framework of continuous quality assurance and 
verification.  Preliminary statistical analysis will be used to describe the univariate distributions 
of key measures of interest to detect outliers or data anomalies that need to be addressed by 
data editing or sequestration of doubtful entries.  Additionally, these analyses will examine 
whether any important risk factors for childhood asthma are imbalanced across treatment arm, 
as well as assess whether differential loss to follow-up is present across treatment groups.  
Detailed blinded codebooks will be provided to investigators as data accumulate to facilitate 
efficient substantive verification of basic distributional summaries and joint distributions of 
measured factors. 
P.2.a. Plan for Specific Aim 1 
The hypothesis that the incidence of asthma and recurrent wheeze at age three years is 
reduced in the high-dose Vitamin D supplementation group will be tested using logistic 
regression, allowing for fixed effects of center.  Additional analyses will consider the modification 
of vitamin D exposure effects by maternal and child demographic/behavioral factors such as 
maternal age, BMI and weight gain during pregnancy, maternal history of asthma/allergy, and 
other factors potentially associated with asthma and/or vitamin D exposure.   The variables to 
be considered are summarized in Table 3. For variables that are measured post-natally, recall 
bias is a potential confounder among parents of infants diagnosed with asthma. However, the 
prospective nature of the data collection should limit the extent of this and other potential 
sources of bias. Due to the design of this clinical trial, we expect that the randomization process 
will distribute these variables equally between the intervention and control groups. However, we 
will check the distribution of these variables prior to conducting the analyses, and will adjust for 
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Table 3. Information on selected potential confounders of the relationship between 25(OH)D levels and 
asthma/recurrent wheeze in 3-yr old children 
Prenatal variables Socioeconomic status 
 Maternal diet 
 Maternal sun exposure behavior 
 Maternal age and parity 
 Maternal history of asthma and allergies 
 Maternal pre-pregnancy BMI and weight gain in 
pregnancy 
 Maternal medication use in pregnancy (antibiotics, 
acetaminophen, NSAIDs, etc.) 
 Pregnancy complications (e.g. gestational diabetes, 
pre-eclampsia) 
 
 Maternal depression 
 Maternal stress 
Delivery variables Gestational age 
 Mode of delivery (caesarian section, normal vaginal 
delivery) 
 Birthweight, length, head circumference 
 Oxygen use 
 Need for NICU stay 
Postpartum and 
infancy variables 
Breastfeeding or bottle feeding 
 Type of formula 
 Timing and type of solid food introduction 
 Daycare, including timing of and  type of daycare 
(home vs. institution) 
 Pets in the home 
 Other siblings in the home (gender and number) 
 Smoking in the home 
 Childhood diet  
 Sun exposure behaviors in the child 
 Maternal depression 
 Maternal stress 
 
Letting Mi be an indicator function for the primary endpoint, asthma, for the ith subject, 
the model is:   
iiiiii aaxaxM ,2211 , ),|1Pr(logit γγβα +++==  
where xi denotes an indicator function for level of vitamin D supplementation (0=400 IU, 1=4400 
IU) in the ith subject, while a1,i and a2,i are indicator functions for study center.  The specific aim 
for this outcome tests the hypothesis that β=0, asthma and recurrent wheeze incidence do not 
significantly differ across treatment groups, after adjusting for the potential effects of study 
center heterogeneity. 
To assess modification of vitamin D exposure levels by other demographic and/or 
behavioral variables, the model is: 
∑∑+++== ++ k kk iikkikiiiiii zxzaaxaxM ηδγγβα ,2211 , ),|1Pr(logit  
where zki represents the k measured covariates for each subject, and the other variables are as 
described above.  This model addresses two hypotheses.  First, main effects testing for 
behavioral/demographic covariates (Table 3), or the hypothesis that δk=0, will be used to 
examine whether maternal age, BMI, or other factors predict asthma and recurrent wheeze risk 
at age 3.  More importantly, inclusion of any significant main effects will adjust for any 
distributional imbalances of these factors across the Vitamin D supplemented and placebo 
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groups.   Second, this model tests the hypothesis that ηk=0, or whether any maternal, child, or 
demographic/behavioral covariates modify the relationship between vitamin D intake and our 
primary outcome.  To obtain a parsimonious model and limit multiple testing, only covariates 
with significant main effects and strong biologic plausibility for an exposure-dependent impact 
on asthma/recurrent wheeze risk will be considered for interaction testing with Vitamin D 
supplementation status. For example, only the prenatal and some delivery variables (e.g., 
gestational age, birthweight, length) listed in Table 3 will be considered, as the factors  
modifying the impact of Vitamin D supplementation on asthma and/or recurrent wheeze should 
occur temporally (i.e. in utero). 
P.2.a.1. Interim Analyses for Specific Aim 1 
 For the primary aim of asthma and/or recurrent wheeze, as well as the other specific 
aims, we have developed an interim analysis plan to monitor this composite endpoint over the 
course of the study.  The interim analysis plan, for all four specific aims, is discussed in section 
VII.K. 
 
P.2.b. Plan for Specific Aim 2 
For this analysis, our N will be 800, since most of the dropouts will be expected to occur 
after delivery. Thus, the expected drop in N due to the 8% miscarriage rate was applied. We will 
test the hypothesis that the dose of 4,400 IU per day is sufficient to get 90% of the women to a 
sufficient level of 25(OH)D of at least 75 nmol/L, primarily using a logistic regression model, with 
randomization group (i.e. intervention group vs. usual care) as the independent variable. The 
dependent variable will be 25(OH)D level at delivery. We will adjust our analyses for other 
covariates that may affect 25(OH)D level, such as sun exposure (from the SmartProbe and the 
sun exposure questionnaire), age, and diet (calculated vitamin D intakes from dietary sources).  
 
P.2.c Plan for Specific Aim 3 
Incidence of allergy, doctor’s diagnosis of eczema, and lower respiratory tract infection 
(LRI) at age 3 will be individually assessed.  Like asthma and recurrent wheeze, two of the three 
secondary outcomes are dichotomous endpoints, and will be analyzed using logistic regression.  
For allergy, logistic regression will be used for specific IgE and linear regression will be used for 
log transformed total serum IgE level.  Both a primary analysis of the relationship between 
vitamin D and the secondary outcome of interest will be conducted, as well as additional 
analyses including demographic and environmental risk factors for allergy, eczema, and LRI.  
The primary analysis, as well as additional analyses testing main demographic/behavioral 
effects and effect modification, will be conducted along the lines of analyses described for 
Specific Aim 2. The covariates to be considered for main effects and interaction analyses will be 
identical to those outlined for Specific Aim 2. 
 
P.2.d. Plan for Specific Aim 4 
 This specific aim investigates the immediate and long-term impact of vitamin D 
supplementation on circulating 25(OH)D blood levels.  The immediate impact of Vitamin D on 
25(OH)D will be assessed through maternal plasma and cord blood measurements taken at 
delivery.  The long-term influence will be examined via longitudinal analyses using children’s 
blood measurements obtained at ages 1 and 3.  
The hypotheses that 25(OH)D levels in maternal plasma and cord blood will be higher in 
the 4400 IU group will be tested using standard linear regression. If necessary, 25(OH)D levels 
will be transformed to meet the distributional requirements for the analysis. The 25(OH)D levels 
in maternal plasma and cord blood will be treated as separate outcomes, although both testing 
procedures for each analysis will be similar and are described jointly below.  As with specific 
aims 1 and 2, the primary analysis will examine the relationship between 25(OH)D and vitamin 
D levels, while the secondary analysis will include other important demographic and 
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environmental factors related to 25(OH)D levels, such as climate and dietary vitamin D intake, 
testing for main effects and effect modification for these factors. 
Letting yi denote the 25(OH)D levels for each subject (as measured in mother’s plasma 
for the first hypothesis, and cord blood for the second hypothesis), the model for the primary 
analysis is: 
iiiii aaxy εγγβα ++++= ,22,11  
where the covariates and parameters are as defined in Specific Aim 1.  However, Specific Aim 3 
tests the hypothesis that β=0, 25(OH)D levels do not significantly differ across the Vitamin D 
supplemented and control groups. All relevant covariates listed in Table 3 will be considered for 
the final model.  For example, covariates measured post-natally would not be considered for 
inclusion in the analysis of maternal plasma or cord blood at delivery.  Additionally, factors 
known to be directly associated with OH(25)D levels (i.e. sun exposure behavior, diet, ethnicity), 
will be included in the final model even if they are not statistically significant predictors of 
circulating vitamin D levels.  
To assess modification of 25(OH)D levels by other demographic and behavioral 
variables, the model is: 
ikiikkikiiii kk zxzaaxy εηδγγβα +++ ∑∑+++= ,22,11  
where the parameters are as defined in Specific Aim 1. The k measured covariates for these 
analyses will be environmental, maternal, and child factors specific to 25(OH)D levels, such as 
sun exposure behavior, dietary intake of Vitamin D, and ethnicity.  Additionally, any relevant 
covariates from Table 9 demonstrating main effects that have biologically plausible interactions 
with Vitamin D supplementation will be tested for effect modification. For both models, it is 
assumed that εi ~ N(0,σ2).  The hypothesis that δk=0 will be used to examine whether any of 
these factors predict 25(OH)D levels, and the results will be used to adjust for any distributional 
imbalances of these factors across Vitamin D supplementation groups.   As with the previous 
specific aims, we will also tests for effect modification via the hypothesis that ηk=0, or whether 
any maternal, child, or demographic/environmental covariates modify the relationship between 
vitamin D intake and circulating 25(OH)D levels in mother’s plasma or cord blood.  Additionally, 
we will follow the guidelines outlined in Specific Aim 2 to obtain the most parsimonious model. 
The hypothesis that 25(OH)D levels in the child’s blood will be higher in the 4400 IU 
group at birth, age 1 and age 3 will be tested using a repeated measures analysis framework 
such as generalized estimating equations. 
 
P.2.d. Plan for Specific Aim 5 
This specific aim investigates whether sufficient vitamin D supplementation in the pregnant 
mother is associated with reduced incidence of preterm birth (birth <37 weeks gestation) and/or 
preeclampsia, gestational hypertension, and/or HELLP syndrome compared to a usual care 
control group in VDAART. 
 The hypothesis that the incidence of preterm birth/preeclampsia, gestational 
hypertension and HELLP syndrome (PB/PE) is reduced in the high-dose vitamin D 
supplementation will be tested using logistic regression, allowing for fixed effect of center. 
Additional analysis will consider the modification of vitamin D exposure effects by maternal 
demographic/behavioral factors such as maternal age, BMI and weight gain during pregnancy, 
and maternal history of asthma/allergy, race, and other factors potentially associated with 
preterm birth/preeclampsia, gestational hypertension, HELLP or vitamin D exposure.  
  Letting Mi be an indicator function for the primary endpoint, PB/PE, for the ith subject, the 
model is:   
 
iiiiii aaxaxM ,2211 , ),|1Pr(logit γγβα +++==  
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where xi denotes an indicator function for level of vitamin D supplementation (0=400 IU, 
1=4,400 IU) in the ith subject, while a1,i and a2,i are indicator functions for study center.  The 
specific aim for this outcome tests the hypothesis that β=0, PB/PE incidence do not significantly 
differ across treatment groups, after adjusting for the potential effects of study center 
heterogeneity. 
 
To assess modification of vitamin D exposure levels by other demographic and/or behavioral 
variables, the model is: 
 
∑∑+++== ++ k kk iikkikiiiiii zxzaaxaxM ηδγγβα ,2211 , ),|1Pr(logit  
 
where zki represents the k measured covariates for each subject, and the other variables are as 
described above. This model addresses two hypotheses. First, main effects testing for 
behavioral/demographic covariates, or the hypothesis that δk=0, will be used to examine 
whether maternal age, BMI, or other factors predict PB/PE. More importantly, inclusion of any 
significant main effects will adjust for any distributional imbalances of these factors across the 
vitamin D supplemented and placebo groups. Second, this model tests the hypothesis that ηk=0, 
or whether any maternal, child or demographic/behavioral covariates modify the relationship 
between vitamin D intake and our primary outcomes. To obtain a parsimonious model and limit 
multiple testing, only covariates with significant main effects and strong biologic plausibility for 
an exposure-dependent impact on PB/PE risk will be considered for interaction testing with 
vitamin D supplementation status. Because of our fixed sample size we have chosen to 
combine PB and PE as our primary outcome. Obviously we would like to explore the disease 
entities separately, and also examine the effect of race independent of vitamin D level. These 
analyses can be done using interaction terms and stratified analyses recognizing that we have 
lower power to detect these influences.  
 
P.3 Multiple comparisons. 
All pre-specified hypotheses will be tested individually at the 0.05 level of significance, 
using a conservative two-sided alternative hypothesis (even when the stated hypothesis is one-
sided). More specifically, the primary and secondary hypotheses of Vitamin D supplementation 
and Asthma/Recurrent Wheeze, Allergy/Eczema/LRI, will not be adjusted for multiple 
comparisons, since they have been defined a priori and are limited in scope.  Additionally, an 
interim analysis plan has been developed for the primary outcome to adjust for the number of 
times (3) asthma and/or recurrent wheeze will be analyzed over the study period.  Since 
25(OH)D status is being examined in 5 separate analyses (maternal plasma at 26-28 weeks, 
maternal plasma at delivery, cord blood at delivery, infant plasma at years 1 and 3), this 
analysis will be adjusted for 5 multiple comparisons (i.e., using Bonferroni correction). Finally, 
any findings with respect to interaction terms (i.e., exploring whether environmental and 
demographic covariates affect the relationship between Vitamin D supplementation and the 
outcome of interest) for any of the hypotheses will be adjusted (i.e., using FDR methodology) for 
the number of models tested, and interaction testing will be limited to those defined in sections 
D.14.2a-c, in order to limit the potential for spurious findings. Any serendipitous findings coming 
from exploratory analyses will be clearly reported as such, and test statistic p-values will be 
adjusted by the number of exploratory hypotheses considered (using FDR or another 
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Q. Power and sample size 
Q.1. Power for Specific Aim 1. The trial is designed to detect a 25% reduction in asthma and 
recurrent wheeze incidence at 3 years in the vitamin D supplemented (4400 IU) group.  Based 
on the observational results in the Viva Study, we estimate that the incidence of asthma and/or 
recurrent wheeze in the standard dosing group (400 IU) will be 40-50%.  This incidence 
estimate is based on observations from Project Viva and the URECA Project. In project Viva, 
the prevalence of persistent wheeze is 44% and of asthma is 56.2% in children born to 
families with parental history of asthma (about twice the prevalence in children without 
family history). These estimates are similar to those observed in the URECA Project in 
children who have turned 2 yrs old. The children in that cohort had a family history (mom or dad) 
of asthma or allergies. In the URECA cohort, 99 of 194 (51.0%) children who have reached 
their 2nd birthday, have experienced "wheezing or asthma by age 2." These observed rates 
in 2 cohorts give us confidence that we will see similar rates when we recruit the high-risk (for 
asthma and allergies in the child) pregnancies for this clinical trial. We anticipate an 8% 
miscarriage rate83 and 17-18% LTF among remaining subjects over the study period, resulting 
in an estimated sample size of 660 subjects (330 per arm) at the end of the study period.  Each 
power estimate is based on 10,000 simulations.  The simulations incorporate an interim analysis 
plan using the Lan-Demets spending function described in section VII.M, although the power 
may be slightly lower than the estimates presented here.   For our group sequential design, we 
plan to use a Lan-Demets spending function with four approximately equally-spaced looks (with 
respect to the amount of information collected) and O’Brien-Fleming type bounds. The software 
program LANDEM (http://www.biostat.wisc.edu/landemets/)97 was used to calculate the 
stopping boundaries, which were |z|=4.3329, 2.9631, 2.3590, and 2.0141 at the first, second, 
third, and final looks, respectively. As noted in N.2.A.1, Lan-DeMets procedure provides a 
spending function approach which does not require pre-specification of the frequency or timing 
of interim looks.  Therefore, the thresholds will be adjusted if the recruitment targets vary of if 
the need for more frequent monitoring arises. The hypothesis tests are conducted with two-
sided alternatives (i.e. a two-sided p-value), The power reflects the proportion of replicates 
where the Wald test statistic from the hypothesis test of β1=0 is less than the stopping boundary 
specified for the first, second, or third looks, where β1 is the coefficient for Vitamin D 
supplementation status from the logistic regression model outlined in section,N.2.a.  The 
replication is considered a ‘success’ if the stopping boundary is exceeded at any of the analysis 
times. In the simulations, the incidence of asthma and/or recurrent wheeze at the first and 
second interim looks is proportionate to the overall incidence expected at the end of the study 
period (i.e. at the first look, the incidence is one-third of the specified rate; at the second look, it 
is two-thirds).  We do not expect incidence rates of 40-50% to be achieved until the third year of 
follow-up; therefore, the simulations reflect the approximate amount of information anticipated at 
each interim analysis.  
        Finally, in the simulation studies, we also incorporate study heterogeneity into the 
model by varying the incidence of asthma and/or recurrent wheeze in the control group (400 IU 
Vitamin D) across study sites. The incidence varies by an absolute difference of 10% (i.e., for a 
mean incidence of 50%, incidence rates varied from 45-55% across study sites).  Thus, the 
absolute reduction in incidence observed in the treated group (4400 IU Vitamin D) will also vary 
according to baseline incidence in the control group [i.e., assuming a 30% reduction in 
incidence, a site with a 50% incidence rate in the control group will have a 35% incidence rate 
(a 15% decrease) in the treated group, while a site with a 45% incidence in controls will have a 
31.5% incidence rate (a 13.5% decrease) among supplemented subjects].    
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Table 4.  Power to detect a 20-30% reduction in asthma and recurrent wheeze for 660 patients in a 
multi-site study* 
 
Percent reduction in Asthma and/or 
Recurrent Wheeze in 4400 IU group 
Mean Incidence of Asthma 
and/or Recurrent Wheeze in 
400  IU group 30% 25% 20% 
 0.50 0.974 0.906 0.726 
 0.45 0.950 0.837 0.653 
 0.40 0.901 0.773 0.574 
*18% LTF and 8% miscarriage rate 
  We anticipate that there will be excellent power (91%) to detect a 25% reduction in 
asthma, assuming a 50% incidence of asthma/recurrent wheeze in the 400 IU dosing group.  
Even if the children in this study have a lower incidence of asthma and recurrent wheeze than 
previous cohorts (i.e., 40-45%), we will still have good power (77-84%) to detect a 25% 
reduction in asthma and/or recurrent wheeze. To assess the potential impact of study center  
heterogeneity and interim analyses on power, power calculations were conducted without 
adjustment for study-center and with a single analysis time point at the end of the study period 
(with a two-sided alpha=0.05).  The calculations were performed in STPLAN 
(http://biostatistics.mdanderson.org), using an arcsine approximation for the binomially 
distributed outcome.  Overall, the power estimates were consistently similar to the empirical 
estimates (shown in Table 5), with at most a 2% difference in absolute power.  Therefore, we do 
not anticipate that multiple study sites or incorporating interim analyses will considerably reduce 
study power. 
 
Q.2. Power for Specific Aim 2.  We expect that there will be 400 women in each arm for this 
analysis due to the 8% miscarriage rate. We do not expect there to be significant LTF by 
delivery.  Like the analysis plan for Specific Aim 1, we plan to incorporate interim analyses, 
using a Lan-Demets spending function with O’Brien-Fleming type bounds.  For this specific aim, 
we plan for three looks, which results in stopping boundaries of |z|=3.7103, 2.5114, and 1.993, 
for the first, second, and final analysis, respectively. As above, the thresholds will be adjusted if 
the recruitment varies from the expected targets.  As shown in Table 5 below, we will have 
excellent power to detect an increase of 20-60% in the proportion of mothers with 25(OH)D 
levels > 75 nmol/L between the intervention and the control group.  The power calculations did 
not explicitly account for the interim analyses, however, the power should still be >0.999 even 
after distributing the alpha level across multiple looks. 
  
Table 5. Power to detect a 20-60% absolute increase in the proportion of mother’s with 25(OH)D > 
75 nmol/L for 800  patients in a multi-site study* 
 
Proportion of mothers with 25(OH)D 
> 75 nmol/L  in 4400 IU group 
Proportion of mothers with 
25(OH)D > 75 nmol/L in 400  IU 
group 90% 80% 70% 
 0.50 >0.999 >0.999 >0.999 
 0.40 >0.999 >0.999 >0.999 
 0.30 >0.999 >0.999 >0.999 
* 8% miscarriage rate 
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Q.3. Power for Specific Aim 3. The estimated incidence of doctor’s diagnosis of allergy (IgE), 
eczema, and lower respiratory tract infection (LRI)  at year 3 in the Viva cohort are 30%, 36%, 
and 45%, respectively, among the children with a parental history of asthma or allergies. 
Estimates of eczema and LRI differ from those submitted in the previous grant application, 
which were based on incidence of these secondary outcomes among all children (including 
those without a parental history of asthma and allergies). Additionally, information on allergy 
incidence in Project Viva is now available.  We anticipate a 30%-45% reduction in each of these 
outcomes in the high-dose vitamin D supplementation (4400 IU) group, though a larger range is 
provided in table 6 below.  Each power calculation is based on 10,000 simulations, and is 
identical to the simulations described above, except that interim analyses are not planned for 
the secondary outcomes, and the studies are powered to detect an effect at the end of the three 
year follow-up period, with a two-sided alpha level of 0.05. As with the methods described 
above, these simulations incorporate an effect for study center heterogeneity in baseline 
incidence of secondary outcomes (i.e., incidence across sites varies by 10%) and 8/18% losses 
to miscarriage and follow-up/miscarriage, respectively.  
This specific aim has an interim analysis plan that is identical to the procedure outlines 
for specific aim 1.  While the power estimates below do not directly incorporate the interim 
looks, we feel that the power reduction will be modest.  With a 30% reduction in incidence, we 
anticipate that there will be good power (83.4%) to detect a clinically important difference in risk 
of eczema.  Due to the lower incidence of allergy, a 35% reduction is required to have very good 
(89.0%) power.  Additionally, since LRI is more prevalent at age 3, only a 25% reduction is 
required to have 85.8% power.  Even if the incidence of these outcomes is 5% lower than the 
estimated rates in Viva, there will still be sufficient power to detect an effect of treatment. 
Overall, there is strong evidence that we will be adequately powered to detect a risk difference 
in treatment group (4400 IU Vitamin D) for the secondary outcomes, in addition to our primary 
outcome of interest, asthma and recurrent wheeze. 
 
Q.4. Power for Specific Aim 4. The 
research to date on the impact of 
vitamin D supplementation on 25(OH)D 
is presented in Table 1.  As noted in the 
table, only 4 studies have been 
conducted on pregnant women, all had 
fewer than 100 subjects, and the 
maximum daily dose for these studies 
was 1,600 IU. The only data available 
on 25(OH)D status in the 
supplementation ranges we are 
proposing has been provided by Dr. 
Bruce Hollis (unpublished data, see 
section III).  In a study of 347 pregnant 
women (African Americans. Hispanic, 
and Caucasians) on either 4000 IU (supplemented) or 400 IU (control) of Vitamin D daily, the 
maternal plasma 25(OH) D levels were 115 nmol/L in supplemented subjects, and 80 nmol/L in 
controls after 8 months of supplementation, an overall difference of 35 nmol/L.  The estimated 
standard deviation for 25(OH)D levels in these ranges is 40.   
Based on the observed differences/variation in 25(OH)D levels, we used simulation 
studies to estimate the power to detect a mean difference of 7.5 – 37 nmol/L across the 
supplemented and control groups in maternal plasma at 26-28 weeks, as well as maternal 
plasma and cord blood at delivery, using an estimated standard deviation of 40.  We anticipate 
that the difference in 25(OH)D levels in maternal plasma across treatment groups will be less 
Table 6. Power to detect a 25-35% reduction in secondary 
outcomes for 870 subjects  in a multi-site study, (effectively 
660 patients, assuming an 8% miscarriage rate and  18% 
loss to follow-up) 
 
Percent reduction in secondary 
 outcome in 4400 IU group 
Mean Incidence of 
secondary outcome 
in 400  IU group 35% 30% 25% 
 0.50 0.998 0.982 0.913 
 0.45 0.992 0.958 0.858 
 0.40 0.973 0.906 0.779 
 0.35 0.936 0.845 0.691 
 0.30 0.890 0.736 0.608 
 0.25 0.795 0.654 0.531 
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pronounced at the 26-28 week measurement period (e.g., 12.5 – 25 nmol/L), and we do not 
expect to observe a significant difference by supplementation status in circulating vitamin D in 
infants at 1 and 3 years of age, since no post-natal treatment intervention is planned.  The 
simulations were generated in a similar manner to method described for Specific Aim 2, except 
that linear regression (rather than logistic) was used to model the relationship between 
circulating vitamin D and vitamin D supplementation status. Study heterogeneity was 
incorporated into the model by allowing 25(OH)D levels to vary by 25 nmol/L across study sites.  
Since this phenotype will be measured five times throughout the study period, the power was 
defined as the proportion of replicates with a Wald test statistic (i.e., testing the null hypothesis 
that the coefficient for vitamin D supplementation status is 0) 2-sided p-value was less than 0.01 
(0.05/5).  Additionally, this specific aim will include 2 interim and a final analysis, which will be 
identical to the procedure outlines for specific aim 2.  While the power estimates below do not 
directly incorporate the interim looks, we feel that the power reduction will be modest.  The 
results are shown in Table 7. 
 
 
Table 7. Power to detect a 7.5 – 37 nmol/L difference in 25(OH)D for 870 subjects  in a multi-site study, 
(effectively 660 patients, assuming an 8% miscarriage rate and  18% loss to follow-up). 
Mean change in 25(OH)D levels in 
4400 IU group (nmol/L) Power 
 7.5 0.444 
 12.5 0.925 
 25 0.999 
 37 0.999 
For a mean difference greater than 7.5 nmol/L, we anticipate having excellent power to detect a 
difference in 25(OH)D status across treatment groups.  This difference of at least this magnitude 
should be observed in both maternal plasma measurements and cord blood, given the 
preliminary data (a difference of 35 nmol/L in maternal plasma) provided by Dr. Hollis.  To 
ensure that the results were not affected by incorporating an effect for study center, the 
simulations were conducted assuming homogenous effects across study sites.   The power 
estimates were within 1.5% of those provided above, and are likely due to variation in estimates 
via simulation. Therefore, we are confident that we have excellent power to achieve this specific 
aim. 
Q.5. Power for Specific Aim 5. 
The trial is 84% powered to detect a 50% reduction in PB/PE in pregnant mothers in the vitamin 
D supplemented (4,400 IU/day) group. We estimate that the incidence of preeclampsia and/or 
spontaneous preterm labor in the standard dosing group (400 IU/day) will be 10%, resulting in 
an estimated sample size of 435 subjects per arm at the end of the antenatal period. Our 
sample size simulations, show that we will have excellent power to detect a 50% reduction in 
preeclampsia and/or preterm labor in the vitamin D supplemented group which is what we 
anticipate based on our preliminary data. 
 
Q.6 Missing data considerations 
It is expected that missing data will be infrequent, that the treatment is sufficiently benign 
that any missingness would be unrelated to treatment group, and that the outcome 
ascertainment process is compatible with standard medical care for children.  Thus it is 
reasonable to predict that missing data would be missing “completely at random” (MCAR) and 
that inference based on the complete cases would be valid, though only slightly inefficient, if 
missingness is rare (less than 5%) .  Methods are available to assess the compatibility of 
response patterns with the MCAR condition (Chen and Little, 1999), and these will be used to 
diagnose the missing data situation.  If missingness is not rare, and it is desired to improve the 
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efficiency of the analysis, two possible approaches to handling the imputation are described 
below. 
Approach A: Impute the overall (ignoring treatment assignment) incidence of asthma and 
recurrent wheeze (or the incidence of the secondary outcome of interest) for children that are 
lost to follow-up, and analyze the resulting imputed dataset as if complete. This is a crude but 
very simple approach that is often proposed.  Approach B: Use subject-specific modeling to 
determine an imputation distribution for those who drop out.  Specifically, model the risk of 
asthma and recurrent wheeze (or secondary outcome) among completers as a function of 
baseline covariates, ignoring treatment assignment. Use the covariates zi observed on dropouts 
to predict logit[Pr(Mi|zi,)].  The predicted estimate is then perturbed by repeatedly drawing 
randomly from a distribution whose variance is the sample variance in the group of completers.  
Both analyses will be conducted to examine the similarity of results to the complete case 
analysis.  If the results are consonant, for simplicity, the complete case analysis will be reported 
along with any variations in findings from the described imputation strategies.  
 
VII. Study Implementation and logistics 
A. Clinical Center Organizational Structure and Infrastructure  
Each Clinical Center has a set organization structure with clearly defined personnel 
roles, a well-maintained computer infrastructure, and plans to establish numerous mechanisms 
to promote the flow of information between study center sites and the DCC. 
 Dr. Strunk and colleagues at the Washington University in St. Louis, MO has been 
designated as the lead Clinical Center for this grant. Dr. O’Connor at Boston University Medical 
Center and Dr. Zeiger at Kaiser Permanente and University of California at San Diego are the 
PIs of their respective Clinical Centers. Dr. Strunk will schedule and lead regular conference 
calls to discuss the processes of recruiting, adherence, and retention throughout the trial, and 
will report directly to Dr. Weiss at the DCC.  
Because recruitment of participants will take place in Obstetrics Clinics, it will be crucial 
for each Clinical Center to establish ties and obtain cooperation from their respective Obstetric 
practices. All three centers have working relationships with the Obstetric practices from prior 
recruitment efforts. In the St. Louis Center, Dr. George Macones will support the trial by setting 
into place the system to recruit the pregnant women and obtain the necessary samples of 
peripheral blood during the prenatal visits and peripheral and cord blood at the time of delivery 
as well as obtaining urine to be measured for creatinine and calcium as safety for vitamin 
administration during pregnancy. Dr. Macones will assure that the OB practitioners are familiar 
with the trial and will support enrollment of their patients into the trial. Dr. Linda Heffner, MD, 
PhD (Chair, Dept. of OB and Gyn) and Ms. Margaret Shepherd, CNM (OB Department 
Manager), will fulfill the same roles for the BUMC and Kaiser Permanente San Diego Clinical 
Centers, respectively. 
In each Center, a Study Coordinator will be responsible for recruiting pregnant women 
into the trial at the time of their first visit to the OB offices and retaining them during the 4 years 
of their involvement in the trial.  Specific activities of this Study Coordinator will include but not 
be limited to: 
• Working with the clerical staff of the OB department to assure that a brochure describing 
the vitamin D trial is included in the materials sent to the pregnant women giving 
information about the first OB visit. 
• Working with the staff at the OB offices to determine when eligible women will have their 
first OB visit and being in the clinic to meet the women to give them information about 
the study, determine their level of interest, perform appropriate screening, give the 
informed consent and arrange a time for discussion of the trial and the consent and 
answer any questions.   
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• Make an appointment in the Study Clinic for enrollment and initiation of the study 
medication.  The trial will also provide standardized prenatal vitamins, which will be 
initiated at this visit. 
• Remain in contact with the participants via scheduled phone calls and as needed for 
problem solving about taking study medication and the prenatal vitamin. 
• Work with the staff in labor and delivery to establish a system for collection of peripheral 
blood from the mother to be used for assay of vitamin D and the cord blood for assay of 
vitamin D and for use in extraction of DNA to be used in the genetic studies.   
• Visit the now new mother and her baby after delivery to deliver a small gift and further 
develop the relationship that will assure long-term follow-up of the child with the quarterly 
phone calls and annual visits. 
Each Center will also have a second Study Coordinator or Study Nurse who will be a partner of 
the other research patient coordinator in performing all the duties listed to assure recruitment 
and retention of the women and their offspring. 
 
B. DCC Organizational Structure and Infrastructure  
The DCC has a set organization structure with clearly defined personnel roles, a well-
maintained computer infrastructure, and plans to establish numerous mechanisms to promote 
the flow of information between study center sites and the DCC. 
The DCC will be chaired by Dr. Scott Weiss and Dr. Augusto Litonjua, and the statistical 
and informatics component will be managed by Dr. Vincent Carey. The DCC informatics 
operations will be executed by Dr. Carey’s staff, which has an outstanding track record running 
multicenter trials funded by AHRQ and NHLBI since the mid 1990s. Nancy Laranjo will be the 
Senior Data Manager for the trial, along with, Deputy Data Manager, John Ziniti, Senior 
Programmer, and Christopher Garcia, Administrator.  In consultation with Dr. Carey, Ms. 
Laranjo will specify the general communications and data archive workflows for the support and 
programming staff members.  As the design of forms and general data flow processes evolves, 
prototypes and “dry run” exercises will be carried out with the clinical sites to verify the 
soundness and feasibility of the operations plan.  The detailed task sets will be noted in the 
DCC Manual of Operations, which will be available through the internal study web site.  The 
DCC will have full staff meetings attended by one of the PIs every month, and basic staff 
meetings every week. In addition, the chairs of the DCC will have a conference call with the PIs 
of the Clinical Centers once a month to obtain updates on recruitment and progress of the trial, 
and discuss any issues that pertain to the conduct of the trial.  
 
C. Randomization and Treatment Assignment 
Participants who consent and are deemed eligible to participate will be randomized by 
the Data Coordinating Center (DCC) to either of the 2 arms of the trial and will be sequentially 
assigned a six-digit Study Identification Number (Study ID). The first digit of the Study ID will 
identify the site (St. Louis, San Diego, or Boston) and the next four digits will identify the 
participant; and the last digit will be a check digit that is calculated from a formula to ensure the 
accuracy of data entry. Only those who indicate their intention to follow-up until the child is 3 
years old will be randomized.  Randomization will be performed prior to enrollment of any study 
participants by the DCC using a system that automates the random assignment of treatment 
groups to Study ID numbers. The randomization scheme will employ permuted blocks, and one 
blocked allocation list per stratum (study site and racial/ethnic group) will be generated. That is, 
separate permuted block randomization lists will be maintained for each racial/ethnic group –  
White/Non-Hispanics, White/Hispanic, Black (including Hispanic Black), and Other – within each 
study site. This will ensure that within each site, there is approximate balance across arms over 
the course of enrollment, and that within ethnic groups within site, there is also approximately 
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equal representation on both arms. A woman who is deemed eligible will receive the next 
available Study ID number for her given study center site and ethnic group.  The Study ID will 
be linked to the women’s Screening ID.  It should be noted that women who are deemed 
ineligible will not receive Study IDs (i.e. randomization to a treatment).  This will help ensure 
balance in treatment and control groups by not ‘wasting’ randomization assignments on 
ineligible subjects. 
C.1. Race and Ethnicity. Race and ethnicity will be collected according to NIH categories. 
Participants will be asked to first categorize their ethnicity as either Hispanic or not Hispanic. 
They will then be asked to categorize their race as either White, Black or African-American, 
Asian, Native Hawaiian or other Pacific Islander, American Indian/Alaskan Native, or Other, If 
the participant categorizes herself as Black or African-American, she will be considered Black 
for purposes of randomization regardless of any other ethnic or racial category she has picked.  
If the participant categorizes herself as non-Hispanic and White, she will be classified as 
White/non-Hispanic. If she picks Hispanic but not Black, she will be classified as 
White/Hispanic. Any other racial or ethnic combinations will be classified as Other. 
 
D. Trial Website 
 Each Center’s participants will have access to the trial website. The DCC will establish a 
website with both public and private (SSL regulated, LDAP database of all study investigators or 
support staff needing website access will be established with private passwords) web portals at 
the beginning of the recruitment period. The public pages will provide information on the scope 
and background of study to assist in recruitment.  The private pages will allow for general 
posting of any protocols changes or announcements, current versions of forms, minutes of 
phone calls, manuscripts in development, allow investigators to monitor recruitment process, 
and provide other general information.  Patient-level treatment information, medical history, or 
endpoint information will not be linked to the website.  The website will be maintained 
throughout the trial and closeout period, and aggregate study findings will be posted at the end 
of the trial. 
 
E. Data management and tracking 
 Clinical data from screening (first prenatal visit), each subsequent pre-natal visit, delivery 
day, quarterly follow-up questionnaires, and clinic assessment visits at 1, 2, and 3 years are 
entered on forms at each study center at the time of the patient visit/contact.  The forms will be 
reviewed by the center coordinator, and uploaded to the internal study website.   
 Calcium/creatinine ratios will be conducted by the study center laboratory on the day of 
the patient visit. The calcium/creatinine ratios will be reviewed by the laboratory head at each 
center.  Alert values will be established and if reached will lead to immediate contact to the 
Study Coordinator and contact with the participant will be attempted within 24 hours of 
identification.  Blood draws for 25(OH)D levels will be sent from the study center laboratory to 
the DCC on a weekly basis, where they will be logged in and aliquots created for 25(OH)D 
assays.   
Upon receipt on collected forms, all data forms (lab work and patient questionnaires, 
clinical assessments, etc.) will be downloaded from the internal website and double entered at 
the DCC with range, logic, and missing data checks built into the data entry software 
application.  The data entry software will be configured to be schema-driven, so that an abstract 
schematic design is at the base, and the concrete (XML) schema that specifies form content 
and logic is automatically transformed to a functional data entry application.  We currently use 
Altova XMLSpy and Microsoft InfoPath technologies to implement the schema-driven design. 
Forms with missing (illegible entries will be considered missing for the purposes of data entry) 
and/or inaccurate (i.e. out-of-range) entries will not be accepted into the system database, but 
will be cycled back to the site for correction.  
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For clinical data, the data monitor will send weekly reports of missing or inappropriate 
entries to the study project coordinators for clarification and resolution. Additionally, cross-form 
edit checks will be performed on a monthly basis, to detect unresolved problems.  Data 
inconsistencies occurring across forms will be resolved with the assistance of study center staff.  
Standardized edit reports that summarize problems in the database provide an additional 
method of assuring data quality.  To ensure accuracy of patient identification numbers (in 
particular, minimizing transposition error), digit checks will be utilized.  Digit checks will identify 
whether there are inconsistencies in patient identification numbers across collection time points.  
Once data have been verified, data will be archived on a monthly basis as a SAS dataset.  Data 
will be stored in coded form (i.e. numeric coding for ethnicity or gender) using standard 
codebooks currently implemented  
 For each patient, a data collection tracking query will be developed, which will contain 
expected time points for each data form/lab work, based upon patient’s initial enrollment date.  
Forms more than one week late (from enrollment to delivery) or one month late (after delivery to 
year 3) will be flagged as missing, and a query will be generated for each site that contains a list 
of patient IDs and their outstanding forms/lab data.  The data manager at the DCC will follow-up 
with site coordinators to track down any missing forms.  For patients at-risk of dropping out (i.e. 
missed appointment or non-response to questionnaire request), the study coordinator or 
research assistant will make repeated attempts to contact the patient. A subject will be dropped 
only with explicit withdrawal request by the pregnant woman (initially) and later, the parent of the 
infant/child. Even with missed appointments or calls, every effort will be made to complete the 
final in-person visit when the child is 3 yrs old. 
 
F. Data Security and Confidentiality 
All computer files are stored in password-controlled accounts on DCC computers.  There 
will be an SSL regulated private web portal established for the study at the DCC, LDAP 
database of all study investigators or support staff will be established with private passwords 
allocated to all who have a need to examine the study web site 
Each participant will be assigned a unique study identification number.  Once these data 
are linked (after a subject successfully enters randomization phase from screening), the study 
identification number will be the primary identification number. The data coordinating center and 
trial statisticians will have access to only the unique identification number and therefore cannot 
link names to data. Files of study data will include the screening and study identification number 
but not participant names.  Any hardcopy of data forms obtained by the coordinating unit (for 
example, as part of spot-checking for quality control) will be maintained in locked file cabinets. If 
a participant withdraws from participation at any point in the trial, and requests withdrawal of any 
information from the database, the clinical center staff will forward the study identification 
number to the DCC and all files pertaining to that identification number will be removed and 
destroyed.  
At the clinical centers, data are collected on forms with fields for study identification 
number but without a field for the participant’s name. Still, separate lists of participant names, 
identification numbers, and contact information are used during the study to maintain contact 
with participants and eventually to provide feedback on study and personal results.   These lists 
will only be available to Center Co-PIs and staff with direct patient contact.  All hardcopies of 
forms are stored in locked file cabinets. All computer files are password protected.  Participant 
results will only be released to the participant unless he/she provides written approval to release 
data (e.g. laboratory results to personal provider).   Data will only be presented and published in 
aggregate, i.e. no identifying characteristics of participants will be published or presented.   
 
G.  QC protocol 
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 To ensure uniform data collection and reporting procedures, training and certification of 
study center research assistants (RAs) will occur at the DCC.  Additionally, there will be a 
weekly conference call between the DCC deputy data manager and the site coordinators at 
each center to globally address any screening or data collection issues and maintain study-wide 
consistency in procedures.  Monthly conference calls will be conducted between the DCC PI 
and all site investigators to check progress and data integrity.    Patient recruitment and follow-
up, as well as data collection and archiving procedures, will be monitored by the DCC with bi-
annual site visits. 20% of the patient questionnaires and lab forms will be randomly sampled and 
queried against stored values in the DCC database and archives. 
 To verify the accuracy of 25(OH)D measurements  obtained by the Channing 
Laboratory, 20% of the maternal blood samples, as well as cord blood samples at delivery, will 
also be sent to Dr. Hollis’ lab.  Any discrepant lab values will be checked to determine the 
source of the variation.  If appropriate, a replicate assay will be conducted.  Samples will also be 
obtained from each lot of the vitamin D supplement (4000 IU vitamin D) and prenatal vitamins 
(400 IU vitamin D) and sent to the lab of Dr. Hollis for analysis to ensure the level of Vitamin D 
compound in each is with the range specified in trial protocol. 
 The DCC will provide monthly reports on the timeliness, quality and completeness of the 
data to the Steering Committee, organized by type of visit, e.g. screening visit 1, randomization 
day, 6-month visit, etc, and by specific data form.  The Steering Committee will remain informed 
of any potential screening or data collection issues (with patient forms or lab work) and be able 




Until the end of the trial, all investigators, clinical staff and participants are masked to 
trial outcome data, with the exception of the trial statisticians, and the data manager.  Due to the 
nature of the intervention, laboratory technicians and staff obtaining calcium/creatinine ratios 
may be able to infer treatment group assignment.   However, there are other more common 
causes of elevated calcium/creatinine ratios (i.e. dehydration).    Therefore, we do not anticipate 
any issues with unintentional unblinding of study investigators or clinical staff.  There may be a 
rare case where emergency unblinding may be necessary (e.g. overdose of study pills or 
persistent elevation of urinary Ca/Cr ratio with hypercalcemia and hypervitaminosis D).  In this 
case, emergency unblinding will occur at the discretion of the DCC and appropriate actions will 
be taken, including immediate reporting to the DSMB. In cases where non-emergent unblinding 
may be necessary, The DCC PIs will seek input from the DSMB prior to unblinding.  
For quality control purposes, 20% of the blood samples will also be sent to Dr. Hollis’ lab 
for 25 (OH) D measurements.  However, we will adhere to established procedures to maintain 
separation between laboratory staff and clinical staff that have patient contact.  For quality 
assurance, Dr. Hollis will receive a report of measured 25(OH)D levels that are stripped of all 
identifying patient information (identifier and clinical information).   
  To ensure rapid intervention in the unexpected event of out-of-range (≥1.55 mmol/mmol) 
calcium/creatinine ratios, urinary calcium and creatinine measurement will be conducted at each 
Clinical Center’s Clinical Chemistry Laboratory.  Again, we will adhere to established 
procedures to maintain separation between laboratory staff and clinical staff that have patient 
contact or are responsible for measuring primary or secondary endpoint outcomes.  In the event 
of an out-of-range calcium/creatinine ratio, the patient will be contacted for follow-up, with the 
procedure detailed in Section I below. 
Given the benign treatment intervention, the manufacturing of prenatal vitamins, placebo 
and Vitamin D supplement by the same drug company (Tishcon Corp), the distribution of study 
vitamins by the DCC, off-site assays of 25(OH)D levels, protocols to maintain separation 
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between information available to laboratory staff, trial statisticians, the DCC, and site clinical 
staff and investigators, we anticipate that we will successfully maintain blinding of all 
investigators, clinical staff and participants to both treatment intervention and trial outcome until 
the end of the trial.   
 
I. Data Safety and Monitoring of Each Subject 
An external Data Safety and Monitoring Board (DSMB), composed of vitamin D 
metabolism experts, early life asthma experts, obstetricians, an ethicist, and a statistician has 
been appointed by the NHLBI.  The board will be convened prior to study initiation to review the 
protocol and to examine and comment upon “shell” reports that will be used to illustrate data 
accumulation as the study proceeds.   
All study subjects will be monitored for hypervitaminosis D, the only known toxicity of 
which is hypercalcemia. Operationally, we will define caution by urinary calcium/creatinine ratio 
≥ 1.55 mmol/mmol from the samples that are obtained monthly starting 1 month after 
randomization. Whenever any patient exceeds the caution limit, the study medication will be 
temporarily discontinued and a specific case study will be initiated. The first elevated urine 
Ca:Cr ratio will trigger the repeat measure of the urine calcium/creatinine ratio after hydration 
(drinking at least 8 oz of water prior to coming in for the visit). If the repeat urinary 
calcium/creatinine after hydration remains elevated, the patient will have serum calcium and 
vitamin D levels checked at the Clinical Center’s Clinical Chemistry Laboratory. If the serum 
calcium and vitamin D levels are within normal limits, the subject will resume study medication. 
Predefined cutoff of a calcium of ≥10.2 mg/dl or vitamin D level of ≥ 300nmol/L are criteria for 
removal from the study treatment. The subject will still be followed in the intention-to-treat 
paradigm. Further evaluation (including the possibility of taking additional calcium or vitamin D 
supplements as well as workup for other disorders such as hyperparathyroidism) will be 
pursued further depending on the serum calcium and vitamin D levels as appropriate. The 
appropriate IRB will be notified, and the NIH and FDA will be notified per their protocols. The 
DSMB chair will be notified, as with any severe adverse event. After the detailed case review 
has been performed by the clinical center to ascertain the cause of the hypervitaminosis D in 
the subject and reviewed by the DSMB to make an informed decision about the study’s 
continuation. If the elevated levels in the subject are attributed to the vitamin D supplement, the 
subject will be withdrawn from supplementation but will continue to be monitored.  
Subjects who have a subsequent elevated urine Ca:Cr that is a lower ratio than the initial 
measurement will remain on the study medication and no further action will be required. If the 
ratio of any subsequent spot urine is greater than the initial ratio, the woman will be asked to 
stop study medication, and be reminded to properly hydrate. She will be asked to return to the 
clinical center where blood will be drawn to determine serum Ca and 25(OH)D levels, no repeat 
urine is required at this time. If the levels of both are within the normal range, the subject will 
resume study medication and continue to be monitored per protocol each month (with any other 
elevated ratio again being compared to the initial elevated ratio).  If either of the serum values 
are outside of the normal range, the procedure outlined above will be followed. 
  
 
J. Adverse Events and Reporting to the DSMB 
  Serious Adverse Events (SAEs) will include the following:  
o Symptomatic hypercalcemia and/or elevated 25(OH)D level (as defined above) 
o Pre-eclampsia and Eclampsia 
o  Any hospitalization of mother (including severe pregnancy complications such as 
HELLP [Hemolytic anemia, Elevated Liver enzymes, Low Platelet count] 
syndrome, deep vein thrombosis or coagulopathy), except for  
 Delivery after 32 weeks 
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 Pre-term labor not resulting in delivery 
o Any newly diagnosed serious maternal illness 
o Maternal death from any cause 
o Pre-term delivery <32 weeks gestation 
o Discovery of major fetal anomalies or diagnosed major congenital anomalies 
(note: an elective abortion in the absence of diagnosed congenital anomalies will 
be considered a study withdrawal, not an SAE)  
o Still birth/Intrauterine fetal death 
o Neonatal demise 
o Any neonatal intensive care admission  
 Adverse Events (AEs) will include (but not limited to): 
o Pre term delivery between 32 and 37 weeks 
o Gestational diabetes 
o Gestational hypertension 
o Perinatal infections 
o Anemia 
o Prolonged rupture of the membranes 
o Placental abnormalities such as previa or marginal abruption 
o Meconium staining 
o Abnormal labor 
o Low birth weight (<1500g) 
o Asymptomatic hypercalcemia (≥10.2mg/dl) 
o Hypercalciuria  
 Urine calcium/creatinine ratio ≥1 after repeat measure. If ratio normalizes 
after hydration this is NOT an adverse event 
  
The occurrence of adverse events (AE) and serious adverse events (SAE) will be monitored by 
each Clinical Center through the monthly maternal health questionnaire and the monthly OB 
medical record review. Additionally, hypercalciuria will be monitored with the monthly urinary 
calcium excretion. Monitoring of these urine samples are detailed above. If a SAE is discovered, 
the Clinical Center staff, under the direction of the Clinical Center PI, will fill out the SAE form 
and determine whether this event was likely to have been related to the study medication. The 
form will then be uploaded to the secure VDAART website and an email will be automatically 
generated to alert the DCC co-PIs and staff. The DCC staff will then review the form for any 
errors, missing or incomplete information, or any inconsistencies. The form will then be 
uploaded within to the secure DSMB page on the website after approval by one of the DCC 
medical staff members (Dr. Litonjua or Dr. Weiss). The DCC is expected to complete this review 
and approval, and upload of the SAE form to the DSMB page of the secure website within 72 
hours of being notified by the Clinical Center. Once the SAE form has been uploaded, an email 
from Dr. Litonjua and Dr. Weiss will be generated notifying the DSMB Chair and the NHLBI 
staff. The DSMB Chair will then review the form and involve other DSMB members as he deems 
appropriate. The DSMB Chair will then communicate with the DCC Staff by email regarding the 
outcome of the review, including instructions for the DCC to report the SAE to the FDA and the 
Clinical Center IRBs, if found to be likely related to the study medication. Otherwise, the DCC 
will prepare annual reports of all SAEs and AEs to the FDA and the IRB at each center. 
 
AEs will also be monitored via the above mechanism. Once an AE is identified, the appropriate 
form will be completed. These forms will be uploaded to the secure VDAART website as soon 
as they are completed. The DCC staff will review these forms and prepare quarterly reports to 
the DSMB. These quarterly reports will be uploaded to the DSMB page of the secure website 
and an email will be generated notifying all DSMB members and NHLBI staff. All adverse events 
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will be reviewed by the entire DSMB at quarterly intervals, by e-mail, in between the regularly 
scheduled semi-annual meetings.  SAEs and AEs will be reported by masked treatment groups. 
In addition, all SAEs and AEs will be reported by ethnicity and gender (for events among the 
infants), and with information about the expected rate of occurrence of these events in a general 
population of pregnant women (or infants). The Director of NHLBI, with advice from the DCC 
and the DSMB, will have the   sole power to stop the study in the event of an unanticipated 
statistically and clinically significant difference between arms in rates of serious adverse events, 
whether or not these are attributable to the study treatment. The definition of statistical 
significance for study stopping will be adjusted alpha = 0.01. 
 
K. Interim Analyses 
For each specific aim, we have developed an interim analysis plan to monitor the 
endpoints over the course of the study.  For specific aims 1 and 3, which monitor primary 
(asthma and recurrent wheeze) and secondary (e.g., eczema, LRI) outcomes in the infants, this 
sequential monitoring plan consists of three interim analyses (conducted at year 3 month 5, year 
4 month 5, and year 5 month 5 and a final analysis at the end of the study, when the three-year 
follow-up has been completed on all subjects.  For specific aims 2 and 4, which involve 
outcomes monitored at delivery (i.e., circulating 25(OH)D levels in maternal and cord blood), 
there will be two interim looks and a final analysis (year 2 month 5, year 3 month 5, and year 4 
month 5, respectively).  
For maximum flexibility in the analysis, we will use a Lan-Demets alpha spending 
function98 with O’Brien-Fleming bounds.  The software program LANDEM 
(http://www.biostat.wisc.edu/landemets/)97 was used to calculate the crossing boundaries, 
which, for the first and third specific aims are |z|=4.3329, 2.9631, 2.3590, and 2.0141, at the 
first, second, third and final analyses, respectively. For the second and fourth specific aim, with 
3 looks in total, the crossing boundaries are |z|=3.7103, 2.5114, and 1.993 at the first, second 
looks and final analysis, respectively.  While the looks in the interim analyses have been 
predetermined, the Lan-DeMets procedure provides a spending function approach which does 
not require pre-specification of the frequency or timing of interim looks.  This can be 
advantageous if the timing of data collection varies of if the need for more frequent monitoring 
arises.  Conservative O’Brien-Fleming bounds are used to preserve most of the type-I error for 
the final analysis.  For all specific aims, the hypothesis tests are conducted with two-sided 
alternatives (i.e. a two-sided p-value). If the boundaries are crossed for efficacy endpoints at 
any interim analyses, for any of the aims, the study will continue. If the boundaries are crossed 
in Specific Aims 2-4, the primary specific aim, whether Vitamin D supplementation in pregnancy 
is association with a reduction in asthma and/or recurrent wheeze risk, still needs to be 
assessed, thus the study should continue to monitor this endpoint.  If the boundaries are 
crossed during an interim analysis of the primary aim, the study will also be continued, as the 
target intervention period (i.e., pregnancy) will have passed for all recruited subjects, and will 
feel that it is most important to examine the impact of this intervention on the children at 3 years 
of age.  If the study is stopped early due to the success of the intervention, important clinical 
and outcome information may be lost.  Therefore, we feel that it is important to continue the 
study even if interim analysis boundaries are crossed. The only situation when consideration will 
be given to prematurely stopping the trial will be for safety considerations. It is inevitable that 
adverse health events will be observed in all contexts noted above even if both treatments have 
no biological effects whatsoever.  If the rate of adverse events on the active arm substantially 
and persistently exceeds the rate on the control arm, even in the absence of biological theory 
that connects the adverse events to vitamin D exposures, and no evidence of therapeutic effect 
or benefit of the active treatment is apparent in interim analyses, then premature termination of 
the study may be considered on safety grounds.  The DSMB will be asked to articulate 
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reasonable definitions of `substantial and persistent excess’ of adverse event rate if this 
situation emerges. 
An IOM committee has been named to undertake a study to assess current relevant 
data and update as appropriate the Daily Reference Intakes (DRIs) for vitamin D and calcium. It 
is likely that the report from this committee (expected to be released in May, 2010 – 10 months 
into the recruitment phase; http://iom.edu/?ID=61170) will recommend a higher DRI for vitamin 
D (currently 200 IU/day for women of child-bearing age). This is one other concern regarding a 
potential cause for early study termination. If the IOM recommends Vitamin D supplementation 
of up to 2,000 IU/day during the course of the study, and if this increase in recommended 
supplementation occurs early in the course of the study (i.e., while the study is still in the 
antenatal monitoring phase), the likely target supplementation recommendation (≤2,000 IU/day) 
is well below the supplementation level indicated for the treatment group in this study. Even if 
the 2,000 IU recommendation results in additional supplementation occurring in the placebo 
arm, there should still be a measurable difference in outcomes, with regard to maternal vitamin 
D levels. Dr. Hollis’ previous trial had shown a statistically significant difference in 25(OH)D 
levels between the 2,400 IU/day and the 4,400 IU/day doses (Figure 1 in the VDAART 
Protocol). 25(OH)D levels will be available in the mothers to assess the impact of the IOM 
recommendation on the study outcomes. Consideration of increasing the dose in the 
intervention arm will be considered, after a meeting with the VDAART Trial Steering Committee, 
the NHLBI staff, and the DSMB.  If an IOM recommended increase in supplementation occurs 
after the antenatal supplementation period, this will have little impact on any study outcome, as 
the crucial window of Vitamin D supplementation for the prevention of asthma occurs in the 
antenatal period. In the unlikely event of an IOM recommended increase in supplementation 
>2,000 IU/day, a meeting between the VDAART Steering Committee, the NHLBI Staff, and the 
DSMB members will be convened to discuss potential alternative plans, including early 
termination of the trial.  
 
L. Study Timeline 
Year 1 Months 0-4 Planning and preparation  
        - Training of RAs 
        - Preparation of Study medications 
        - Printing of questionnaires 
  Month 6 Screening and recruitment begins 
   Randomization and intervention 
  Month 12 First group of mothers deliver 
Year 2 Month 3 First group of quarterly calls for follow-up of infants begins 
  Month 6 Data clean up, interim analysis of  SA2 and SA4 
  Month 11 Last group of mothers screened, recruited, and randomized 
  Month 12 First group of in-person visits for 1-yr old infants 
Year 3 Month 6 Last group of mothers deliver 
   Data clean up, interim analysis of  all specific aims 
  Months 6-12 Quarterly follow-up calls and yearly in-person visits continue 
Year 4 Month 1-5 
Quarterly follow-up calls and yearly in-person visits continue . Data clean 
up, interim analysis of  all SA1/SA3, final analysis of SA2/SA4 
  Months 6-12 Quarterly follow-up calls and yearly in-person visits continue 
Year 5 Months 1-5 Quarterly follow-up calls and yearly in-person visits continue 
  Month 5 First group of in-person visits for 3-yr old children 
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   Data clean up, interim analysis of  all SA1/SA3 
  Months 5-12 Quarterly follow-up calls and yearly in-person visits continue 
No Cost 
Extension  Month 4 Finish in-person visits for last group of 3-yr old children 
 Months 5-10 Finish data clean-up and statistical analyses 




VIII. HUMAN SUBJECTS RESEARCH 
Protection of Human Subjects 
Risks to the Subjects 
Human Subjects Involvement and Characteristics: For this project, we will be conducting a 
clinical trial of “high dose” vitamin D supplementation vs. “usual dose” prenatal vitamins in 
pregnant women for the prevention of asthma and allergies in the women’s offspring at 3 years 
of age. We propose to randomize 870 pregnant women during their 1st trimester with 435 
women to the “high dose” arm and 435 women to the usual care arm, follow them through their 
pregnancy and delivery, and follow the women and their offspring until the 3rd birthday of the 
children, with the expectation that we will evaluate at least 660 three year olds. A brief study 
description and a copy of the consent form will be given to pregnant women receiving their care 
at 3 Clinical Centers (Boston, St. Louis, and San Diego) at their first prenatal visit. Women 
interested in the study will be invited to a separate visit for more detailed explanation and 
providing informed consent. There are several reasons for this separate visit: 1) allow the 
pregnant women to review the informed consent, and 2) to assure as much as possible the 
dedication of the women to participation in the study until the 3rd birthday of their child. 
Pregnant women will be selected on the basis of an age >18 years but <40 years, ability to 
speak English or Spanish, intention to participate in the trial for the full 4 years, no pre-existing 
type 1 or type 2 diabetes mellitus, hypertension, parathyroid or uncontrolled thyroid disease, 
kidney stones, and sarcoidosis. Written informed consent (in English or Spanish, according to 
individual preferences) will be obtained from each subject by study coordinators at each Clinical 
Center prior to voluntary participation. Participating women will be followed during the remainder 
of their pregnancy, and their newborns will be followed after delivery. 
Sources of Research Material: Data from questionnaires, maternal (labor and delivery) and 
neonatal medical records will be used for research purposes only. Peripheral blood will be 
obtained from the mothers at a prenatal visit, at 32-38 weeks gestation, and at 1 yr after delivery 
for measurement of vitamin D levels. Cord blood will be obtained from the research subjects to 
be used by the investigators for measurement of vitamin D levels and storage of white cell 
pellets for future genetic studies. Peripheral blood will be obtained from the children to be used 
by the investigators for measurement of vitamin D levels at 1 yr and 3yrs and total and allergen-
specific IgE in the child at 3 yrs. These blood samples will be used by the investigators for 
research purposes only; the results will be kept strictly confidential. With parental permission, 
results of measurements of serum total and allergen-specific IgE at age 3 years will be sent to 
the child’s primary care physician.  
The major risk involved with vitamin D toxicity is hypercalcemia, which can be detected 
by measurement in serum or by calcium excretion in urine. Based on Dr. Hollis’ extensive 
review of the literature and his experience with his current vitamin D supplementation in 
pregnancy trial, vitamin D supplementation of 4,400 IU/day throughout pregnancy is safe. 
Nevertheless, we will be monitoring urine calcium-to-creatinine ratios as a measure to calcium 
excretion in the urine each time the mothers come for their prenatal visits. This method of 
monitoring was chosen because it is reliable and does not require phlebotomy.  
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Another risk of participation in this study is the social-psychological risk resulting from 
inadvertent disclosure of medical history information. This potential risk is guarded against by 
storage of completed questionnaires in a locked filing system and by labeling other 
phenotypic/genotypic data using ID numbers only. In certain instances, the funding agency for 
this grant may require posting of data for sharing with outside researchers. In these instances, 
these researchers will be asked to sign a statement of confidentiality before being allowed 
access to the data. In addition, no personal identifiers will be included in datasets that will be 
shared with outside researchers. 
The only potential risks of blood drawing are hematoma and infection at the skin site, 
minimal pain of venous puncture, uncommonly fainting reactions, and additionally discomfort 
and crying from the child. 
Adequacy of Protection against Risks 
Recruitment of Subjects and Informed Consent: Subjects will be recruited voluntarily from 
those meeting entry criteria. Written consent will be obtained from participating women before 
randomization, collection of questionnaire data, extraction of information from maternal (labor 
and delivery) and neonatal records, and samples of cord blood and peripheral blood. Subjects 
are under no obligation to participate. All signed consent forms are copied times three, one 
placed in the patient’s research file and a second in a common consent form folder for the 
study and a copy given to the patient. The consenting process is an ongoing process and 
participants will be informed of important new developments that relate importantly to the safety 
of the study. In addition at each follow-up visit study procedures and requirements are reviewed. 
Protection against Risks: To monitor for the rare potential for Vitamin D toxicity urine samples 
will be evaluated for Calcium/Creatinine at each clinical prenatal visit and for vitamin D levels at 
the blood samples collected during pregnancy. Should levels of Calcium/Creatinine exceed 1.55 
mmol/mmol or Vitamin D levels exceed 300 nmol/L, a specific case study will be initiated to 
examine the contribution of confounding factors (e.g. diet, sunlight exposure, other over the 
counter pills, etc.). The appropriate IRB will be notified, and the NIH and FDA will be notified per 
their protocols. If the elevated levels in the subject are attributed to the vitamin D supplement, 
the subject will be withdrawn from supplementation but will continue to be monitored. As noted 
above, steps will be taken to ensure that study information remains confidential. As we have 
mentioned in the background section, there have been no reported adverse effects on the fetus 
due to vitamin D supplementation. By monitoring the urinary calcium/creatinine ratio in the 
pregnant mothers and ensuring that the vitamin D levels do not exceed 300 nmol/L, the risks to 
the fetus will be minimized. The discomforts associated with blood drawing are minimal. 
Phlebotomy will be performed by licensed phlebotomists or research assistants that are 
adequately trained for blood drawing in infants. For maternal samples, we will minimize blood 
draws by piggybacking the collection at delivery with the blood draw for clinical purposes. 
Potential Benefit to Individual Subjects and Society: For the participating mothers, a direct 
benefit will be close monitoring, and thus better adherence, of prenatal vitamin intake, which has 
already established benefits for fetal wellbeing. Additionally, even for those women in the 
placebo group, they will be receiving 400 IU of vitamin D per day in the prenatal vitamin that the 
study will be supplying at no charge. This 400 IU dose is twice that of the current AI 
recommendations of the IOM. The prenatal vitamins will be provided free of charge to all 
participants in the trial. The benefits of vitamin D on several outcomes related to bone health are 
well-documented99.  
For infants in the trial, a potential benefit is the close monitoring for the development of 
asthma and allergies. Additionally, we will offer 400 IU/day of vitamin D to all the infants who 
consume less than 1000 ml of formula per day, according to the recommendations of the 
American Academy of Pediatrics. This includes all children who are breastfed, either partially or 
exclusively and all formula-fed infants until they consume at least 1000 ml of formula per day. 
These vitamin D supplements will be provided free of charge to the infants in the trial.  
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The potential benefit to society is significant if the trial shows a decrease in the 
prevalence of asthma, wheezing illnesses, and allergies at 3 years of age. Allergic diseases 
such as asthma are a major public health problem in the U.S. Since the risks involved in the 
protocol are small and the societal benefits are potentially large, the risk-benefit ratio is strongly 
on the side of benefit. 
Importance of the Knowledge to Be Gained: 
As previously stated, the main potential benefit of this research proposal is that it may lead to 
public health interventions that could lead to a decrease of up to 50% of the asthma prevalence 
worldwide, and may contribute to our understanding of the pathogenesis of allergic diseases 
such as asthma. While there are individual risks involved in this project, we will institute 
mechanisms to minimize these risks. Thus, because of the potentially great societal benefit, the 
individual risks are reasonable. 
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Summary of Protocol 
Changes 
Summary of Changes to VDAART Protocol 
Table of changes to VDAART Protocol  
Change Page/Section Reason for change Date 




Recommended change by 
DSMB 
8.6.09 
2. Added two paragraphs reviewing vitamin D 
effects on immune system 
bottom of page 
2 to top of page 
3 
Recommended change by 
DSMB 
8.6.09 
3. Switched order of Aims 1 and 2 pages 2-3 Steering Committee decision; 
to conform with scientific 
aims in NIH grant 
8.6.09 
4. Changed dose of vitamin D3 for 




Recommended change by 
DSMB; to account for the 400 
IU contained in prenatal 
vitamins 
8.6.09 
5. Defined current smoker page 7 Recommended change by 
DSMB 
8.6.09 
6. Added to exclusion criteria:      8.6.09 
     a. kidney stones and sarcoidosis page 8  Steering Committee decision; 
these conditions increase risk 
for hypercalcemia and stone 
formation 
8.6.09 
    b. Patient health questionnaire depression 
scale > 15 
page 8 Steering Committee decision; 
attempt to avoid enrolling 
patients with severe 
depression. 
8.6.09 
     c. Illicit drug use page 8 Requested by DSMB; also 
increases risk of 
noncompliance with study 
procedures 
8.6.09 
     d. not previously enrolled in this trial for a 
previous pregnency 
page 8 Recommended change by 
DSMB 
8.6.09 
     e. discovery of any fetal abnormalities page 8 Recommended change by 
DSMB 
8.6.09 
     f. PI discretion page 8 Steering Committee decision; 
in the event of any other 
condition that may prohibit 
compliance with trial 
medications and procedures 
8.6.09 
7. Rewrite Section V (Recruitment) page 8-9 Steering Committee decision; 
clarifications and added 
details to screening, 
recruitment and follow-up 
procedures 
8.6.09 
8. Addition of protocol schemata (Figure 2) page 10 DSMB request to provide 
summary of protocol process 
8.6.09 
9. Table 2: page 11   8.6.09 
     a. remove 6-8 week post-enrollment visit   Steering Committee decisions 
to streamline visits and 
decrease participant burden 
8.6.09 
     b. remove maternal blood at delivery   Steering Committee decisions 
to streamline visits and 
decrease participant burden 
8.6.09 
     c. 28-32 week visit changed to 32-38 week 
third trimester visit 
  Steering Committee decisions 
to streamline visits and 
decrease participant burden 
8.6.09 
     d. change monthly post natal calls for the 
first 6 months to quarterly for the duration of 
the trial 
  Steering Committee decisions 
to streamline visits and 
decrease participant burden 
8.6.09 
10. Added definition of Asthma, wheeze; 
added eosinphil count; moved IgE 
measurement to this section 
page 12, Section 
VI. Data 
Collection 
Recommended change by 
DSMB 
8.6.09 
11.  Addition of croup, 
laryngotracheobronchitis to lower respiratory 
illnesses 
page 12, Section 
VI.A4. 
Recommended change by 
DSMB: more complete listing 
of lower respiratory illnesses 
8.6.09 
12. Added description of Screening 
Questionnaire 
page 12, Section 
VI.B. 
Steering Committee decision; 
not previously described 
8.6.09 
13. Added description of Baseline Maternal 
Questionnaire 
page 12, Section 
VI.C. 
Steering Committee decision; 
not previously described 
8.6.09 
14. Monthly Maternal Questionnaire replaces 
Section VI.B. 
page 13, Section 
VI.D. 
Steering Committee decision; 
Clarification of flow of data 
and questionnaire 
8.6.09 
15. Remove sentence beginning with "EMR 
systems are in place…" 
page 13 Steering Committee decision; 
Clarification of protocol and 
EMR systems. Paper-based in 
some centers. 
8.6.09 
16. Change method for measurement of 
25(OH)D; will not use Heartland Assays, Inc.; 
this will now be measured at the DCC 
(Channing Lab) 
page 13 Recommended by DSMB; 
potential conflict of interest 
with Heartland Assays, Inc. 
8.6.09 
17. Added procedure to follow after discovery 
of elevated urinary Ca/Cr ratio 
pages 13-14, 
Section VI.G. 
Recommended by DSMB; 
clarification of procedures 
8.6.09 
18. Changed timing of adminstration of FFQ; 
second FFQ will now be adminstered at the 
32-38 week visit. Added FFQ to 6 month call 
and 1 year visit 
page 14, Section 
VI.H. 
Reflect change in timing of 
prenatal visit; post natal 
questionnaires added on 
recommendation by DSMB 
8.6.09 
19. Added phrase "…2 readings from each site 
averaged…" 
page 14, Section 
VI.J. 
Clarification to skin 
pigmentation procedure 
8.6.09 




Steering Committee decision; 
not previously described 
8.6.09 
21. Addition of process for handling 
depression should it be identified after 
randomization: The participant will be 
counseled by the Study Coordinator and the 
PI will be notified. The participant will then be 
referred back to her obstetrician for further 
psychiatric evaluation.   
pages 15, 
Section VI.K. 
Steering Committee decision 
and DSMB recommendation; 
strategy to handle significant 
depression should it arise. 
8.6.09 
22. Changed timing of infant questionnaires 
from monthly for the first 6 months to 
quarterly for the duration of the trial 
Section VI.M., 
page 15 
Steering Committee decision 
to streamline data flow and 
decrease participant burden 
8.6.09 
23. Switched plans for Specific Aims 1 and 2 
to reflect switch in order for these aims 
pages 17-18 Steering Committee decision 8.6.09 
24. Added details for randomization and block 
assignment 
page 26, Section 
VII.C. 
Recommended change by 
DSMB 
8.6.09 
25. Added details about unblinding, interim 
analysis, and stopping rules 
Section VII. H., 
page 29 
Recommended change by 
DSMB 
8.6.09 
26. Added details on safety and monitoring of 
urine Ca/Cr ratio 
Section VII. I., 
pages 29-30 
Recommended change by 
DSMB 
8.6.09 




Recommended change by 
DSMB 
8.6.09 
28. Added details of process of reporting AEs page 31 Recommended change by 
DSMB 
8.6.09 
29. Added details of interim analyses and 
stopping rules 
Section VII. K., 
page 31 
Recommended change by 
DSMB 
8.6.09 




Recommended change by 
DSMB 
8.6.09 
31. Corrected exclusion criteria for depression 
questionnaire from >15 to >  or  = to 15 
Section IV,            
page 7 
Clarification of the inclusion 
criteria 
1.8.2010 
32. Eliminated Follow-Up Sun Exposure 
Questionnaire and Determination of Skin 
Pigmentation for the mother in year 3.  
Section V, Table 
2, page 11 
Corrected the table to reflect 
the text of the protocol 
1.8.2010 
33. Corrected procedure for distributing 
MEMS caps (done locally, not by IDS at the 
DCC) 
Section VI, O., 
page 16 
Clarification of MEMS 
distribution procedure 
1.8.2010 
34. Removed wording about each site posting 




Corrected the functionality of 
the VDAART website 
1.8.2010 
35. Changed age inclusion criteria from 18 -35 
to 18-39 
Section IV, page 
7 and Section 
VII, page 34 
Steering Committee decision, 
DSMB approval. See 
proposal: Expanding the Age 
Requirement for details. 
2.8.2010 
36 . Changed urine Ca: Cr ratio to >/= 
.55mg/mg (or 1.55 mmol/mmol) 
Section VI, G., 
page 14 and 
SectionVII H., I., 
page 29, and 
page 35 
Steering Committee decision, 
DSMB approval. See 
proposal: Changing the Urine 
Ca:Cr Ratio Limit 
2.8.2010 
37. Changed procedure for elevated urine 
Ca:Cr ratio 
Section VI, G., 
page 14 and 
Section VII, I., 
page 30 
Steering Committee decision, 
DSMB approval. See 
proposal: Changing the Urine 
Ca:Cr Ratio Limit 
2.8.2010 
38. Removed Melissa McEnery and changed 
administrator to Christopher Garcia 
VII, B., page 26 Corrected to reflect current 
personnel 
2.17.2010 
39. Outlined the procedure for a subsequent 
elevated urine Ca:Cr ratio 
Section VI, G., 
page 14 and 
Section VII, I., 
page 30-31 
Steering Committee decision 2.17.2010 
40. Added 5th aim: preeclampsia and preterm 
birth 
Section  II page 
4; Section VI ,P., 
pages 21-22 ; 
Section VI, Q., 
page 25 
DCC requested changed, 
approved by DSMB 
3.4.2011 
41. Added language about taking 
anthropometric measurements at office visits 
Section V, Page 
9 and Section V, 
Table 2, page 
11; Section VI, 
M., page 15 
DCC requested changed, 
approved by DSMB 
3.4.2011 
42. Updated the allergens to be assayed at 
years 1 and 3 
Secction VI, A., 
page 12 
DCC initiated  1.23.2012 
43. Added the collection of a 2.5 ml pax gene 




Steering Committee decision.  






Addendum to Analysis Plan 
VDAART Analysis Plan (Addendum to Protocol) 
All analyses of primary and secondary outcomes stated in the VDAART Protocol will be 
performed using the intent-to-treat (ITT) paradigm, unless specifically stated. 
I. Definition of outcomes. 
A. Asthma and recurrent wheezing. The primary outcome of the trial will be development of a 
doctor’s diagnosis of asthma and/or recurrent wheeze. While asthma is acknowledged to have 
its roots in early life, making a definite diagnosis is difficult until the child is older, and wheezing 
illnesses may be precursors of an asthma diagnosis. Thus, we will have a composite definition 
for the primary outcome.  
• Asthma will be defined as a parent’s report of physician’s diagnosis at any time during 
the first three years of life, based on questionnaire responses. For time-to-event 
analyses, the time of incident asthma will be determined by the time of first positive 
questionnaire response.  
• Recurrent wheezing will be defined as at least one report of wheezing in the third year of 
life plus any report of wheezing in any of the first two years of life.  
Recognizing that wheezing symptoms may be modified by medication use, variable age of 
onset, and other variables, the following will be included in the composite outcome: 
• children who had at least one wheezing episode (during the 1st 2 years of life), plus an 
asthma controller medication (defined as steroid inhalers or nebulizers OR steroid pills 
or liquids OR leukotriene modifiers) in the third year 
• children who did not report any wheezing in the first 2 years but who report 2 separate 
episodes of wheezing in the third year OR are on controller medication (defined as 
above) on at least 2 separate reports in the third year OR at least 1 report of wheezing 
and at least 1 separate report of controller medication use in the third year 
For recurrent wheezing (and the other wheezing phenotypes), the time of incident recurrent 
wheezing will be determined by the time of first report of wheezing, for time-to-event analyses. 
In the event that the child meets the definition based solely on the use of controller medication, 
the first report of use of this controller medication will be used to determine the time of onset of 
wheezing for time-to-event analyses. 
For these outcomes, because the questions were asked every 3 months, and recognizing that 
missing questionnaires occurred, event times will be treated as interval-censored. 
B. Eczema. Eczema will be defined as a positive response to parent’s report of physician’s 
diagnosis at any time during the first three years of life based on the questionnaire responses. 
C. Lower respiratory tract infections (LRI). Lower respiratory tract infections (LRIs) will be 
defined based on parental responses to questionnaires. LRIs will be defined as a parental report of 
a physician’s diagnosis of pneumonia, bronchiolitis, bronchitis, or croup (laryngotracheobronchitis). 
1 
 
LRIs may occur multiple times over a three-year period in a child. Information on repeated 
episodes of LRI will be employed for rate estimation and comparison. 
D. Total and specific IgE. Total and specific serum IgE will be measured from cord blood 
samples, and from year 3 samples from the children. Total IgE will be analyzed as a continuous 
outcome. Sensitization will be defined as any specific IgE ≥ 0.35 IU. 
II. Secondary Analyses. 
A. Analyses based on levels. Secondary analyses using baseline and follow-up maternal 
25OHD levels will be performed. We will investigate the effect of baseline and follow-up 
maternal levels separately on the development of primary and secondary outcomes in the trial. 
Additionally, we will categorize mothers into categories based on joint baseline and follow-up 
levels. Mothers who have baseline levels and follow-up levels ≥ 40 mg/dl will be categorized in 
the HI-HI group; those who have baseline levels and follow-up levels < 40 mg/dl will be 
categorized in the LO-LO group; mothers who do not meet these definitions will be categorized 




Summary of changes to 
Analysis Plan 
Summary of Changes to VDAART Analysis Plan 
Change Date 
1. Amendment to recurrent wheeze phenotype and other
phenotypes for analysis 
2. Amendment to analysis plan incorporating time-to-
event analyses, using interval censoring 
Approved by Steering Committee 
on January 29, 2015 
Uploaded to VDAART Website and 
ClinicalTrials.gov website on 
February 4, 2015; released on 
ClinicalTrials.gov website on June 
5, 2015 
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DETAILED PROTOCOL – Continuation Study  
“Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma” 
Acronym: VDAART (Vitamin D Antenatal Asthma Reduction Trial 
 
I. Background and Significance  
 Asthma is one of the leading causes of morbidity in children with 90% of all cases 
diagnosed by age 61, 2. It remains the most common chronic disease of childhood in the world3, 
4, and incurs significant healthcare costs5, 6. The burden of the disease in both the developed 
and the developing world is significant and increasing rapidly with over 300 million people 
affected worldwide. Thus, preventing the development of this disorder would be of great public 
health importance. 
Vitamin D deficiency has been documented in many populations worldwide7, 8, and has 
been reported in healthy children, young adults (especially African Americans), and middle-aged 
and elderly adults7, 8. Vitamin D deficiency has occurred despite fortification of foods in some 
countries and despite intake of multivitamins containing vitamin D. This suggests that as 
countries adopt a western lifestyle, there is shift from outdoor activities to more time spent 
indoors. For example, it is estimated that in the US alone, Americans spend an average of 93% 
of their time indoors9. Relevant to this study, pregnant and lactating mothers and their 
neonates are at especially high risk for vitamin D deficiency10-13. The importance of vitamin 
D deficiency in pregnancy in relation to asthma development is that it has many recognized 
effects in on the developing lung and immune system.  
We have completed a double-blind intervention trial where we randomized pregnant 
women to high vitamin D (4,400 IU/day) vs. low vitamin D (400 IU/day). The original protocol 
proposed to follow the offspring of the women to age 3 years. This protocol is a continuation of 
that protocol, as we propose to follow the children through ages 6-7 years, since it is very 
difficult to be certain of the diagnosis of asthma before this age. 
 
 
II. Hypothesis and Specific Aims 
 Our hypothesis is that supplementing pregnant women with sufficient vitamin D will 
decrease the incidence of allergies, asthma and wheezing illnesses in children.  
 
Our primary aims are: 
 
1. To determine whether vitamin D supplementation in the pregnant mother is associated with 
reduced incidence of asthma in the child by age 6 years. Our primary outcomes will be 
doctor’s diagnosis of asthma and/or recurrent wheeze in the child at age 6 years. 
a. Among children with asthma, to determine whether vitamin D supplementation in the 
mother reduces severity of asthma in the children. 
 
2. To determine whether vitamin D supplementation in the pregnant mother is associated with 
improved lung function and bronchodilator response in the child. 
 
3. To determine whether vitamin D supplementation in the pregnant mother is associated with 
reduced allergic sensitization (total and specific IgE).   
 
II. Study Overview  
This is a continuation of the observational phase of a multicenter, randomized, double-
blind, controlled clinical trial that compares high-dose vitamin D3 supplementation (4,400 IU/day) 
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vs. usual dose vitamin D3 supplementation (400 IU/day) in pregnancy to prevent asthma in the 
women’s children. The study base will be all pregnant women from each Clinical Center who 
have a personal history of asthma and/or allergies or a history of asthma and/or allergies in the 
biologic father of the child (i.e. a “high risk” cohort for asthma and allergies in the child). We had 
recruited 881 women from the three centers, resulting in 810 live infant births. We will continue 
to follow these 810 infants after their 3rd birthday, on to age 6-7 years. 
IV. Schedule of Data Collection 
 The data collection will continue every 3 months. An in-person visit will occur every year.  
A. Quarterly calls. As with the period during the first 3 years of the study, the study coordinator 
at each center will contact the mother/primary caregiver every 3 months and administer a brief 
questionnaire inquiring about the child’s health, with particular emphasis on respiratory 
conditions. Every 6 months, in addition to the brief health questionnaire, questionnaires about 
the child’s home environment (including environmental smoke exposures), diet and behaviors 
will be administered. These questionnaires will be the same questionnaires that were 
administered during the quarterly calls in the first 3 years of life, with modifications accounting 
for the growth of the child. 
 
B. Yearly in-person visits. Yearly in-person visits will be conducted. At these visits, all 
questionnaires will be administered. In addition, anthropometric measures – height, weight, 
chest circumference and abdominal circumference – will be collected, and measurement of skin 
pigmentation will also be done. At these visits, we will collect stool samples and impulse 
oscillometry will be performed.  Nasal samples will be collected at the 6-yr visit.  At the 4-yr or 5-
yr visit a urine sample will be collected from subjects whose urine sample was not collected at 
the 3-yr visit.  Beginning at the 5-yr visits, spirometry will be performed and both spirometry and 
bronchodilator response will be performed at the 6-yr visit. At the 6-yr visit, blood will also be 
collected for 25OHD levels, total and specific IgE levels, and RNA samples for gene expression 
studies.  
 
V. Data Collection 
A. Definition of Outcome Variables 
A.1. Asthma and recurrent wheeze. Asthma will be defined as a parent’s report of physician’s 
diagnosis at any time during the first six years of life, based on questionnaire responses. A 
diagnosis of asthma in early childhood is difficult, as only a third of children who wheeze before 
the age of 3 years will develop asthma. However, children who experience more frequent 
(recurrent) wheeze in early life are more likely to develop asthma14, 15. We will define recurrent 
wheezing as at least one report of wheezing in the first three years of life plus any report of 
wheezing in the past year at age 6. Any wheeze will be defined as any report of wheezing in any 
of the three years of the child’s life. 
 
A.2. Eczema. Similarly to the case for asthma and wheeze, eczema will be defined based on 
responses to questionnaires. We will use the standardized questions from the International 
Study for Asthma and Allergy in Children which asks about an itchy rash with a specific 
distribution. We will also enquire about a physician’s diagnosis of eczema. 
 
A.3. Serum Total and Allergen-Specific IgE; Eosinophil count. Total serum IgE will be 
measured from year 6 samples from the children. In addition, allergen-specific IgE and 
eosinophil counts will be measured from the year 6 samples from the children. Serum from each 
child will also be assayed for IgE to 13 allergens (dust mite [D. farinae], cockroach [Bla g], cat 
dander, dog dander, rye grass pollen, ragweed pollen, Alternaria tenuis, Aspergillus, wheat, 
soybean, egg white, milk, and peanut) using the UniCAP system (Phadia AB in Portage, MI ). We 
will define sensitization to each allergen as a specific IgE level ≥ 0.35 IU/ml. Atopy will then be 
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defined as sensitization to at least one of the 13 allergens included in the study. Total serum IgE 
is increased in atopic individuals. For the statistical analysis, total serum IgE will be transformed to 
a log natural scale, in recognition of the distribution of total serum IgE in human populations16. Total 
eosinophil counts will be determined at each clinical center’s laboratory. 
 
A.4. Respiratory tract infections. Lower respiratory tract infections (LRIs) will be defined based 
on parental responses to questionnaires. LRIs will be defined as a parental report of a physician’s 
diagnosis of pneumonia, bronchiolitis, bronchitis, or croup (laryngotracheobronchitis).  
 
B. Measurement of 25(OH)D 
 Blood from the child will be collected at 6 yrs. All specimens will be shipped to the DCC, 
where they will be logged in and processed. Measurement of 25(OH)D will be performed at the 
Channing Laboratory DCC as previously described17. Twenty five (25) microliters of serum or 
plasma (EDTA or Heparin) is required for the 25-OH-D extraction, however, 100 microliter 
samples will be aliquoted to allow for duplicate measurements on each sample. A 
chemiluminescence assay will be employed. The LIAISON
® 
25 OH Vitamin D assay (DiaSorin, 
Inc., Stillwater, MN) is a direct competitive chemiluminescence immunoassay (CLIA) for 
quantitative determination of total 25 OH vitamin D in serum or plasma.  
 
C. Sun Exposure Questionnaire. We will collect UV exposure history using a modification of 
the UV exposure questionnaire that is used in the Nurses’ Health Study18. Briefly, this 
questionnaire will inquire about UV exposure information such as average hours per week spent 
outdoors in summer and winter, sunscreen habits, and average times for sunlamp use or 
tanning salon attendance. 
 
D. Measurement of Skin Pigmentation. Children will have the degree of pigmentation/melanin 
measured at each yearly visit using the Smart Probe 400 (IMS, Inc., Milford, CT) and a skin tone 
chart (IMS, Inc.). This is a spectrophotometer device that measures degrees of pigmentation on 
a continuous scale from 0 to 100, 0 being absolute black and 100 being absolute white. Each 
child will have pigmentation measurements recorded from her forehead, exposed forearm, 
underarm, and abdomen, with two readings from each site averaged and recorded. These 
measurements were performed during the first 3 years of follow-up. 
 
E. DNA Extraction and Samples for Gene Expression Studies: We will extract high molecular 
weight genomic DNA from the white blood cells from maternal peripheral blood and cord blood 
with commercially available PureGene Kits (Gentra Systems, Minneapolis, MN). Optical density 
(OD) will be measured to confirm DNA quality and quantity for each sample. This amount is 
sufficient to perform approximately 16,000 genotype assays using PCR technology (assuming a 
conservative use of 25 ng/reaction, although we routinely amplify single copy gene sequences 
from 10 ng of genomic DNA). Every sample undergoes additional quality control before 
use/release by subjecting it to PCR amplification. After DNA quantification, samples will be 
adjusted to TE buffer and partitioned into aliquots stored at -80°C. Information about quantity 
and storage of extracted DNA will be added as variables to each patient’s database. DNA 
samples will then be stored at the Channing Laboratory for future genetic studies. 
 
F. Stool: Samples from children will be collected in the home around the time of each visit using 
the specimen collection kit provided.  The stool sample will allow us to measure bacteria in the 
child’s intestines that may influence the development of asthma and allergies.  All specimens 
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G. Nasal: Samples from children will be collected at the 6-yr visit using the nasal collection kit.  
The nasal sample will allow us to measure exposure to allergens encountered in everyday 
life.   
 
H. Impuse Oscillometry (IOS):  This test will be done at each yearly visit.  Sometimes, children 
are unable to perform spirometry, and IOS is another way to obtain measures of lung 
function. Children will be asked to breathe quietly into a mouthpiece attached to an IOS 
machine. During quiet breathing, the machine will deliver small-pressure oscillations 
(vibrations) that are applied at the mouth and transmitted into the lungs. The IOS machine 
will then measure how the lungs respond to the vibrations. 
 
I. Spirometry: All spirometries will be conducted with a standardized spirometer. All subjects 
should be free of respiratory illnesses for at least 4 weeks before spirometry, and they will also be 
instructed to avoid use of inhaled short- and long-acting bronchodilators for at least 4 and 12 hours 
before testing, respectively. Tests are done with the subjects standing and wearing a plastic 
noseclip. Forced expiratory maneuvers are judged to be acceptable if they meet or exceed ATS 
criteria modified for children.19 As many as eight forced expiratory flow volume maneuvers from 
total lung capacity will be performed to obtain three acceptable measures. At the 6-yr visit, after 
performing baseline spirometry, subjects will be given two puffs (180 :g) of albuterol by a metered-
dose inhaler with a spacer. After waiting 15 minutes, each subject will repeat the spirometric 
maneuvers to assess bronchodilator responsiveness.  
The research assistants will calibrate the spirometer daily with a 3-liter calibration syringe. 
Volumes within 3% of 3 liters (2.91 to 3.09 liters) will be considered acceptable.19 Each calibration 
syringe will be returned biannually to the manufacturer for recalibration to within 10 ml. If repeated 
calibration checks with different flow sensors indicate a volume outside the acceptable range, the 
syringe will be replaced.  
 
J. Urine: Samples from children will be collected in the home around the time of the year 3, year 
4, or year 5 visit using the specimen collection kit provided.  The urine sample will allow us to 
measure exposure to chemicals encountered in everyday life and asthma or allergy-related 
inflammation. All specimens will be shipped to the DCC, where they will be logged in and 
processed. 
 
K. Statistical considerations 
K.1. Overview 
 This is an observational study of subjects who were offspring of women in a randomized, 
double blinded, multi-center, placebo controlled, clinical trial of prenatal vitamin exposure as a 
preventive measure to reduce the risk of asthma and recurrent wheeze in childhood.  There 
were 810 live births in the trial and we intend to follow these children. The main purpose of this 
study is to follow the children to age 6-7 years, where the diagnosis of asthma is more certain 
than at younger ages. 
 
L.2 Analytic plan 
Preliminary statistical analysis will be used to describe the univariate distributions of key 
measures of interest to detect outliers or data anomalies that need to be addressed by data 
editing or sequestration of doubtful entries.  Additionally, these analyses will examine whether 
any important risk factors for childhood asthma are imbalanced across treatment arm, as well as 
assess whether differential loss to follow-up is present across treatment groups.  Detailed 
blinded codebooks will be provided to investigators as data accumulate to facilitate efficient 
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The hypothesis that the incidence of asthma and recurrent wheeze at age 6 years is 
reduced in the high-dose Vitamin D supplementation group will be tested using logistic 
regression, allowing for fixed effects of center.  Additional analyses will consider the modification 
of vitamin D exposure effects by maternal and child demographic/behavioral factors such as 
maternal age, BMI and weight gain during pregnancy, maternal history of asthma/allergy, and 
other factors potentially associated with asthma and/or vitamin D exposure.    
Letting Mi be an indicator function for the primary endpoint, asthma, for the ith subject, 
the model is:   
iiiiii aaxaxM ,2211 , ),|1Pr(logit γγβα +++==  
where xi denotes an indicator function for level of vitamin D supplementation (0=400 IU, 1=4400 
IU) in the ith subject, while a1,i and a2,i are indicator functions for study center.  The specific aim 
for this outcome tests the hypothesis that β=0, asthma and recurrent wheeze incidence do not 
significantly differ across treatment groups, after adjusting for the potential effects of study 
center heterogeneity. 
To assess modification of vitamin D exposure levels by other demographic and/or 
behavioral variables, the model is: 
∑∑+++== ++ k kk iikkikiiiiii zxzaaxaxM ηδγγβα ,2211 , ),|1Pr(logit  
where zki represents the k measured covariates for each subject, and the other variables are as 
described above.  This model addresses two hypotheses.  First, main effects testing for 
behavioral/demographic covariates (Table 3), or the hypothesis that δk=0, will be used to 
examine whether maternal age, BMI, or other factors predict asthma and recurrent wheeze risk 
at age 6.  More importantly, inclusion of any significant main effects will adjust for any 
distributional imbalances of these factors across the Vitamin D supplemented and placebo 
groups.   Second, this model tests the hypothesis that ηk=0, or whether any maternal, child, or 
demographic/behavioral covariates modify the relationship between vitamin D intake and our 
primary outcome.  To obtain a parsimonious model and limit multiple testing, only covariates 
with significant main effects and strong biologic plausibility for an exposure-dependent impact 
on asthma/recurrent wheeze risk will be considered for interaction testing with Vitamin D 
supplementation status.  
 
M. Data Security and Confidentiality 
All computer files are stored in password-controlled accounts on DCC computers.  There 
will be an SSL regulated private web portal established for the study at the DCC, LDAP 
database of all study investigators or support staff will be established with private passwords 
allocated to all who have a need to examine the study web site 
Each participant will be assigned a unique study identification number.  Once these data 
are linked (after a subject successfully enters randomization phase from screening), the study 
identification number will be the primary identification number. The data coordinating center and 
trial statisticians will have access to only the unique identification number and therefore cannot 
link names to data. Files of study data will include the screening and study identification number 
but not participant names.  Any hardcopy of data forms obtained by the coordinating unit (for 
example, as part of spot-checking for quality control) will be maintained in locked file cabinets. If 
a participant withdraws from participation at any point in the trial, and requests withdrawal of any 
information from the database, the clinical center staff will forward the study identification 
number to the DCC and all files pertaining to that identification number will be removed and 
destroyed.  
At the clinical centers, data are collected on forms with fields for study identification 
number but without a field for the participant’s name. Still, separate lists of participant names, 
identification numbers, and contact information are used during the study to maintain contact 
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with participants and eventually to provide feedback on study and personal results.   These lists 
will only be available to Center Co-PIs and staff with direct patient contact.  All hardcopies of 
forms are stored in locked file cabinets. All computer files are password protected.  Participant 
results will only be released to the participant unless he/she provides written approval to release 
data (e.g. laboratory results to personal provider).   Data will only be presented and published in 
aggregate, i.e. no identifying characteristics of participants will be published or presented.   
 
N. Risks and Discomfort 
A risk of participation in this study is the social-psychological risk resulting from 
inadvertent disclosure of medical history information. This potential risk is guarded against by 
storage of completed questionnaires in a locked filing system and by labeling other 
phenotypic/genotypic data using ID numbers only. In certain instances, the funding agency for 
this grant may require posting of data for sharing with outside researchers. In these instances, 
these researchers will be asked to sign a statement of confidentiality before being allowed 
access to the data. In addition, no personal identifiers will be included in datasets that will be 
shared with outside researchers. No personal identifiers will be transmitted to the central DCC. 
All questionnaires and forms will be uploaded with only Study ID. 
Genetic information from this study will not have immediate medical or treatment 
implications. Information about a subject´s participation and results from the study will not be 
placed in the patient´s medical records. Subjects will not be informed about any individual 
genetic data obtained from this study. 
The only potential risks of blood drawing are hematoma and infection at the skin site, 
minimal pain of venous puncture, uncommonly fainting reactions, and additionally discomfort 
and crying from the child. 
The risks associated with performing spirometry are transient. Forced exhalation into a 
mouthpiece can cause coughing or lightheadedness. Albuterol has recognized side effects, 
such as tachycardia and palpitations, raised blood pressure, nausea and headaches. These are 
rare in children. Spirometry and bronchodilator response testing have become standard 
measurements in epidemiologic studies and surveys of children with and without asthma21-28. 
These procedures have been found to be safe in infants, preschool, and school-aged children. 
The Channing Laboratory has recently conducted these tests in two cohorts of 6-12 yr old 
children. Both spirometry and bronchodilator response testing were conducted. In the Home 
Allergens and Asthma Study, comprised of 400 children, and in the Project Viva cohort, 
comprised of over 700 children, no adverse events occurred in any of these tests. No risks are 
associated with IOS, stool or urine collection.  There is minimal risk associated with some slight 
discomfort with nasal collection.  This procedure has been done in previous studies without 
adverse events. 
 
O. Potential Benefits 
Subjects will be provided with background information regarding asthma. The potential 
benefit to society is significant if the trial shows a decrease in the prevalence of asthma, 
wheezing illnesses, and allergies at 6 years of age. Allergic diseases such as asthma are a 
major public health problem in the U.S. Since the risks involved in the protocol are small and the 
societal benefits are potentially large, the risk-benefit ratio is strongly on the side of benefit. 
Importance of the Knowledge to Be Gained: 
As previously stated, the main potential benefit of this research proposal is that it may lead to 
public health interventions that could lead to a decrease of up to 50% of the asthma prevalence 
worldwide, and may contribute to our understanding of the pathogenesis of allergic diseases 
such as asthma. While there are individual risks involved in this project, we will institute 
mechanisms to minimize these risks. Thus, because of the potentially great societal benefit, the 
individual risks are reasonable. 
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